<SEC-DOCUMENT>0001213900-24-066142.txt : 20240807
<SEC-HEADER>0001213900-24-066142.hdr.sgml : 20240807
<ACCEPTANCE-DATETIME>20240807163011
ACCESSION NUMBER:		0001213900-24-066142
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240801
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240807
DATE AS OF CHANGE:		20240807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40439
		FILM NUMBER:		241184285

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0210740-8k_neuro.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:NMTC="http://n1mtc.com/20240801">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_NMTC_n1mtc.com_20240801 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20240801_20240801 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001500198 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000004" name="dei:EntityCentralIndexKey">0001500198</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nmtc-20240801.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20240801__20240801_za9T51sazhli"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):
<b><span id="xdx_906_edei--DocumentPeriodEndDate_c20240801__20240801_zpRefzmp9Hhd"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 1, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20240801__20240801_zugMYVWpYMzb"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000011" name="dei:EntityRegistrantName">NeuroOne Medical Technologies Corporation</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20240801__20240801_zue2am5I45zg"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b><span id="xdx_900_edei--EntityFileNumber_c20240801__20240801_zMc8UujSygJ8"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000013" name="dei:EntityFileNumber">001-40439</ix:nonNumeric></span></b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20240801__20240801_z1Hr2cIqyZ5"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-0863354</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(State or other jurisdiction<br/>
of incorporation)</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">(IRS Employer<br/>
Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20240801__20240801_z4KgrMRpaoXl"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000015" name="dei:EntityAddressAddressLine1">7599 Anagram Dr.</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressCityOrTown_c20240801__20240801_zg8b8gcugNXj"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000016" name="dei:EntityAddressCityOrTown">Eden Prairie</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20240801__20240801_zSk7oI0nGExc"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000017" name="dei:EntityAddressStateOrProvince">MN</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20240801__20240801_zpCpYowjR9b3"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000018" name="dei:EntityAddressPostalZipCode">55344</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--CityAreaCode_c20240801__20240801_zhfedKXXzXvd"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000019" name="dei:CityAreaCode">952</ix:nonNumeric></span>-<span id="xdx_902_edei--LocalPhoneNumber_c20240801__20240801_zUmueDR0eC08"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000020" name="dei:LocalPhoneNumber">426-1383</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s former name or former address,
if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--WrittenCommunications_c20240801__20240801_zMVnsA9WTQc"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the
    Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--SolicitingMaterial_c20240801__20240801_zqKCidMFYKs1"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementTenderOffer_c20240801__20240801_zqkEQesFyXJj"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20240801__20240801_zd3vRS3zhSB5"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b>Title of each class</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b>Trading Symbol(s)</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span id="xdx_908_edei--Security12bTitle_c20240801__20240801_zgdXQpgcrZZi"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000025" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_edei--TradingSymbol_c20240801__20240801_zq22SgM4tuj8"><ix:nonNumeric contextRef="AsOf2024-08-01" id="Fact000026" name="dei:TradingSymbol">NMTC</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center">The <span id="xdx_901_edei--SecurityExchangeName_c20240801__20240801_z96qsYoMPqs8"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Emerging Growth Company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20240801__20240801_zVN750cAtG11"><ix:nonNumeric contextRef="AsOf2024-08-01" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Private Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2024, NeuroOne Medical Technologies Corporation (the &#8220;<b><i>Company</i></b>&#8221;)
entered into a&#160;Securities Purchase Agreement&#160;(the &#8220;<b><i>Purchase Agreement</i></b>&#8221;) with certain accredited investors
(the &#8220;<b><i>Purchasers</i></b>&#8221;), pursuant to which the Company, in a private placement (the &#8220;<b><i>Private Placement</i></b>&#8221;),
agreed to issue and sell an aggregate of (i) 2,944,446 shares (the &#8220;<b><i>Shares</i></b>&#8221;) of the Company&#8217;s common stock,
par value $0.001 per share (the &#8220;<b><i>Common Stock</i></b>&#8221;), and (ii) warrants to purchase an aggregate of 2,208,333 shares
of Common Stock (the &#8220;<b><i>PIPE Warrants</i></b>&#8221;) at a purchase price of $0.90 per unit, consisting of one Share and a PIPE
Warrant to purchase 0.75 shares of Common Stock, resulting in total gross proceeds of approximately $2.65 million before deducting estimated
expenses. The Private Placement closed on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Private Placement, the Company agreed to file
a registration statement with the U.S. Securities and Exchange Commission (the &#8220;<b><i>SEC</i></b>&#8221;) covering the resale of
the Shares and the shares of Common Stock issuable upon exercise of the PIPE Warrants (the &#8220;<b><i>Warrants Shares</i></b>&#8221;).
The Company has agreed to file such registration statement within 30 days of the closing of the Private Placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PIPE Warrants are exercisable beginning on
the date of issuance, have an exercise price of $1.19 per share, subject to adjustment, and will expire on the third anniversary of the
date of issuance. Prior to expiration, subject to the terms and conditions set forth in the PIPE Warrants, the holders of such PIPE Warrants
may exercise the PIPE Warrants for Warrant Shares by providing notice to the Company and paying the exercise price per share for each
share so exercised. One Purchaser in the Private Placement included Paul Buckman, a director on the Company&#8217;s Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the net proceeds from the Private Placement
for funding operations, working capital and general corporate purposes, including to expand commercialization of the OneRF ablation limited
launch, completion of product development intended for a new ablation indication and completion of the diligence process with a potential
OneRF strategic partner. The Company has granted the Purchasers indemnification rights with respect to its representations, warranties
and agreements under the Purchase Agreement. The foregoing summary description of the PIPE Warrants and Purchase Agreement do not purport
to be complete and is qualified in its entirety by reference to the forms of PIPE Warrants and Purchase Agreement, which are attached
as Exhibits 4.1 and 10.1 hereto, respectively, and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The representations, warranties and covenants contained in the Purchase
Agreement and the PIPE Warrants were made solely for the benefit of the parties to the Purchase Agreement and the PIPE Warrants and may
be subject to limitations agreed upon by the contracting parties. Accordingly, the Purchase Agreement and form of PIPE Warrant are incorporated
herein by reference only to provide investors with information regarding the terms of such documents and not to provide investors with
any other factual information regarding the Company or its business and should be read in conjunction with the disclosures in the Company&#8217;s
periodic reports and other filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>New Debt Facility Financing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 2, 2024, the Company entered into a&#160;loan and security
agreement (the &#8220;<b><i>Debt Facility Agreement</i></b>&#8221;) with Growth Opportunity Funding, LLC, as the lender (the &#8220;<b><i>Lender</i></b>&#8221;),
which provides for a delayed draw term loan facility in an aggregate principal amount not to exceed $3.0 million (the &#8220;<b><i>Debt
Facility</i></b>&#8221;). The Company is permitted to borrow loans under the Debt Facility from time to time (collectively, the &#8220;<b><i>Loans</i></b>&#8221;),
for general corporate purposes and subject to certain specified conditions, until the earliest of: (i) November 30, 2024, (ii) the occurrence
of any Monetization Event (as defined below) or Change of Control (as defined in the Debt Facility Agreement), or (iii) at the Lender&#8217;s
option, upon the occurrence and during the continuance of an event of default under the Debt Facility Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loans mature on February 2, 2026. The outstanding principal
amount of any outstanding Loans will bear interest at a rate of 10% per annum, payable monthly in arrears and at the maturity date. As
of the closing date of the Debt Facility Agreement, no amounts were drawn by the Company thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At closing of the Debt Facility, the Company
issued to the Lender a warrant exercisable for five years for 100,000 shares of Common Stock at an exercise price of $0.66 per
share, subject to adjustment (the &#8220;<b><i>Closing Date Debt Facility Warrant</i></b>&#8221;). At the time of any borrowing of
Loans, the Company will issue to the Lender additional warrants exercisable for five years for 50,000 shares of Common Stock (for
each $500,000 of Loans borrowed) at the same per share exercise price as the Closing Date Debt Facility Warrant (
the &#8220;<b><i>Additional Debt Facility Warrants</i></b>&#8221;, and together with the Closing Date Debt Facility Warrant, the
&#8220;<b><i>Debt Facility Warrants</i></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is permitted to voluntarily
prepay the outstanding Loans at any time, without premium or penalty, upon five business days&#8217; prior written notice to the
Lender. The Company is required to prepay outstanding Loans upon the occurrence of (i) any Change of Control or (ii) certain other
events as more fully described in the Debt Facility Agreement, but in any event including any capital raise or other transaction
pursuant to which the Borrower receives cumulative cash proceeds in excess of $5.0 million in the aggregate (each
such event in this prong (ii), a &#8220;<b><i>Monetization Event</i></b>&#8221;). The obligations of the Company under the Debt
Facility are secured by a first-priority security interest in substantially all assets of the Company, subject to certain exceptions
set forth in the Debt Facility Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Debt Facility Agreement includes other customary representations
and warranties, conditions, affirmative and negative covenants, and events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summary description of the Debt Facility Warrants and
Debt Facility Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Debt Facility Warrants
and the Debt Facility Agreement, which are attached as Exhibits 4.2 and 10.2 hereto, respectively, and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The representations, warranties and covenants contained in the Debt
Facility Agreement and the Debt Facility Warrants were made solely for the benefit of the parties to the Debt Facility Agreement and the
Debt Facility Warrants and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Debt Facility Agreement
and form of Debt Facility Warrant are incorporated herein by reference only to provide investors with information regarding the terms
of such documents and not to provide investors with any other factual information regarding the Company or its business and should be
read in conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2.03 Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth in Item 1.01 of this current report is incorporated
by reference into this Item 2.03.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described more fully in Item 1.01 above, which description is hereby
incorporated by reference into this Item 3.02, the Company agreed to issue Shares and PIPE Warrants to the Purchasers and Debt Facility
Warrants to the Lender, all of whom are accredited investors, in reliance on the exemption from registration provided by Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;), and Rule&#160;506&#160;of&#160;Regulation
D&#160;promulgated thereunder. The Company will rely on this exemption from registration based in part on representations made by the
Purchasers. The Shares, Warrants, and Warrant Shares have not been registered under the&#160;Securities Act&#160;or applicable state securities
laws and may not be offered or sold in the United States absent registration under the&#160;Securities Act&#160;or an exemption from such
registration requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this Current Report on Form 8-K nor any exhibit attached hereto
shall constitute an offer to sell or the solicitation of an offer to buy the Warrants, Shares or any other securities of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Cautionary Note Regarding Forward-Looking
Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This Current Report on
Form 8-K contains &#8220;forward-looking&#8221; statements within the meaning of the Securities Act, the Exchange Act, and of the &#8220;safe
harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the
expected net proceeds of the offering, the anticipated use of net proceeds of the offering and satisfaction of the closing conditions
of the offering. Statements including words such as &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;continue,&#8221; &#8220;expect,&#8221;
&#8220;will be,&#8221; &#8220;develop,&#8221; &#8220;signal,&#8221; &#8220;potential,&#8221; &#8220;anticipate&#8221; or &#8220;ongoing&#8221;
and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as
well as assumptions, which, if they do not fully materialize or prove incorrect, could cause the Company&#8217;s results to differ materially
from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties
that may cause the Company&#8217;s actual activities or results to differ significantly from those expressed in any forward-looking statement,
including risks and uncertainties disclosed in its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, filed with
the SEC on December 15, 2023, and its other filings with the SEC. Forward-looking statements in this Current Report on Form 8-K speak
only as of the date hereof, and the Company specifically disclaims any obligation to update these forward-looking statements, whether
as a result of new information, future events or otherwise, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><b>Exhibit No.</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><b>Description</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>4.1</td>
    <td>&#160;</td>
    <td><a href="ea021074001ex4-1_neuro.htm">Form of PIPE Warrant.</a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>4.2</td>
    <td>&#160;</td>
    <td><a href="ea021074001ex4-2_neuro.htm">Form of Debt Facility Financing Warrant.</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td>10.1&#x5E;</td>
    <td>&#160;</td>
    <td><a href="ea021074001ex10-1_neuro.htm">Form of Securities Purchase Agreement, dated August 1, 2024.</a></td></tr>
  <tr style="vertical-align: top">
    <td>10.2#</td>
    <td>&#160;</td>
    <td><a href="ea021074001ex10-2_neuro.htm">Loan and Security Agreement with Growth Opportunities Funding LLC, dated August 2, 2024.</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td>104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (embedded with Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#x5E;</td><td style="text-align: justify"><span style="font-size: 10pt">Schedules and exhibits to this
agreement have been omitted pursuant to Item&#160;601(a)(5) of&#160;Regulation S-K. The Company agrees to furnish any omitted schedules
or exhibits upon the request of the SEC. A list of the omitted schedules and exhibits to this agreement is as follows: Exhibit A: Schedule
of Purchasers; Exhibit B: Form of Warrant; Exhibit C: Accredited Investor Qualification Questionnaire; Exhibit D: Bad Actor Questionnaire;
and Exhibit E: Selling Stockholder Questionnaire.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">#</td><td style="text-align: justify"><span style="font-size: 10pt">Certain identified information
in schedules and exhibits to this agreement have been omitted pursuant to Item&#160;601(a)(5) and Item 601(b)(10)(iv)&#160;of&#160;Regulation
S-K because it is both&#160;not material and is the type that the Company treats as private or confidential. The Company agrees to furnish
any omitted schedules or exhibits upon the request of the SEC. A list of the omitted schedules and exhibits to this agreement is as follows:
Exhibit B: Notice Addresses and Bank Account Information.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="vertical-align: bottom"><b>NEUROONE MEDICAL TECHNOLOGIES CORPORATION </b></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">Dated: August 7, 2024</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>By:</td>
    <td style="border-bottom: black 1.5pt solid">/s/ David Rosa</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>David Rosa</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">4</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LhrjL320VBGrSBHxNdhVgm22bOLfkbylsUVcFpZl5psRIhZLWpgKGY7zIoc91k2lPUKBZ2S0JwyOdLVOINwCL8Z51ta37w9MKTAYmHFPDXUQWuvdOCwTkLO+nPTVCOQwUVPYbUT01VOyZ1Oi9UZXoG0JO6aGDXrNry5hr59kqX61VQdkZ8gmMOjJTn6DkgMFW7rrB/HVQZ6nIorbicSS6dYEV/b0aL8kZBXWoc519H+jDwqNSpM= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea021074001ex4-1_neuro.htm
<DESCRIPTION>FORM OF PIPE WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NEITHER THIS SECURITY NOR
THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE
AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE
STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY
MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF
COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE
SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN
AND IN A SECURITIES PURCHASE AGREEMENT, DATED AS OF AUGUST 1, 2024 AND AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH
THE SECRETARY OF THE COMPANY.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">NeuroOne
Medical Technologies Corporation<BR>
<BR>
Warrant to Purchase Common Stock </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Number of Shares: ________________ (subject to adjustment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left">Warrant No. [___]</TD><TD STYLE="text-align: right; width: 50%">Original Issue Date: August 2, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>NeuroOne
Medical Technologies Corporation</B></FONT>, a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>), hereby certifies that,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [__________________] or its registered
assigns (the <B><I>&ldquo;Holder&rdquo;</I></B>), is entitled, subject to the terms set forth below, to purchase from the Company up to
a total of [____________] shares of Common Stock, $0.001 par value per share (the <B><I>&ldquo;Common Stock&rdquo;</I></B>), of the Company
(each such share, a <B><I>&ldquo;Warrant Share&rdquo;</I></B> and all such shares, the <B><I>&ldquo;Warrant Shares&rdquo;</I></B>) at
an exercise price per share equal to $1.19 per share (as adjusted from time to time as provided in Section 9 herein, the <B><I>&ldquo;Exercise
Price&rdquo;</I></B>) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued
in exchange, transfer or replacement hereof, the <B><I>&ldquo;Warrant&rdquo;</I></B>) at any time and from time to time on or after the
date hereof (the <B><I>&ldquo;Original Issue Date&rdquo;</I></B>) and through and including 5:30 P.M., New York City time, on August 2,
2027 (the <B><I>&ldquo;Expiration Date&rdquo;</I></B>), subject to the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.   <FONT STYLE="font-variant: small-caps">Definitions.</FONT></B>
All capitalized terms that are used but not defined herein shall have the respective meanings ascribed to them in the Securities Purchase
Agreement, dated August 1, 2024, by and between the Company and Holder (the <B><I>&ldquo;Securities Purchase Agreement&rdquo;</I></B>).
For purposes of this Warrant, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)
<I>&ldquo;Closing Sale Price&rdquo;</I></B> means, for any security as of any date, the last trade price for such security on the Principal
Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended
hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City
time, as reported by Bloomberg L.P., or if the security is not listed for trading on a Trading Market on the relevant date, the last quoted
bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization
or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular
date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined
by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the
Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&rsquo;
determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for
any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)   <I>&ldquo;Marketable
Securities&rdquo;</I></B> means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting
requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the <B><I>&ldquo;Exchange Act&rdquo;</I></B>),
and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the
class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction
(as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized
securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction,
the Holder would not be restricted from publicly re-selling all of the issuer&rsquo;s shares and/or other securities that would be received
by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of
such Fundamental Transaction, except to the extent that any such restriction (x) arises solely under applicable securities laws, rules
or regulations, and (y) does not extend beyond six (6) months from the closing of such Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.
<FONT STYLE="font-variant: small-caps">Warrant Register. </FONT></B><FONT STYLE="background-color: white">The Warrant, as initially issued
by the Company, is offered and sold pursuant to the Securities Purchase Agreement. </FONT>The Company shall register ownership of this
Warrant, upon records to be maintained by the Company for that purpose (the <B><I>&ldquo;Warrant Register&rdquo;</I></B>), in the name
of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder)
from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of
any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.   <FONT STYLE="font-variant: small-caps">Registration
of Transfers.</FONT></B> Subject to compliance with all applicable securities laws, the conditions herein and such reasonable requirements
as the Company may require, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this
Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a <B><I>&ldquo;New
Warrant&rdquo;</I></B>) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing
the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New
Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of
the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue
and deliver at the Company&rsquo;s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer,
the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by
any notice to the contrary. The Warrants and the Warrant Shares are and may continue to be subject to resale restrictions and hold periods,
and the Holder (and any transferee) should consult its legal advisor in respect of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>4.   Exercise
and Duration of Warrants. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)   </B>All
or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from
time to time on or after the Original Issue Date and through and including 5:30 P.M., New York City time, on the Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)   </B>The
Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the <B><I>&ldquo;Exercise
Notice&rdquo;</I></B>), completed and duly signed. Within one (1) Trading Day following the date of delivery of the Exercise Notice, the
Holder shall make payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may
take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the Exercise Notice pursuant to Section 10 below). The date on which
such Exercise Notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an <B><I>&ldquo;Exercise
Date&rdquo;</I></B>; provided, that if the Exercise Price is not delivered on or before one (1) Trading Day following the date of delivery
of the Exercise Notice, the Exercise Date shall be deemed to be one (1) Trading Day following the date of that the Exercise Price is delivered
to the Company. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or
notarization) of any Notice of Exercise be required. The Holder shall not be required to deliver the original Warrant in order to effect
an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant
and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than
the amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>5.   Delivery
of Warrant Shares. </B></FONT>Upon exercise of this Warrant, the Company shall promptly (but in no event later than two (2) Trading Days
after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is
entitled pursuant to such exercise in book entry form with the Company&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.   <FONT STYLE="font-variant: small-caps">Charges,
Taxes and Expenses.</FONT></B> Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any
applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company;
<I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer
involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate
thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant
or receiving Warrant Shares upon exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.   <FONT STYLE="font-variant: small-caps">Replacement
of Warrant.</FONT></B> If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt
of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and
reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply
with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If
a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company
as a condition precedent to the Company&rsquo;s obligation to issue the New Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.   <FONT STYLE="font-variant: small-caps">Reservation
of Warrant Shares.</FONT></B> The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available
out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue
Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable
upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the
Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable
and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and
validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to
assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of
any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further
covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common
Stock at any time while this Warrant is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.   <FONT STYLE="font-variant: small-caps">Certain
Adjustments.</FONT></B> The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment
from time to time as set forth in this Section 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)   Stock
Dividends and Splits.</B> If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock
or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with
the terms of such stock on the Original Issue Date that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of
Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number
of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company,
then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record
date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly
as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the
time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately
after the effective date of such subdivision or combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)   Adjustment
Upon Issuance of Common Stock</B>. If and whenever on or after the date hereof, the Company issues or sells, or in accordance with this
Section 9 is deemed to have issued or sold, any Common Stock (including the issuance or sale of Common Stock owned or held by or for the
account of the Company) issued or sold or deemed to have been issued or sold) for a consideration per share (the &ldquo;New Issuance Price&rdquo;)
less than the Exercise Price then effect (such Exercise Price then in effect is referred to as the &ldquo;Applicable Price&rdquo;) (the
foregoing a &ldquo;Dilutive Issuance&rdquo;), then immediately after such Dilutive Issuance, the Exercise Price then in effect shall be
reduced to the New Issuance Price; provided however that an adjustment of the Exercise Price pursuant to this Section 9(b) shall not be
result in an Exercise Price which is higher than the Exercise Price prior to such adjustment. For all purposes of the foregoing (including,
without limitation, determining the adjusted Exercise Price and the New Issuance Price under this Section&nbsp;9(b)), the following shall
be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)   <U>Issuance
of Options</U>. If the Company in any manner grants, issues or sells (or enters into any agreement to grant, issue or sell) any Options
and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon
conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the
terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued
and sold by the Company at the time of the granting, issuance or sale (or the time of execution of such agreement to grant, issue or sell,
as applicable) of such Option for such price per share. For purposes of this Section&nbsp;9(b)(i), the &ldquo;lowest price per share for
which one share of Common Stock is at any time issuable upon the exercise of any such Options or upon conversion, exercise or exchange
of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&rdquo; shall be equal
to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to
any one share of Common Stock upon the granting, issuance or sale (or pursuant to the agreement to grant, issue or sell, as applicable)
of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise
of such Option or otherwise pursuant to the terms thereof and (y) the lowest exercise price set forth in such Option for which one share
of Common Stock is issuable (or may become issuable assuming all possible market conditions) upon the exercise of any such Options or
upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to
the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Option (or any other Person) upon the granting,
issuance or sale (or the agreement to grant, issue or sell, as applicable) of such Option, upon exercise of such Option and upon conversion,
exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the terms thereof plus
the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option (or any other Person).
Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common
Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant to the terms of or upon the actual issuance
of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)   <U>Issuance
of Convertible Securities</U>. If the Company in any manner issues or sells (or enters into any agreement to issue or sell) any Convertible
Securities and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or
exchange thereof or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be
deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale (or the time of execution
of such agreement to issue or sell, as applicable) of such Convertible Securities for such price per share. For the purposes of this Section&nbsp;9(a)(ii),
the &ldquo;lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange
thereof or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration
(if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale (or pursuant to the
agreement to issue or sell, as applicable) of the Convertible Security and upon conversion, exercise or exchange of such Convertible Security
or otherwise pursuant to the terms thereof and (y) the lowest conversion price set forth in such Convertible Security for which one share
of Common Stock is issuable (or may become issuable assuming all possible market conditions) upon conversion, exercise or exchange thereof
or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Convertible Security
(or any other Person) upon the issuance or sale (or the agreement to issue or sell, as applicable) of such Convertible Security plus the
value of any other consideration received or receivable by, or benefit conferred on, the holder of such Convertible Security (or any other
Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares
of Common Stock upon conversion, exercise or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if
any such issuance or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has
been or is to be made pursuant to other provisions of this Section&nbsp;9(b), except as contemplated below, no further adjustment of the
Exercise Price shall be made by reason of such issuance or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)   <U>Change
in Option Price or Rate of Conversion</U>. If the purchase or exercise price provided for in any Options, the additional consideration,
if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible Securities
are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time (other than proportional
changes in conversion or exercise prices, as applicable, in connection with an event referred to in Section 2(a)), the Exercise Price
in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which would have been in effect at such time
had such Options or Convertible Securities provided for such increased or decreased purchase price, additional consideration or increased
or decreased conversion rate, as the case may be, at the time initially granted, issued or sold . For purposes of this Section&nbsp;9(b)(ii)
if the terms of any Option or Convertible Security (including, without limitation, any Option or Convertible Security that was outstanding
as of the Subscription Date) are increased or decreased in the manner described in the immediately preceding sentence, then such Option
or Convertible Security and the shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to
have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section 9(b) shall be made if such adjustment
would result in an increase of the Exercise Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)   <U>Calculation
of Consideration Received</U>. If any Option and/or Convertible Security and/or Adjustment Right is issued in connection with the issuance
or sale or deemed issuance or sale of any other securities of the Company (as determined by the Holder, the &ldquo;<B>Primary Security</B>&rdquo;,
and such Option and/or Convertible Security and/or Adjustment Right, the &ldquo;<B>Secondary Securities</B>&rdquo;), together comprising
one integrated transaction, (or one or more transactions if such issuances or sales or deemed issuances or sales of securities of the
Company either (A) have at least one investor or purchaser in common, (B) are consummated in reasonable proximity to each other and/or
(C) are consummated under the same plan of financing) the aggregate consideration per share of Common Stock with respect to such Primary
Security shall be deemed to be equal to the difference of (x) the lowest price per share for which one share of Common Stock was issued
(or was deemed to be issued pursuant to Section 9(b)(i) or 9(b)(ii) above, as applicable) in such integrated transaction solely with respect
to such Primary Security, minus (y) with respect to such Secondary Securities, the sum of (I) the Black Scholes Consideration Value of
each such Option, if any, (II) the fair market value (as determined by the Holder in good faith) or the Black Scholes Consideration Value,
as applicable, of such Adjustment Right, if any, and (III) the fair market value (as determined by the Holder) of such Convertible Security,
if any, in each case, as determined on a per share basis in accordance with this Section 9(b)(iv). If any shares of Common Stock, Options
or Convertible Securities are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor (for
the purpose of determining the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the
calculation of the Black Scholes Consideration Value) will be deemed to be the net amount of consideration received by the Company therefor.
If any shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount of
such consideration received by the Company (for the purpose of determining the consideration paid for such Common Stock, Option or Convertible
Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be the fair value of such consideration,
except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company
for such securities will be the arithmetic average of the VWAPs of such security for each of the five (5) Trading Days immediately preceding
the date of receipt. If any shares of Common Stock, Options or Convertible Securities are issued to the owners of the non-surviving entity
in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor (for the purpose of determining
the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the Black
Scholes Consideration Value) will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity
as is attributable to such shares of Common Stock, Options or Convertible Securities (as the case may be). The fair value of any consideration
other than cash or publicly traded securities will be determined jointly by the Company and the Holder. If such parties are unable to
reach agreement within ten (10) days after the occurrence of an event requiring valuation (the &ldquo;<B>Valuation Event</B>&rdquo;),
the fair value of such consideration will be determined within five (5) Trading Days after the tenth (10<SUP>th</SUP>) day following such
Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Holder. The determination of such appraiser
shall be final and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)   <U>Record
Date</U>. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A)&nbsp;to receive
a dividend or other distribution payable in shares of Common Stock, Options or in Convertible Securities or (B)&nbsp;to subscribe for
or purchase shares of Common Stock, Options or Convertible Securities, then such record date will be deemed to be the date of the issuance
or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other
distribution or the date of the granting of such right of subscription or purchase (as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)   <U>Termination
of Adjustments</U>. Notwithstanding anything to the contrary in this <U>Section 9(b)</U>, following such date that the Closing Sale Price
per share of Common Stock is greater than $2.00 (subject to adjustment as set forth in <U>Section 9(a)</U>) for sixty (60) trading days,
there shall be no additional adjustments pursuant to this <U>Section 9(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)   Pro
Rata Distributions.</B> If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for
no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding
paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, a <B><I>&ldquo;Distribution&rdquo;</I></B>),
other than a reclassification as to which Section 9(d applies, then in each such case, the Holder shall be entitled to participate in
such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common
Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in
such Distribution (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result
in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent)
and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until the earlier of (i) such time, if ever,
as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section
11(a) hereof and (ii) such time as the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)   Fundamental
Transactions. </B>If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the Company in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater
than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company, except, in each case of (i) through (v), actions taken solely in connection with any internal reorganization
(each a &ldquo;<B><I>Fundamental Transaction</I></B>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have
the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such
Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 11(a) on the exercise of this Warrant),
the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<B><I>Alternate Consideration</I></B>&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 11(a) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company
or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30
days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental
Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined
below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided,
however, that, if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors,
the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the
same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders
of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock
or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid
any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor
Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<B><I>Black
Scholes Value</I></B>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;<B><I>OV</I></B>&rdquo;
function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting
(A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement
of the applicable contemplated Fundamental Transaction and the Expiration Date, (B) an expected volatility equal to the 100 day volatility
obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following
the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation
shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered
in such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Expiration Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will
be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the
Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<B><I>Successor Entity</I></B>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions
of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent
to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall
be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental
Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall
refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity
or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the
Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other
Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had
been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)   Number
of Warrant Shares.</B> Simultaneously with any adjustment to the Exercise Price pursuant to Section 9 (including any adjustment to the
Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may
be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate
Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price
in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the
par value of the Common Stock then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f)   Calculations.</B>
All calculations under this Section 9 shall be made to the nearest one-tenth of one cent or the nearest share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g)   Notice
of Adjustments. </B> Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written
request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate
setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other
securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing
in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate
to the Holder and to the Company&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(h)   Notice
of Corporate Events.</B> If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash,
securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe
for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating
or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding
up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public
information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record
or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction;
provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action
required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters
into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other
than a Fundamental Transaction under clause (iii) of Section 9(c), then the Company shall deliver to the Holder a notice of such Fundamental
Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information
disclosed pursuant to this Section 9(g) in confidence until such information is publicly available, and shall comply with applicable law
with respect to trading in the Company&rsquo;s securities following receipt any such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)   Voluntary
Adjustment By Company.</B> Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.   <FONT STYLE="font-variant: small-caps">Payment
of Exercise Price. </FONT></B> This Warrant shall be exercised either (i) for cash or (ii) the Holder may, in its sole discretion, satisfy
its obligation to pay the Exercise Price through a &ldquo;cashless exercise&rdquo;, in which event the Company shall issue to the Holder
the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act, as determined as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">X = Y [(A-B)/A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&ldquo;X&rdquo;
equals the number of Warrant Shares to be issued to the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&ldquo;Y&rdquo;
equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&ldquo;A&rdquo;
equals the Closing Sale Price per share of Common Stock as of the Trading Day immediately preceding the Exercise Date if the Exercise
Notice is delivered prior to market close on the Exercise Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&ldquo;B&rdquo;
equals the Exercise Price per Warrant Share then in effect on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of Rule 144 promulgated under the
Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a &ldquo;cashless exercise&rdquo; transaction
shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced,
on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper
at the time of such exercise). Except as set forth in Section 13 (payment of cash in lieu of fractional shares), in no event will the
exercise of this Warrant be settled in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>11.   Limitations
on Exercise. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)   </B>Notwithstanding
anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled
to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately
prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates
and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section 13(d)
of the Exchange Act to exceed [4.99][9.99]% (the <B><I>&ldquo;Maximum Percentage&rdquo;</I></B>) of the total number of issued and outstanding
shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially
owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s
for purposes of Section 13(d) of the Exchange Act to exceed [4.99][9.99]% of the combined voting power of all of the securities of the
Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common
Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&rsquo;s most recent Form
10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the
Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon
the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as
of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to
time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided
that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes
of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates
and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section 13(d)
of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised
and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled
portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company
which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right,
option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein
and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&rsquo;s for purposes of Section 13(d) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)   </B>This
Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine
the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated
in Section 9(c) of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12. <FONT STYLE="font-variant: small-caps">Reserved.</FONT></B>
 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.   <FONT STYLE="font-variant: small-caps">No
Fractional Shares.</FONT></B> No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of
any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole
number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14.   <FONT STYLE="font-variant: small-caps">Notices.</FONT></B>
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing
and shall be deemed given and effective, whether or not received by the recipient party, on the earliest of (i) the time of transmission,
if such notice or communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next
Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading
Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally
recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice
is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">Attention: CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">7559 Anagram Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">Eden Prairie, MN 55344</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to the Holder, notice shall be given to its
address or e-mail address set forth in the Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Or, in each of the above instances,
notice shall be given to such other address or e-mail address as the recipient party has specified by written notice given to each other
party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except pursuant to Section
9(g) hereof, to the extent that any notice provided to the Holder hereunder constitutes, or contains, material, non-public information
regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.   <FONT STYLE="font-variant: small-caps">Warrant
Agent.</FONT></B> The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&rsquo; notice to the Holder,
the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation
resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company
or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant
agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant
agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>16.   Miscellaneous.
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)   No
Rights as a Stockholder.</B> The Holder, solely in such Person&rsquo;s capacity as a holder of this Warrant, shall not be entitled to
vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this
Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder of this Warrant, any of the rights
of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue
of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities
on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)   Authorized
Shares.</B> Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (iii)
use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)   Successors
and Assigns.</B> Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not
be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction.
This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject
to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any
legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company
and the Holder, or their successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)   Amendment
and Waiver.</B> Except as otherwise provided herein, the provisions of the Warrant may be amended and the Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent
of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)   Acceptance.</B>
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f)   Governing
Law; Jurisdiction.</B> ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED
BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW
THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION
CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY
WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING
SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE
OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT
SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g)   Headings.</B>
The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(h)   Severability.</B>
In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder
will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT>, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>NeuroOne Medical Technologies Corporation</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">Ronald McClurg</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">Chief Financial Officer</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE 1<BR>
FORM OF EXERCISE NOTICE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[To be executed by the Holder to purchase shares
of Common Stock under the Warrant]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)   The
undersigned is the Holder of Warrant No. ___ (the <B><I>&ldquo;Warrant&rdquo;</I></B>) issued by NeuroOne Medical Technologies Corporation,
a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>). Capitalized terms used herein and not otherwise defined herein have
the respective meanings set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)   The
undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)   The
Holder intends that payment of the Exercise Price shall be made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> Cash
Exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> &ldquo;Cashless
Exercise&rdquo; under Section 10 of the Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)   If
the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ in immediately available funds to the Company in accordance
with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)    Pursuant
to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant.
The Warrant Shares shall be delivered in book entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)   By
its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced
hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice
relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 211.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Holder:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 28%"></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSN/EIN:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 211.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature must conform in all respects to name
of Holder as specified on the face of the Warrant)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ea021074001ex4-2_neuro.htm
<DESCRIPTION>FORM OF DEBT FACILITY FINANCING WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NEITHER THIS SECURITY NOR
THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE
AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE
STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY
MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF
COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE
SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN
AND IN A LOAN AND SECURITY AGREEMENT, DATED AS OF AUGUST 2, 2024 AND AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH
THE SECRETARY OF THE COMPANY.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">NeuroOne
Medical Technologies Corporation<BR>
<BR>
Warrant to Purchase Common Stock </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Number of Shares: 100,000 (subject to adjustment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%">Warrant No. L-1</TD>
<TD STYLE="text-align: right; width: 50%">&#9;Original Issue Date: August 2, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>NeuroOne
Medical Technologies Corporation</B></FONT>, a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>), hereby certifies that,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Growth Opportunity Funding, LLC, or
its registered assigns (the <B><I>&ldquo;Holder&rdquo;</I></B>), is entitled, subject to the terms set forth below, to purchase from the
Company up to a total of 100,000 shares of Common Stock, $0.001 par value per share (the <B><I>&ldquo;Common Stock&rdquo;</I></B>), of
the Company (each such share, a <B><I>&ldquo;Warrant Share&rdquo;</I></B> and all such shares, the <B><I>&ldquo;Warrant Shares&rdquo;</I></B>)
at an exercise price per share equal to $0.66 per share (as adjusted from time to time as provided in Section 9 herein, the <B><I>&ldquo;Exercise
Price&rdquo;</I></B>) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued
in exchange, transfer or replacement hereof, the <B><I>&ldquo;Warrant&rdquo;</I></B>) at any time and from time to time on or after the
date hereof (the <B><I>&ldquo;Original Issue Date&rdquo;</I></B>) and through and including 5:30 P.M., New York City time, on August 2,
2029 (the <B><I>&ldquo;Expiration Date&rdquo;</I></B>), subject to the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1. <FONT STYLE="font-variant: small-caps">Definitions.</FONT></B>
All capitalized terms that are used but not defined herein shall have the respective meanings ascribed to them in the Loan and Security
Agreement, dated August 2, 2024, by and between the Company and Holder (the <B><I>&ldquo;Loan Agreement&rdquo;</I></B>). For purposes
of this Warrant, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) </B>&ldquo;<B><I><U>Affiliate</U></I></B>&rdquo;
means, with respect to a specified Person, another Person that directly or indirectly through one or more intermediaries, Controls or
is Controlled by or is under common Control with the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) <I>&ldquo;Closing
Sale Price&rdquo;</I></B> means, for any security as of any date, the last trade price for such security on the principal trading market
for such security, as reported by Bloomberg L.P., or, if such principal trading market begins to operate on an extended hours basis and
does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported
by Bloomberg L.P., or if the security is not listed for trading on a principal trading market on the relevant date, the last quoted bid
price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization
or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular
date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined
by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the
fair market value shall be determined by an independent qualified appraiser selected mutually by the Company and the Holder and paid for
by the Company. The independent qualified appraiser&rsquo;s determination shall be binding upon all parties absent demonstrable error.
All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction
during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c) </B>&ldquo;<B><I><U>Control</U></I></B>&rdquo;
means the right to appoint or remove a majority of the members of the board of directors (excluding independent directors) or other governing
body of a Person; the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies
of a Person, whether through the ownership of share capital or the ability to exercise voting power, by contract or otherwise. &ldquo;<U>Controlling</U>&rdquo;
and &ldquo;<U>Controlled</U>&rdquo; have meanings analogous thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d) <I>&ldquo;Marketable
Securities&rdquo;</I></B> means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting
requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the <B><I>&ldquo;Exchange Act&rdquo;</I></B>),
and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the
class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction
(as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized
securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction,
the Holder would not be restricted from publicly re-selling all of the issuer&rsquo;s shares and/or other securities that would be received
by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of
such Fundamental Transaction, except to the extent that any such restriction (x) arises solely under applicable securities laws, rules
or regulations, and (y) does not extend beyond six (6) months from the closing of such Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.
<FONT STYLE="font-variant: small-caps">Warrant Register. </FONT></B><FONT STYLE="background-color: white">The Warrant, as initially issued
by the Company, is offered and sold pursuant to the Loan Agreement. </FONT>The Company shall register ownership of this Warrant, upon
records to be maintained by the Company for that purpose (the <B><I>&ldquo;Warrant Register&rdquo;</I></B>), in the name of the record
Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from
time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any
exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3. <FONT STYLE="font-variant: small-caps">Registration
of Transfers.</FONT></B> Subject to compliance with all applicable securities laws, the conditions herein and such reasonable requirements
as the Company may require, the Company shall, or will cause its transfer agent to, register the transfer of all or any portion of this
Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a <B><I>&ldquo;New
Warrant&rdquo;</I></B>) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing
the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New
Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of
the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its transfer agent to, prepare, issue
and deliver at the Company&rsquo;s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer,
the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by
any notice to the contrary. The Warrants and the Warrant Shares are and may continue to be subject to resale restrictions and hold periods,
and the Holder (and any transferee) should consult its legal advisor in respect of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>4. Exercise
and Duration of Warrants. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) </B>All
or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from
time to time on or after the Original Issue Date and through and including 5:30 P.M., New York City time, on the Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) </B>The
Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the <B><I>&ldquo;Exercise
Notice&rdquo;</I></B>), completed and duly signed. Within one (1) Business Day following the date of delivery of the Exercise Notice,
the Holder shall make payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which
may take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the Exercise Notice pursuant to Section 10 below). The date
on which such Exercise Notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an <B><I>&ldquo;Exercise
Date&rdquo;</I></B>; provided, that if the Exercise Price is not delivered on or before one (1) Business Day following the date of delivery
of the Exercise Notice, the Exercise Date shall be deemed to be one (1) Business Day following the date of that the Exercise Price is
delivered to the Company. No ink-original Exercise Notice shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Exercise Notice be required. The Holder shall not be required to deliver the original Warrant in order to effect
an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant
and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than
the amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>5. Delivery
of Warrant Shares. </B></FONT>Upon exercise of this Warrant, the Company shall promptly (but in no event later than two (2) Business Days
after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is
entitled pursuant to such exercise in book entry form with the Company&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6. <FONT STYLE="font-variant: small-caps">Charges,
Taxes and Expenses.</FONT></B> Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any
applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company;
<I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer
involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate
thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant
or receiving Warrant Shares upon exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7. <FONT STYLE="font-variant: small-caps">Replacement
of Warrant.</FONT></B> If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt
of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and
reasonable indemnity and surety bond, if requested by the Company which shall not be required in the Holder provides an affidavit of loss
and self-indemnity. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and
procedures and pay such other reasonable third-party costs as the Company may prescribe (for the avoidance of doubt, the Holder shall
not be required to pay any costs related to legal counsel for the Company). If a New Warrant is requested as a result of a mutilation
of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&rsquo;s obligation
to issue the New Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8. <FONT STYLE="font-variant: small-caps">Reservation
of Warrant Shares.</FONT></B> The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available
out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue
Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are then issuable and deliverable upon
the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder
(taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable
shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized,
issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares
of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any
securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will
not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while
this Warrant is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9. <FONT STYLE="font-variant: small-caps">Certain
Adjustments.</FONT></B> The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment
from time to time as set forth in this Section 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) Stock
Dividends and Splits.</B> If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock
or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with
the terms of such stock on the Original Issue Date that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of
Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number
of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company,
then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record
date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly
as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the
time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately
after the effective date of such subdivision or combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) Pro
Rata Distributions.</B> If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for
no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding
paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, a <B><I>&ldquo;Distribution&rdquo;</I></B>),
other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in
such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common
Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in
such Distribution,provided, however, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result
in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent)
and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until the earlier of (i) such time, if ever,
as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section
11(a) hereof and (ii) such time as the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c) Fundamental
Transactions. </B>If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company
with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately
prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately
after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one
transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another
Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and
the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with
another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for
any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same
proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the
Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a)
above) (in any such case, a <B><I>&ldquo;Fundamental Transaction&rdquo;</I></B>), then following such Fundamental Transaction the Holder
shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have
been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise
contained herein (the <B><I>&ldquo;Alternate Consideration&rdquo;</I></B>). The Company shall not effect any Fundamental Transaction in
which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate
Consideration is solely cash and the Company provides for the simultaneous &ldquo;cashless exercise&rdquo; of this Warrant pursuant to
Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other
Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration
as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant.
The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding
the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of
cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed
to be exercised in full in a &ldquo;cashless exercise&rdquo; pursuant to Section 10 below effective immediately prior to and contingent
upon the consummation of such Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d) Number
of Warrant Shares.</B> Simultaneously with any adjustment to the Exercise Price pursuant to Section 9 (including any adjustment to the
Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may
be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate
Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price
in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the
par value of the Common Stock then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e) Calculations.</B>
All calculations under this Section 9 shall be made to the nearest one-tenth of one cent or the nearest share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f) Notice
of Adjustments. </B> Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written
request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate
setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other
securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing
in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate
to the Holder and to the Company&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g) Notice
of Corporate Events.</B> If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash,
securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe
for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating
or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding
up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public
information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record
or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction;
provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action
required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters
into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other
than a Fundamental Transaction under clause (iii) of Section 9(c), then the Company shall deliver to the Holder a notice of such Fundamental
Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information
disclosed pursuant to this Section 9(g) in confidence until such information is publicly available, and shall comply with applicable law
with respect to trading in the Company&rsquo;s securities following receipt any such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(h) Voluntary
Adjustment By Company.</B> Subject to the rules and regulations of the principal trading market, the Company may at any time during the
term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of
directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10. <FONT STYLE="font-variant: small-caps">Payment
of Exercise Price. </FONT></B> This Warrant shall be exercised either (i) for cash or (ii) the Holder may, in its sole discretion, satisfy
its obligation to pay the Exercise Price through a &ldquo;cashless exercise&rdquo;, in which event the Company shall issue to the Holder
the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act, as determined as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">X = Y [(A-B)/A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&ldquo;X&rdquo;
equals the number of Warrant Shares to be issued to the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&ldquo;Y&rdquo;
equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&ldquo;A&rdquo;
equals the Closing Sale Price per share of Common Stock as of the Business Day immediately preceding the Exercise Date if the Exercise
Notice is delivered prior to market close on the Exercise Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&ldquo;B&rdquo;
equals the Exercise Price per Warrant Share then in effect on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of Rule 144 promulgated under the
Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a &ldquo;cashless exercise&rdquo; transaction
shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced,
on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper
at the time of such exercise). Except as set forth in Section 13 (payment of cash in lieu of fractional shares), in no event will the
exercise of this Warrant be settled in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>11. Limitations
on Exercise. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) </B>Notwithstanding
anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled
to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately
prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates
and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section 13(d)
of the Exchange Act to exceed 9.99% (the <B><I>&ldquo;Maximum Percentage&rdquo;</I></B>) of the total number of issued and outstanding
shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially
owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s
for purposes of Section 13(d) of the Exchange Act to exceed 9.99% of the combined voting power of all of the securities of the Company
then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock,
the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&rsquo;s most recent Form 10-Q
or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company
or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the
written request of the Holder, the Company shall within three (3) Business Days confirm in writing or by electronic mail to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as
of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to
time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided
that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes
of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates
and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section 13(d)
of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised
and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled
portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company
which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right,
option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein
and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&rsquo;s for purposes of Section 13(d) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) </B>This
Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine
the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated
in Section 9(c) of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.&#9;<FONT STYLE="font-variant: small-caps">Reserved.</FONT></B>
&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13. <FONT STYLE="font-variant: small-caps">No
Fractional Shares.</FONT></B> No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of
any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole
number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14. <FONT STYLE="font-variant: small-caps">Notices.</FONT></B>
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing
and shall be deemed given and effective, whether or not received by the recipient party, on the earliest of (i) the time of transmission,
if such notice or communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Business Day, (ii) the
next Business Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not
a Business Day or later than 5:30 P.M., New York City time, on any Business Day, (iii) the Business Day following the date of mailing,
if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person
to whom such notice is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">Attention: CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">7559 Anagram Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">Eden Prairie, MN 55344</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">Email: Daver@nmtc1.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Holder, notice shall be given to its
address or e-mail address set forth in the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Or, in each of the above instances,
notice shall be given to such other address or e-mail address as the recipient party has specified by written notice given to each other
party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except pursuant to Section
9(g) hereof, to the extent that any notice provided to the Holder hereunder constitutes, or contains, material, non-public information
regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15. <FONT STYLE="font-variant: small-caps">Warrant
Agent.</FONT></B> The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&rsquo; notice to the Holder,
the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation
resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company
or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant
agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant
agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>16. Miscellaneous.
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) No
Rights as a Stockholder.</B> The Holder, solely in such Person&rsquo;s capacity as a holder of this Warrant, shall not be entitled to
vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this
Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder of this Warrant, any of the rights
of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue
of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities
on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b) Authorized
Shares.</B> Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (iii)
use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c) Successors
and Assigns.</B> Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not
be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction.
This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject
to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any
legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company
and the Holder, or their successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d) Amendment
and Waiver.</B> Except as otherwise provided herein, the provisions of the Warrant may be amended and the Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent
of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e) Acceptance.</B>
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f) Governing
Law; Jurisdiction.</B> ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED
BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW
THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION
CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY
WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING
SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE
OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT
SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g) Headings.</B>
The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(h) Severability.</B>
In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder
will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT>, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>NeuroOne Medical Technologies Corporation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 6%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 34%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">   &nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE 1<BR>
FORM OF EXERCISE NOTICE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[To be executed by the Holder to purchase shares
of Common Stock under the Warrant]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) The
undersigned is the Holder of Warrant No. ___ (the <B><I>&ldquo;Warrant&rdquo;</I></B>) issued by NeuroOne Medical Technologies Corporation,
a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>). Capitalized terms used herein and not otherwise defined herein have
the respective meanings set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) The
undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) The
Holder intends that payment of the Exercise Price shall be made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&#9;&ldquo;Cash
exercise&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&#9;&ldquo;Cashless
exercise&rdquo; under Section 10 of the Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4) If
the Holder has elected a cash exercise, the Holder shall pay the sum of $ in immediately available funds to the Company in accordance
with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)  Pursuant
to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant.
The Warrant Shares shall be delivered in book entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6) By
its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced
hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice
relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 211.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Holder:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 28%"></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSN/EIN:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 211.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature must conform in all respects to
name of Holder as specified on the face of the Warrant)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ea021074001ex10-1_neuro.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT, DATED AUGUST 1, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SECURITIES PURCHASE AGREEMENT</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">This
Securities Purchase Agreement</FONT> (this <B><I>&ldquo;Agreement&rdquo;</I></B>) is dated as of August 1, 2024, between <FONT STYLE="font-variant: small-caps"><B>NeuroOne
Medical Technologies Corporation</B></FONT>, a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>), and each purchaser identified
on <FONT STYLE="font-variant: small-caps"><U>Exhibit&nbsp;A</U></FONT> hereto (each, including its successors and assigns, a <B><I>&ldquo;Purchaser&rdquo;</I></B>
and collectively, the <B><I>&ldquo;Purchasers&rdquo;</I></B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Recitals</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
on the terms and subject to the conditions set forth in this Agreement and pursuant to Section&nbsp;4(a)(2) of the Securities Act of 1933,
as amended, and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally
and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
the Company has authorized, upon the terms and conditions stated in this Agreement, the sale and issuance of an aggregate of up to three
million dollars ($3,000,000) in value (or such higher amount as the Board of Directors of the Company shall determine, the <B><I>&ldquo;Total
Amount&rdquo;</I></B>) of shares (each, a &ldquo;<B><I>Share</I></B>&rdquo;) of the Company&rsquo;s Common Stock, par value $0.001 per
share (the <B><I>&ldquo;Common Stock&rdquo;</I></B>), and warrants to purchase shares of Common Stock in the form annexed hereto as <FONT STYLE="font-variant: small-caps"><U>Exhibit&nbsp;B</U></FONT>
(each a &ldquo;<B><I>Warrant</I></B>&rdquo; and collectively, the &ldquo;<B><I>Warrants</I></B>&rdquo;, and together with the Shares,
the &ldquo;<B><I>Securities</I></B>&rdquo;), in the manner and upon the terms and conditions hereinafter set forth herein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
at the Closing (as hereinafter defined), each Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell,
upon the terms and conditions stated in this Agreement, that number of Shares and Warrants set forth on <FONT STYLE="font-variant: small-caps"><U>Exhibit&nbsp;A</U></FONT>
attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-variant: small-caps"><B>Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>N<FONT STYLE="font-size: 10pt">OW</FONT>,
T<FONT STYLE="font-size: 10pt">HEREFORE</FONT>,</B> in consideration of the mutual covenants contained in this Agreement, and for other
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE 1<U><BR>
DEFINITIONS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Definitions.</FONT></B> In addition to the terms defined elsewhere in this Agreement, for
all purposes of this Agreement, the following terms have the meanings set forth in this <U>Section&nbsp;1.1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Additional Registration
Statement&rdquo;</I></B> shall have the meaning ascribed to such term in <U>Section&nbsp;5.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Affiliate&rdquo;</I></B>
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Agreement&rdquo;</I></B>
shall have the meaning ascribed to such term in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Board of Directors&rdquo;</I></B>
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Closing&rdquo;</I></B>
shall have the meaning ascribed to such term in <U>Section&nbsp;2.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Commission&rdquo;</I></B>
and/or <B><I>&ldquo;SEC&rdquo;</I></B> means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Common Stock&rdquo;</I></B>
shall have the meaning ascribed to such term in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Company&rdquo;</I></B>
shall have the meaning ascribed to such term in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Derivative Transaction&rdquo;</I></B>
shall have the meaning ascribed to such term in <U>Section&nbsp;4.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Effective Date&rdquo;</I></B>
means the date that a Registration Statement is first declared effective by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Effectiveness
Period&rdquo;</I></B> shall have the meaning ascribed to such term in <U>Section&nbsp;5.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Eligible Purchaser&rdquo;</I></B>
shall have the meaning ascribed to such term in <U>Section&nbsp;6.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Exchange Act&rdquo;</I></B>
means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;GAAP&rdquo;</I></B>
shall have the meaning ascribed to such term in <U>Section&nbsp;3.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Indemnified Party&rdquo;</I></B>
shall have the meaning ascribed to such term in <U>Section&nbsp;5.4(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Indemnifying
Party&rdquo;</I></B> shall have the meaning ascribed to such term in <U>Section&nbsp;5.4(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Initial Registration
Statement&rdquo;</I></B> has the meaning set forth in <U>Section&nbsp;5.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Intellectual
Property&rdquo;</I></B> means (i)&nbsp;worldwide patents, patent applications, invention disclosures and other rights of invention, filed
with any governmental authority, and all reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part
thereof and all reexamined patents or other applications or patents claiming the benefit of the filing date of any of the foregoing; (ii)&nbsp;worldwide
(A)&nbsp;registered trademarks and service marks and registrations and applications for such registrations, and (B)&nbsp;unregistered
trademarks and service marks, trade names, fictitious business names, corporate names, trade dress, logos, product names and slogans,
including any common law rights; in each case together with the goodwill associated therewith; (iii)&nbsp;worldwide (A)&nbsp;registered
copyrights in published or unpublished works, mask work rights and similar rights, including rights created under Sections 901-914 of
Title&nbsp;17 of the United States Code, mask work registrations, and copyright applications for registration, including any renewals
thereof, and (B)&nbsp;any unregistered copyrightable works and other rights of authorship in published or unpublished works; (iv)&nbsp;worldwide
(A)&nbsp;internet domain names; (B)&nbsp;website content; (C)&nbsp;telephone numbers; and (D)&nbsp;moral rights and publicity rights;
(v)&nbsp;any computer program or other software (irrespective of the type of hardware for which it is intended), including firmware and
other software embedded in hardware devices, whether in the form of source code, assembly code, script, interpreted language, instruction
sets or binary or object code (including compiled and executable programs), including any library, component or module of any of the foregoing,
including, in the case of source code, any related images, videos, icons, audio or other multimedia data or files, data files, and header,
development or compilations tools, scripts, and files, and (vi)&nbsp;worldwide confidential or proprietary information or trade secrets,
including technical information, inventions and discoveries (whether or not patentable and whether or not reduced to practice) and improvements
thereto, know-how, processes, discoveries, developments, designs, techniques, plans, schematics, drawings, formulae, preparations, assays,
surface coatings, diagnostic systems and methods, patterns, compilations, databases, database schemas, specifications, technical data,
inventions, concepts, ideas, devices, methods, and processes; and includes any rights to exclude others from using or appropriating any
Intellectual Property rights, including the rights to sue for or assets claims against and remedies against past, present or future infringements
or misappropriations of any or all of the foregoing and rights of priority and protection of interests therein, and any other proprietary,
intellectual property or other rights relating to any or all of the foregoing anywhere in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Losses&rdquo;</I></B>
means any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts
paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Material Adverse
Effect&rdquo;</I></B> means a material adverse effect on (i)&nbsp;the assets, liabilities, results of operations, condition (financial
or otherwise), business, or prospects of the Company taken as a whole, or (ii)&nbsp;the ability of the Company to perform its obligations
under the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Person&rdquo;</I></B>
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Principal Purchasers&rdquo;</I></B>
means, as of any time, the Purchaser or Purchasers holding or having the right to acquire, as of such time, at least a majority-in-interest
of the total amount of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Principal Trading
Market&rdquo;</I></B> means the Trading Market, if any, on which the Common Stock is primarily listed on and quoted for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Proceeding&rdquo;</I></B>
means an action, claim, suit, investigation or proceeding (including, without limitation, a partial proceeding, such as a deposition),
whether commenced or threatened in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Prospectus&rdquo;</I></B>
means the prospectus included in the Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under
the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion
of the Registrable Securities covered by the Registration Statement, and all other amendments and supplements to the Prospectus including
post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Purchasers&rdquo;</I></B>
shall have the meaning ascribed to such term in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Registration
Statement&rdquo; </I></B>means each registration statement required to be filed under <U>ARTICLE 5</U>, including the Initial Registration
Statement, all Additional Registration Statements, and, in each case, the Prospectus, amendments and supplements to such registration
statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference
or deemed to be incorporated by reference in such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Registrable Securities&rdquo;</I></B>
means the Shares and Warrant Shares and any shares of Common Stock issued as a dividend or other distribution with respect to, or in exchange
for, or in replacement of, the Shares or Warrant Shares, <U>provided</U>, that the holder of such Shares and Warrant Shares has completed
and delivered to the Company a Selling Stockholder Questionnaire; and <U>provided further</U>, that the Shares shall cease to be Registrable
Securities upon the earliest to occur of the following: (A) sale by any Person to the public either pursuant to a registration statement
under the Securities Act or under Rule 144 (in which case, only such Shares and/or Warrant Shares sold shall cease to be Registrable Securities)
or (B) becoming eligible for sale by the holder thereof pursuant to Rule 144 without volume or manner of sale restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Rule 144,&rdquo;
&ldquo;Rule 415,&rdquo;</I></B> and <B><I>&ldquo;Rule 424&rdquo;</I></B> means Rule 144, Rule 415 and Rule 424, respectively, promulgated
by the Commission pursuant to the Securities Act, as such Rules may be amended from time to time, or any similar rule or regulation hereafter
adopted by the SEC having substantially the same effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;SEC Reports&rdquo;
</I></B>shall have the meaning ascribed to such term in <U>Section&nbsp;3.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Securities&rdquo;</I></B>
shall have the meaning ascribed to such terms in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Securities Act&rdquo;</I></B>
means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Selling Stockholder
Questionnaire&rdquo;</I></B> shall have the meaning ascribed to such term in <U>Section&nbsp;5.2(g)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Shares&rdquo;
</I></B>shall have the meaning ascribed to such term in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Subsidiaries&rdquo;
</I></B>shall have the meaning ascribed to such term in <U>Section 3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Trading Day&rdquo;</I></B>
means a day on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &ldquo;Trading
Day&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on
which banking institutions in New York City are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Trading Market&rdquo;</I></B>
<FONT STYLE="background-color: white">means any of the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
or the New York Stock Exchange (or any successors to any of the foregoing)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Transaction Documents&rdquo;</I></B>
means this Agreement and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with
the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Transfer Agent&rdquo;</I></B>
means Equiniti Trust Company, the Company&rsquo;s transfer agent and registrar for the Common Stock, and any successor appointed in such
capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Voting Commitment&rdquo;
</I></B>shall have the meaning ascribed to such term in <U>Section&nbsp;4.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Warrant&rdquo;
</I></B>shall have the meaning ascribed to such term in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&ldquo;Warrant Shares&rdquo;
</I></B>means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE 2<U><BR>
PURCHASE AND SALE</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Purchase and Sale.</FONT></B> Subject to and upon the terms and conditions set forth in
this Agreement, at the Closing, the Company shall issue and sell to each Purchaser, and each Purchaser shall, severally and not jointly,
purchase from the Company the number of Shares and Warrants indicated opposite such Purchaser&rsquo;s name on <FONT STYLE="font-variant: small-caps"><U>Exhibit
A</U></FONT> attached hereto (which, for avoidance of doubt, reflects Warrants to purchase 0.75 Warrant Shares for every one Share purchased
in the Closing), at a price per Share and accompanying Warrant equal to $0.90.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Closing</B>. </FONT>The sale and purchase of the Securities shall occur at a closing (the <B><I>&ldquo;Closing&rdquo;</I></B>)
to be held at the offices of Honigman LLP at 650 Trade Centre Way, Suite 200, Kalamazoo, Michigan 49002 at 10:00 a.m., local time, on
such date, or at such other time and place, upon which the Company and the Purchasers purchasing the Securities at the Closing shall agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Payment.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></B>At
the Closing, (a)&nbsp;each Purchaser purchasing the Securities shall pay to the Company such Purchaser&rsquo;s Subscription Amount
as indicated on <FONT STYLE="font-variant: small-caps"><U>Exhibit A</U></FONT> attached hereto in United States dollars and in
immediately available funds, by wire transfer to the account as set forth in instructions previously delivered to such Purchaser,
(b)&nbsp;the Company shall instruct the Transfer Agent to deliver shares to each Purchaser in book entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Promptly following the Closing, the Company shall deliver the Warrants to each Purchaser indicated opposite such Purchaser&rsquo;s
name on <FONT STYLE="font-variant: small-caps"><U>Exhibit A</U></FONT> attached hereto at the address set forth for such Purchaser on
the signature page hereto<FONT STYLE="font-variant: small-caps">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Deliveries.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT>The Company.</B> On or prior to the Closing, the Company shall deliver or cause to be delivered to each Purchaser a copy of this
Agreement duly executed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The Purchasers.</B> On or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></B>this
Agreement duly executed by such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>a fully completed and duly executed Accredited Investor Qualification Questionnaire in the form attached hereto as <FONT STYLE="font-variant: small-caps"><U>Exhibit
C</U></FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></B>a
fully completed and duly executed Bad Actor Questionnaire in the form attached hereto as <FONT STYLE="font-variant: small-caps"><U>Exhibit
D</U></FONT>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iv) </B>such
Purchaser&rsquo;s Subscription Amount as indicated on <FONT STYLE="font-variant: small-caps"><U>Exhibit A</U></FONT> attached hereto
by wire transfer to the account specified by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Closing Conditions.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></B>The
obligations of the Company hereunder with respect to any Purchaser in connection with the Closing are subject to the following
conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></B>the
accuracy in all material respects on the Closing of the representations and warranties of such Purchaser contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>all obligations, covenants and agreements of such Purchaser required to be performed at or prior to the Closing shall have
been performed in all material respects; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii) </B>the
delivery by such Purchaser of the items set forth in <U>Section&nbsp;2.4(b)</U> of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions
being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i) </B>the
representations and warranties made by the Company in <U>ARTICLE&nbsp;3</U> hereof qualified as to materiality shall be true and
correct as of the date hereof and the Closing, except to the extent any such representation or warranty expressly speaks as of an
earlier date, in which case such representation or warranty shall be true and correct as of such earlier date, and, the
representations and warranties made by the Company in <U>ARTICLE&nbsp;</U>3 hereof not qualified as to materiality shall be true and
correct in all material respects as of date hereof, except to the extent any such representation or warranty expressly speaks as of
an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier
date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing, whether under
this Agreement or the other Transaction Documents, shall have been performed in all material respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii) </B>the
delivery by the Company of the items set forth in <U>Section&nbsp;2.4(a)</U> of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iv) </B>the Company
shall have obtained any and all consents, permits, approvals, registrations and waivers necessary or appropriate for consummation of
the purchase and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Documents,
all of which shall be in full force and effect, except for such that could not reasonably be expected to have a Material Adverse
Effect; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(v) </B>no judgment,
writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or
judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been
instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the
other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE 3<U><BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby represents
and warrants to the Purchasers that, except as otherwise disclosed to the Purchasers or as disclosed in the SEC Reports:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Organization, Good Standing and Qualification.</FONT></B> The Company is a corporation duly
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate
power and authority to carry on its business as now conducted and to own its properties. The Company is duly qualified to do business
as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing
of property makes such qualification or leasing necessary unless the failure to so qualify has not had and could not reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">No Subsidiaries.</FONT></B> The Company does not presently own or control, directly or indirectly,
and has no stock or other interest as owner or principal in, any other corporation or partnership, joint venture, association or other
business venture or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Authorization; Enforcement.</FONT></B> The Company has all corporate right, power and authority
to enter into the Transaction Documents and to consummate the transactions contemplated hereby and thereby. All corporate action on the
part of the Company, its directors and stockholders necessary for the authorization, execution, delivery and performance of the Transaction
Documents by the Company, the authorization, sale, issuance and delivery of the Securities contemplated herein and the performance of
the Company&rsquo;s obligations hereunder and thereunder has been taken. The Transaction Documents have been (or upon delivery will have
been) duly executed and delivered by the Company and constitute the legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with their terms, except: (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar
as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Capitalization.</FONT></B> The authorized capital stock of the Company consists of: (a)
100,000,000 shares of the Common Stock, of which 26,321,750 shares were outstanding as of March 31, 2024 (prior to the issuance of the
Securities); and (b) 10,000,000 shares of the Company&rsquo;s preferred stock, $0.001 par value per share, none of which are issued and
outstanding as of the date hereof.&nbsp; All of the issued and outstanding shares of the Common Stock have been duly authorized and validly
issued and are fully paid and nonassessable.&nbsp;Except (i)&nbsp;for options to purchase Common Stock or other equity awards issued to
employees of the Company, consultants and service providers of the Company and members of the Board of Directors pursuant to the equity
compensation plans or arrangements disclosed in the SEC Reports, (ii)&nbsp;shares of capital stock issuable and reserved for issuance
pursuant to securities exercisable for, or convertible into or exchangeable for any shares of capital stock of the Company disclosed in
the SEC Reports, and (iii) as contemplated by this Agreement, as of the date hereof, there are no existing options, warrants, calls, preemptive
(or similar) rights, subscriptions or other rights, agreements, arrangements or commitments of any character obligating the Company to
issue, transfer or sell, or cause to be issued, transferred or sold, any shares of the capital stock of, or other equity interests in,
the Company or any securities convertible into or exchangeable for such shares of capital stock or other equity interests, and there are
no outstanding contractual obligations of the Company to repurchase, redeem or otherwise acquire any shares of its capital stock or other
equity interests.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Issuance; Reservation of Shares.</FONT></B> The issuance of the Securities has been duly
and validly authorized by all necessary corporate actions, and the Shares, when issued and paid for pursuant to this Agreement, and the
Warrant Shares, upon exercise of the Warrants in accordance with their terms, including the payment of any exercise price therefor, will
be validly issued, fully paid and non-assessable, and shall be free and clear of all encumbrances and restrictions (other than as provided
in the Transaction Documents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">No Conflicts.</FONT></B> The execution, delivery and performance of the Transaction Documents
by the Company and the issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the terms
and provisions of, or constitute a default under (i)&nbsp;the Company&rsquo;s Certificate of Incorporation or the Company&rsquo;s Amended
and Restated Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Purchasers
through the EDGAR system), (ii)&nbsp;any statute, rule, regulation or order of any governmental agency or body or any court, domestic
or foreign, having jurisdiction over the Company or any of its respective assets or properties, or (iii)&nbsp;any material agreement or
instrument to which the Company is a party or by which the Company is bound or to which any of their respective assets or properties is
subject, in each case except for any such conflict, breach, violation or default that would not reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Filings, Consents and Approvals.</FONT></B> The Company is not required to obtain any consent,
waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local
or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction
Documents, other than filings that have been made, or will be made, or consents that have been obtained, or will be obtained, pursuant
to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities laws which the Company undertakes
to file or obtain within the applicable time periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">SEC Reports.</FONT></B> The Company has filed all reports, schedules, forms, statements
and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to <U>Section&nbsp;13(a)</U>
or <U>15(d)</U> thereof, since October 1, 2021 (the foregoing materials, including the exhibits thereto and documents incorporated by
reference therein, being collectively referred to herein as the <B><I>&ldquo;SEC Reports&rdquo;</I></B>) or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates,
the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and
none of the SEC Reports, when filed (or amended), contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading. The Company has not received any letters of comment from the staff of the Commission that have not been satisfactorily
resolved as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Financial Statements. </FONT></B>The financial statements of the Company included in the
SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with
respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally
accepted accounting principles (<B><I>&ldquo;GAAP&rdquo;</I></B>), applied on a consistent basis during the periods involved, except as
may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain
all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company as of and for the dates
thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><FONT STYLE="font-variant: small-caps">Certificates, Authorities and Permits.</FONT></B> The Company is operating in compliance
in all material respects with, all registrations, approvals, certificates, authorizations and permits of any governmental authority or
self-regulatory body required for the conduct of its business as described in the SEC Reports, including without limitation, all such
registrations, approvals, certificates, authorizations and permits required by the FDA or any other federal, state, local or foreign agencies
or bodies engaged in the regulation of pharmaceuticals or biohazardous substances or materials; and the Company has not received notice
of any revocation or modification of any such registration, approval, certificate, authorization and permit or has reason to believe that
any such registration, approval, certificate, authorization and permit will not be renewed in the ordinary course that could lead to,
the withdrawal, revocation, suspension, modification or termination of any such registration, approval, certificate, authorization or
permit, which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, could result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><FONT STYLE="font-variant: small-caps">Title to Assets.</FONT></B> The Company has good and marketable title to all property (whether
real or personal) described in the SEC Reports as being owned by it, in each case free and clear of all liens, claims, security interests,
other encumbrances or defects except as described in the SEC Reports, and except those that could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. The property held under lease by the Company is held under valid, subsisting
and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any material respect with
the conduct of the business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.12 <FONT STYLE="font-variant: small-caps">Intellectual
Property.</FONT></B> The Company owns, possesses, or can acquire on reasonable terms, all Intellectual Property necessary for the
conduct of its business as now conducted or as described in the SEC Reports to be conducted in all material respects, except as such
failure to own, possess, or acquire such rights would not have a Material Adverse Effect. Except as set forth in the SEC Reports,
(A)&nbsp;to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any such
Intellectual Property, except as such infringement, misappropriation or violation would not have a Material Adverse Effect;
(B)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging
the Company&rsquo;s rights in or to any such Intellectual Property, and the Company is unaware of any material facts which would
form a reasonable basis for any such claim; (C)&nbsp;the Intellectual Property owned by the Company, and to the knowledge of the
Company, the Intellectual Property licensed to the Company, have not been adjudged invalid or unenforceable, in whole or in part,
and there is no pending or threatened action, suit, proceeding or claim by others challenging the validity or scope of any such
Intellectual Property, and the Company is unaware of any material facts which would form a reasonable basis for any such claim;
(D)&nbsp;to the Company&rsquo;s knowledge, there is no pending or threatened action, suit, proceeding or claim by others that the
Company infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, the
Company has not received any written notice of such claim and the Company is unaware of any other material fact which would form a
reasonable basis for any such claim; and (E)&nbsp;to the Company&rsquo;s knowledge, no Company employee is obligated under any
contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or
order of any court or administrative agency, that would interfere with the use of such employee&rsquo;s best efforts to promote the
interest of the Company or that would conflict with the Company&rsquo;s business; none of the execution and delivery of this
Agreement, the carrying on of the Company&rsquo;s business by the employees of the Company, and the conduct of the Company&rsquo;s
business as proposed, will conflict with or result in a breach of terms, conditions, or provisions of, or constitute a default
under, any contract, covenant or instrument under which any such employee is now obligated; and it is not and will not be necessary
to use any inventions, trade secrets or proprietary information of any of its consultants, or its employees (or Persons it currently
intends to hire) made prior to their employment by the Company, except for technology that is licensed to or owned by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.13 <FONT STYLE="font-variant: small-caps">No
General Solicitation or General Advertising.</FONT></B> Neither the Company nor any Person acting on its behalf has conducted any
general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of
the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.14 <FONT STYLE="font-variant: small-caps">No
Integrated Offering. </FONT></B>Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under
circumstances that would adversely affect reliance by the Company on Section 4(a)(2) for the exemption from registration for the
transactions contemplated hereby or would require registration of the Shares under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.15 <FONT STYLE="font-variant: small-caps">Private
Placement. </FONT></B> Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in <U>ARTICLE&nbsp;4</U>,
no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.16 <FONT STYLE="font-variant: small-caps">Investment
Company.</FONT></B> The Company is not and, after giving effect to the offering and sale of the Securities, will not be an
&ldquo;investment company,&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.17 <FONT STYLE="font-variant: small-caps">Foreign
Corrupt Practices.</FONT></B> The Company, nor, to the best knowledge of the Company, any director, officer, agent, employee or
other Person associated with or acting on behalf of the Company has (A) used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expense relating to political activity; (B) made any direct or indirect unlawful payment to
any foreign or domestic government official or employee from corporate funds; (C) violated or is in violation of any provision of
the Foreign Corrupt Practices Act of 1977; or (D) made any bribe, rebate, payoff, influence payment, kickback or other unlawful
payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE 4<U><BR>
REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Purchaser, for itself
and for no other Purchaser, hereby represents and warrants to the Company as follows (unless as of a specific date therein) as of the
date hereof and as of the date of the Closing in which such Purchaser purchases the Securities from the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Organization; Authority.</FONT></B> Such Purchaser is either an individual or an entity
duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation
with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the
transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution
and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents
have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the
part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered
by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable
against it in accordance with its terms, except: (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar
as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Purchaser Status. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a) </B>At the time
such Purchaser was offered the Securities, it was, and as of the date hereof it is, and each date on which such Purchaser exercises
the Warrants the Purchaser will be, an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501 under the Securities Act. Such
Purchaser is not a broker-dealer registered under Section&nbsp;15 of the Exchange Act. Such Purchaser is acting alone in its
determination as to whether to invest in the Securities. Such Purchaser is not a party to any voting agreements or similar
arrangements with respect to the Securities. Except as expressly disclosed in a Schedule 13D or Schedule 13G (or amendments thereto)
filed by such Purchaser with the Commission with respect to the beneficial ownership of the Company&rsquo;s Common Stock, such
Purchaser is not a member of a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding,
voting or disposing of the Securities. Each Purchaser represents and warrants that it (i) is not and will not become a party to (A)
any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any Person as to how such
Person, if serving as a director or if elected as a director of the Corporation, will act or vote on any issue or question (a <B><I>&ldquo;Voting
Commitment&rdquo;</I></B>) or (B) any Voting Commitment that could limit or interfere with such Person&rsquo;s ability to comply, if
serving as or elected as a director of the Company, with such Person&rsquo;s fiduciary duties under applicable law; (ii) is not and
will not become a party to any agreement, arrangement or understanding with any Person other than the corporation with respect to
any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Each Purchaser has disclosed in writing to the Company a description of all Derivative Transactions (as defined below) by each
such Purchaser in effect as of the date hereof, including the date of the transactions and the class, series and number of securities
involved in, and the material economic terms of, such Derivative Transactions. For purposes of this Agreement, a <B><I>&ldquo;Derivative
Transaction&rdquo;</I></B> means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit
of, any Purchaser or any of its affiliates or associates, whether record or beneficial: (w) the value of which is derived in whole or
in part from the value of any class or series of shares or other securities of the Company, (x) which otherwise provides any direct or
indirect opportunity to gain or share in any gain derived from a change in the value of securities of the Company, (y) the effect or intent
of which is to mitigate loss, manage risk or benefit of security value or price changes, or (z) which provides the right to vote or increase
or decrease the voting power of, such Purchaser, or any of its affiliates or associates, with respect to any securities of the Company,
which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond,
convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related
fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or
series), and any proportionate interest of such Purchaser in the securities of the Company held by any general or limited partnership,
or any limited liability company, of which such Purchaser is, directly or indirectly, a general partner or managing member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">General Solicitation; Pre-Existing Relationship.</FONT></B> Such Purchaser is not purchasing
the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper,
magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general
advertisement. Such Purchaser also represents that such Purchaser was contacted regarding the sale of the Securities by the Company (or
an authorized agent or representative thereof) with which such Purchaser had a prior substantial pre-existing relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Purchase Entirely for Own Account.</FONT></B> The Securities to be received by such Purchaser
hereunder will be acquired for such Purchaser&rsquo;s own account, not as nominee or agent, and not with a view to the resale or distribution
of any part thereof in violation of the Securities Act, and such Purchaser has no present intention of selling, granting any participation
in, or otherwise distributing the same in violation of the Securities Act without prejudice, however, to such Purchaser&rsquo;s right
at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities
laws. Nothing contained herein shall be deemed a representation or warranty by such Purchaser to hold the Securities for any period of
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Experience of Such Purchaser.</FONT></B> Such Purchaser, either alone or together with its
representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating
the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such
Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete
loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Disclosure of Information.</FONT></B> Such Purchaser has had an opportunity to receive all
information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company,
its business and the terms and conditions of the offering of the Securities. Such Purchaser acknowledges receipt of copies of the SEC
Reports (or access thereto via EDGAR). Neither such inquiries nor any other due diligence investigation conducted by such Purchaser shall
modify, limit or otherwise affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations and warranties contained
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Restricted Securities. </FONT></B>Such Purchaser understands that the Securities are &ldquo;restricted
securities&rdquo; and have not been registered under the Securities Act and may not be offered, resold, pledged or otherwise transferred
except (i)&nbsp;pursuant to an exemption from registration under the Securities Act or pursuant to an effective registration statement
in compliance with Section&nbsp;5 under the Securities Act and (ii)&nbsp;in accordance with all applicable securities laws of the states
of the United States and other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Commissions.</FONT></B> No Person will have, as a result of the transactions contemplated
by the Transaction Documents, any valid right, interest or claim against the Company or upon any Purchaser for any commission, fee or
other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Bad Actor. </FONT></B>Such Purchaser hereby represents that neither such Purchaser nor any
of its Rule 506(d) Related Parties is a &ldquo;bad actor&rdquo; within the meaning of Rule 506(d) promulgated under the Securities Act.
For purposes of this Agreement, &ldquo;Rule 506(d) Related Party&rdquo; shall mean a person or entity covered by the &ldquo;Bad Actor
disqualification&rdquo; provision of Rule 506(d) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE 5<U><BR>
REGISTRATION RIGHTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Registration Statement. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>On or prior to the thirtieth (30<SUP>th</SUP>) day following the Closing under this Agreement, the Company shall prepare and
file with the Commission a Registration Statement covering the resale of all Registrable Securities for an offering to be made on a continuous
basis pursuant to Rule 415. The Registration Statement shall be on Form S-3 (except if the Company is not then eligible to register for
resale all of the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance
with the Securities Act). Notwithstanding any other provision of this <U>ARTICLE 5</U>: (i) if the staff of the Commission does not permit
all of the Registrable Securities to be registered on the initial Registration Statement filed pursuant to this <U>Section 5.1(a)</U>
(the <B><I>&ldquo;Initial Registration Statement&rdquo;</I></B>), unless otherwise directed in writing by a Purchaser as to its Registrable
Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced by Registrable Securities
represented by the Shares and Warrant Shares (applied, in the case that some Shares and Warrant Shares may be registered, to the Purchasers
on a <I>pro rata</I> basis based on the total number of unregistered Shares and Warrant Shares held by such Purchasers, subject to a determination
by the Commission that certain Purchasers must be reduced first based on the number of Shares and Warrant Shares held by such Purchasers);
and (ii) in the event the Company amends the Initial Registration Statement to effect the reduction contemplated under clause (i) above,
the Company shall file with the Commission, as promptly as allowed by the Commission or one or more registration statements on Form S-3
or such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration
Statement, as so amended (each, an <B><I>&ldquo;Additional Registration Statement&rdquo;</I></B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>The Company shall use its commercially reasonable best efforts to cause each Registration Statement to be declared effective
by the Commission as promptly as possible after the filing thereof, and shall use commercially reasonable best efforts to keep the Registration
Statement continuously effective under the Securities Act until the earlier of (i) the date that all Registrable Securities covered by
such Registration Statement have been sold or can be sold publicly pursuant to Rule 144 without volume or manner of sale restrictions
or (ii) the date that is one year following the Effective Date (the <B><I>&ldquo;Effectiveness Period&rdquo;</I></B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Notwithstanding anything in this Agreement to the contrary, the Company may, by written notice to the Purchasers, suspend sales
under a Registration Statement after the Effective Date thereof and/or require that the Purchasers immediately cease the sale of shares
of Common Stock pursuant thereto and/or defer the filing of any Additional Registration Statement if the Company is engaged in a material
merger, acquisition or sale or any other material pending development and the Board of Directors determines in good faith, by appropriate
resolutions, that, as a result of such activity, it would be materially detrimental to the Company to maintain a Registration Statement
at such time. Upon receipt of such notice, each Purchaser agrees to immediately discontinue any sales of Registrable Securities pursuant
to such Registration Statement until such Purchaser is advised in writing by the Company that the current Prospectus or amended Prospectus,
as applicable, may be used. In no event, however, shall this right be exercised to suspend sales beyond the period during which (in the
good faith determination of the Board of Directors) the failure to require such suspension would be materially detrimental to the Company.
The Company&rsquo;s rights under this <U>Section 5.1(c)</U> may be exercised for a period of no more than thirty (30) consecutive Trading
Days and not more than three times in any twelve-month period. Immediately after the end of any suspension period under this <U>Section
5.1(c)</U> during the Effectiveness Period, the Company shall take all necessary actions (including filing any required supplemental prospectus)
to restore the effectiveness of the applicable Registration Statement and the ability of the Purchasers to publicly resell their Registrable
Securities pursuant to such effective Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Registration Procedures.</FONT></B> In connection with the Company&rsquo;s registration
obligations hereunder, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>(i) Subject to <U>Section 5.1(c)</U>, prepare and file with the Commission such amendments, including post-effective amendments,
to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement
continuously effective, as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission
such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; and
(ii) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect to the disposition of
all Registrable Securities covered by the Registration Statement during the applicable period in accordance with the intended methods
of disposition by the Purchasers thereof set forth in the Registration Statement as so amended or in such Prospectus as so supplemented;
<U>provided</U>, <U>however</U>, that, subject to applicable requirements, each Purchaser shall be responsible for the delivery of the
Prospectus to the Persons to whom such Purchaser sells any of the Securities (including in accordance with Rule 172 under the Securities
Act), and each Purchaser agrees to dispose of Registrable Securities in compliance with the plan of distribution described in the Registration
Statement and otherwise in compliance with applicable federal and state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Notify the Purchasers as promptly as reasonably possible, and if requested by the Purchasers, confirm such notice in writing
no later than ten (10) Trading Days thereafter, of any of the following events: (i) any Registration Statement or any post-effective amendment
is declared effective; (ii) the Commission issues any stop order suspending the effectiveness of any Registration Statement or initiates
any Proceedings for that purpose; or (iii) the Company receives notice of any suspension of the qualification or exemption from qualification
of any Registrable Securities for sale in any jurisdiction, or the initiation or threat of any Proceeding for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Use commercially reasonable best efforts to avoid the issuance of or, if issued, obtain the withdrawal of (i) any order suspending
the effectiveness of any Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any
of the Registrable Securities for sale in any jurisdiction, as soon as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>If requested by a Purchaser, provide such Purchaser, without charge, at least one (1) conformed copy of each Registration Statement
and each amendment thereto, including financial statements and schedules, and all exhibits to the extent requested by such Person (including
those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; <I>provided</I>,
that the Company shall have no obligation to provide any document pursuant to this clause that is available on the Commission&rsquo;s
EDGAR system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Promptly deliver to each Purchaser, without charge, as many copies of the Prospectus or Prospectuses (including each form of
prospectus) and each amendment or supplement thereto as such Persons may reasonably request. The Company hereby consents to the use of
such Prospectus and each amendment or supplement thereto by each of the selling Purchasers in connection with the offering and sale of
the Registrable Securities covered by such Prospectus and any amendment or supplement thereto to the extent permitted by federal and state
securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Prior to any resale of Registrable Securities by a Purchaser, use commercially reasonable best efforts to register or qualify
or cooperate with the selling Purchasers in connection with the registration or qualification (or exemption from such registration or
qualification) of such Registrable Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions within the
United States as any Purchaser requests in writing, to keep each such registration or qualification (or exemption therefrom) effective
for so long as required, but not to exceed the duration of the Effectiveness Period, and to do any and all other acts or things reasonably
necessary or advisable to enable the disposition in such jurisdictions of the Registrable Securities covered by a Registration Statement;
<U>provided</U>, <U>however</U>, that the Company shall not be obligated to file any general consent to service of process or to qualify
as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation
in respect of doing business in any jurisdiction in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement
with respect to the Registrable Securities of any particular Purchaser that such Purchaser furnish to the Company a completed Selling
Stockholder Questionnaire in the form attached hereto as <FONT STYLE="font-variant: small-caps"><U>Exhibit E</U></FONT> (the <B><I>&ldquo;Selling
Stockholder Questionnaire&rdquo;</I></B>) and such other information regarding itself, the Registrable Securities and other shares of
Common Stock held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required
to effect the registration of such Registrable Securities and shall complete and execute such documents in connection with such registration
as the Company may reasonably request, except in the case of any such information referred to in this paragraph, to the extent the failure
to provide such information does not materially affect the Company&rsquo;s ability to comply with such obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>The Company shall comply with all applicable rules and regulations of the Commission under the Securities Act and the Exchange
Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or amendment
thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Purchasers in writing if, at any time
during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Purchasers
are required to make available a Prospectus in connection with any disposition of Registrable Securities and take such other actions as
may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Registration Expenses. </FONT></B> The Company shall pay all fees and expenses incident
to the performance of or compliance with <U>ARTICLE 5</U> of this Agreement by the Company, including without limitation (a) all registration
and filing fees and expenses, including without limitation those related to filings with the Commission, any Trading Market, and in connection
with applicable state securities or Blue Sky laws, (b) printing expenses (including without limitation expenses of printing certificates
for Registrable Securities), (c) messenger, telephone and delivery expenses, (d) fees and disbursements of counsel for the Company and
(e) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated
by this Agreement. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Purchaser
or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Indemnification. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Indemnification by the Company.</B> The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless
each Purchaser, the officers, directors, partners, members, agents and employees of each of them, each Person who controls any such Purchaser
(within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, partners, members,
agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all
Losses, as incurred, arising out of or relating to any violation or alleged violation by the Company of the Securities Act, the Exchange
Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer
or sale of the Registrable Securities, any untrue or alleged untrue statement of a material fact contained in the Registration Statement,
any Prospectus or in any amendment or supplement thereto, or arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or
supplement thereto, in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the
extent, that (A) such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding
such Purchaser furnished in writing to the Company by such Purchaser for use therein, or to the extent that such information relates to
such Purchaser or such Purchaser&rsquo;s proposed method of distribution of Registrable Securities and was reviewed and expressly approved
by such Purchaser expressly for use in the Registration Statement, or (B) with respect to any Prospectus, if the untrue statement or omission
of material fact contained in such Prospectus was corrected on a timely basis in the Prospectus, as then amended or supplemented, if such
corrected prospectus was timely made available by the Company to the Purchaser, and the Purchaser seeking indemnity hereunder was advised
in writing not to use the incorrect prospectus prior to the use giving rise to Losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Indemnification by Purchasers.</B> Each Purchaser shall, severally and not jointly, indemnify and hold harmless the Company, its
directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act
and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent
permitted by applicable law, from and against all Losses (as determined by a court of competent jurisdiction in a final judgment not subject
to appeal or review) arising solely out of any untrue statement of a material fact contained in the Registration Statement, any Prospectus,
or any form of prospectus, or in any amendment or supplement thereto, or arising out of or relating to any omission of a material fact
required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement
thereto, in the light of the circumstances under which they were made) not misleading, but only to the extent that such untrue statement
or omission is contained in any information so furnished by such Purchaser in writing to the Company specifically for inclusion in such
Registration Statement or such Prospectus or to the extent that (i) such untrue statements or omissions are based solely upon information
regarding such Purchaser furnished to the Company by such Purchaser in writing expressly for use in the Registration Statement or Prospectus,
or to the extent that such information relates to such Purchaser or such Purchaser&rsquo;s proposed method of distribution of Registrable
Securities and was reviewed and expressly approved by such Purchaser expressly for use in the Registration Statement, such Prospectus
or such form of Prospectus or in any amendment or supplement thereto. In no event shall the liability of any selling Purchaser hereunder
be greater in amount than the dollar amount of the net proceeds received by such Purchaser upon the sale of the Registrable Securities
giving rise to such indemnification obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Conduct of Indemnification Proceedings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an <B><I>&ldquo;Indemnified
Party&rdquo;</I></B>), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the <B><I>&ldquo;Indemnifying
Party&rdquo;</I></B>) in writing, and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably
satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof; provided,
that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities
pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which
determination is not subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced
the Indemnifying Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the Indemnifying
Party has agreed in writing to pay such fees and expenses; or (ii) the Indemnifying Party shall have failed within fifteen (15) days of
receiving notification of a Proceeding from an Indemnified Party to assume the defense of such Proceeding and to employ counsel reasonably
satisfactory to such Indemnified Party in any such Proceeding; (iii) any counsel engaged by the applicable Indemnifying Party shall fail
to timely commence or diligently conduct the defense of any such claim and such failure has materially prejudiced (or, in the reasonable
judgment of the Indemnified Party, is in danger of materially prejudicing) the outcome of the applicable claim; or (iv) such Indemnified
Party shall have been advised by counsel that a conflict of interest is likely to or may exist between the applicable Indemnifying Party
and Indemnified Party or that there may be one or more different or additional defenses, claims, counterclaims or causes of action available
to such Indemnified Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ
separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof
and the reasonable fees and expenses of separate counsel shall be at the expense of the Indemnifying Party). It being understood, however,
that the Indemnifying Party shall not, in connection with any one such Proceeding (including separate Proceedings that have been or will
be consolidated before a single judge) be liable for the fees and expenses of more than one separate firm of attorneys at any time for
all Indemnified Parties, which firm shall be appointed by a majority of the Indemnified Parties. The Indemnifying Party shall not be liable
for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying
Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of
which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability
on claims that are the subject matter of such Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT></B>All reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in
connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to
the Indemnified Party, as incurred, within twenty (20) Trading Days of written notice thereof to the Indemnifying Party (regardless of
whether it is ultimately determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying
Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined
(not subject to appeal) that such Indemnified Party is not entitled to indemnification hereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Contribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>If a claim for indemnification under <U>Section 5.4(a)</U> or (<U>b)</U> is unavailable to an Indemnified Party (by reason
of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the
amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative
fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses
as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined
by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact
or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying
Party or Indemnified Party, and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent
such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject
to the limitations set forth in <U>Section 5.4(c)</U>, any reasonable attorneys&rsquo; or other reasonable fees or expenses incurred by
such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification
provided for in this Section was available to such party in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>The parties hereto agree that it would not be just and equitable if contribution pursuant to this <U>Section 5.4(d)</U> were
determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to in the immediately preceding paragraph. Notwithstanding the provisions of this <U>Section 5.4(d)</U>, no Purchaser shall be required
to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Purchaser from the
sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Purchaser has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT></B>The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying
Parties may have to the Indemnified Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Dispositions.</FONT></B> Each Purchaser agrees that it will comply with the prospectus delivery
requirements of the Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration
Statement. Each Purchaser further agrees that, upon receipt of a request from the Company, such Purchaser will discontinue disposition
of such Registrable Securities under the Registration Statement until such Purchaser is advised in writing by the Company that the use
of the Prospectus, or amended Prospectus, as applicable, may be used. The Company may provide appropriate stop orders to enforce the provisions
of this paragraph. Each Purchaser, severally and not jointly with the other Purchasers, agrees that the removal of the restrictive legend
from certificates representing Securities is predicated upon the Company&rsquo;s reliance that the Purchaser will comply with the provisions
of this subsection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Amendments; Waivers.</FONT></B> Notwithstanding anything in this Agreement to the contrary,
the provisions of this <U>ARTICLE 5</U> may be amended or waived (either generally or in a particular instance, either retroactively or
prospectively and either for a specified period of time or indefinitely), with the written consent of (i) the Company and (ii) the Purchaser
or Purchasers holding at least a majority of the then outstanding Registrable Securities. Notwithstanding the foregoing, a waiver or consent
to depart from the provisions of this <U>ARTICLE 5</U> with respect to a matter that relates exclusively to the rights of Purchasers and
that does not directly or indirectly affect the rights of other Purchasers may be given by Purchasers of all of the Registrable Securities
to which such waiver or consent relates; <U>provided</U>, <U>however</U>, that the provisions of this sentence may not be amended, modified
or supplemented except in accordance with the provisions of the immediately preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE 6<U><BR>
OTHER AGREEMENTS OF THE PARTIES</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Transfer Restrictions.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer
of Securities other than pursuant to an effective registration statement under the Securities Act or Rule 144, to the Company or to an
Affiliate of a Purchaser, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company,
to the effect that such transfer does not require registration of such transferred Securities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>The Purchasers agree to the imprinting, so long as is required by this <U>Section 6.1</U>, of a legend on any of the Securities
in substantially the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES
ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED
EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION
OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE
PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT
THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS SECURITY
IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN A SECURITIES PURCHASE AGREEMENT, DATED AS OF AUGUST 1, 2024 AND AS AMENDED
FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Confidentiality.</FONT></B> Each Purchaser, severally and not jointly with the other Purchasers,
covenants that such Purchaser (i) has maintained the confidentiality of all disclosures of Confidential Information made to it (including
information disclosed by any of the Company&rsquo;s officers, directors, employees, consultants or agents, including legal counsel) in
connection with this transaction (including the existence and terms of this transaction), whether in oral, written, graphic, electronic
or other form, which shall be deemed to be &ldquo;<B><I>Confidential Information</I></B>&rdquo;, (ii) will maintain the confidentiality
of all Confidential Information (including information disclosed by any of the Company&rsquo;s officers, directors, employees, consultants
or agents, including legal counsel), except that such Purchaser may disclose the terms to its financial, accounting, legal and other advisors,
and (iii) shall have a duty of confidentiality to the Company not to trade on the basis of, any material, non-public Confidential Information
that it has received from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Use of Proceeds.</FONT></B> The Company shall use the net proceeds from the sale of the
Securities hereunder for funding operations or for working capital or other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Form D; Blue Sky Filings.</FONT></B> The Company agrees to timely file a Form D with respect
to the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall
take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities
for, sale to the Purchasers at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States,
and shall provide evidence of such actions promptly upon request of any Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Acknowledgment of Dilution.</FONT></B> The Company acknowledges that the issuance of the
Securities may result in dilution of the outstanding shares of the Common Stock, which dilution may be substantial under certain market
conditions. The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its
obligation to issue the Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set
off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser
and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Reserved.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE 7<U><BR>
TERMINATION</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Termination.</FONT></B> The obligations of the Company, on the one hand, and the Purchasers,
on the other hand, to effect the Closing shall terminate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Upon the mutual written consent of the Company and the Purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>By the Company if any of the conditions set forth in <U>Section&nbsp;2.5(a)</U> shall have become incapable of fulfillment,
and shall not have been waived by the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>By a Purchaser (with respect to itself only) if any of the conditions set forth in <U>Section&nbsp;2.5(b)</U> shall have become
incapable of fulfillment, and shall not have been waived by such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Notice of Termination; Effect of Termination.</FONT></B> In the event of termination by
the Company or any Purchaser of its obligations to effect the Closing pursuant to this <U>ARTICLE&nbsp;7</U>, written notice thereof shall
forthwith be given to the other Purchasers by the Company and the other Purchasers shall have the right to terminate their obligations
to effect the Closing upon written notice to the Company and the other Purchasers. Nothing in this <U>ARTICLE&nbsp;7</U> shall be deemed
to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction
Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement
or the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE 8<U><BR>
MISCELLANEOUS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Fees and Expenses.</FONT></B> Each Purchaser and the Company shall pay its own respective
costs and expenses in connection the Transaction Documents and the transactions contemplated hereby and thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Entire Agreement.</FONT></B> The Transaction Documents, together with the exhibits and schedules
thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute
and deliver to the other such further documents as may be reasonably requested in order to give practical effect to the intention of the
parties under the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Notices.</FONT></B> Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the time of
transmission, if such notice or communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day,
(b) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that
is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (b) the Trading Day following the date of mailing,
if sent by nationally recognized overnight courier service specifying next business day delivery, or (d) upon actual receipt by the Person
to whom such notice is required to be given, if by hand delivery. The address for such notices and communications shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>if to the Company, to NeuroOne Medical Technologies Corporation, 7599 Anagram Dr., Eden Prairie, Minnesota 55344, Attention:
Chief Executive Officer, daver@nmtc1.com, with a copy to Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, Michigan 49002, Attention:
Phillip D. Torrence, ptorrence@honigman.com; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>if to the Purchasers, to their respective addresses or e-mail addresses as set forth on the signature page hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Amendments; Waivers.</FONT></B> No provision of this Agreement may be waived or amended
except in a written instrument signed by the Company; provided that such written instrument for such waiver or amendment is also signed
by the Principal Purchasers if, and only if, in the reasonable and good faith determination of the Principal Purchasers, such waiver or
amendment would reasonably be expected to be adverse to the interests of any Purchaser in a more than <I>de minimis</I> way or that would
reasonably be expected to have more than a <I>de minimis</I> adverse effect on the value of such Purchaser&rsquo;s investment in the Securities.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration
shall be offered or paid to any Purchaser to amend or consent to a waiver or modification of any provision of any Transaction Document
unless the same consideration is also offered to all of the Purchasers who then hold the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Headings. </FONT></B> The headings herein are for convenience only, do not constitute a
part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Successors and Assigns.</FONT></B> This Agreement shall be binding upon and inure to the
benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations
hereunder without the prior written consent of each Purchaser. With the consent of the Company which will not be unreasonably withheld,
any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities,
<U>provided</U>, that a Purchaser may assign any or all rights under this Agreement to an Affiliate of such Purchaser without the consent
of the Company, and <U>provided</U>, <U>further</U>: (i)&nbsp;such transferor agrees in writing with the transferee or assignee to assign
such rights, and a copy of such agreement is furnished to the Company after such assignment; (ii)&nbsp;the Company is furnished with written
notice of (x)&nbsp;the name and address of such transferee or assignee and (y)&nbsp;if the transferor is assigning any registration rights
under <U>ARTICLE 5</U> hereof, the Registrable Securities with respect to which such registration rights are being transferred or assigned;
(iii)&nbsp;following such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted
under the Securities Act and applicable state securities laws, unless such disposition was made pursuant to an effective registration
statement or an exemption under Rule 144 under the Securities Act; (iv)&nbsp;such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers&rdquo;; and (v)&nbsp;such
transfer shall have been made in accordance with the applicable requirements of this Agreement and with all laws applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">No Third-Party Beneficiaries.</FONT></B> This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and, except as provided in the immediately preceding sentence, is
not for the benefit of, nor may any provision hereof be enforced by, any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Governing Law; Jurisdiction.</FONT></B> This Agreement shall be governed by, and construed
in accordance with, the internal laws of the State of Delaware without regard to the choice of law principles thereof. Each of the parties
hereto irrevocably submits to the exclusive jurisdiction of the state and federal courts located in the State of Delaware for the purpose
of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service
of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same
methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction
of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives
any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that
any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>WAIVER OF JURY TRIAL.</B> IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><FONT STYLE="font-variant: small-caps">Survival.</FONT></B> The representations and warranties of the Company contained herein
shall survive the Closing for a period of six (6) months. The representations and warranties of the Purchasers shall survive the Closing
indefinitely. Notwithstanding anything in this Agreement to the contrary, no Purchaser shall have any claim for a breach of any representation
or warranty of the Company and each Purchaser shall be deemed to have waived and released any claims for such a breach if such Purchaser
had actual knowledge of the particular breach prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><FONT STYLE="font-variant: small-caps">Counterparts/Electronic Execution and Delivery.</FONT></B> This Agreement may be executed
in one or more counterparts and by facsimile, each of which shall constitute an original and all of which together shall constitute one
and the same instrument. Signatures of the parties transmitted by facsimile or via .pdf format shall be deemed to be their original signatures
for all purposes. The words &ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature,&rdquo; and words of like import shall be
deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect,
validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the
extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the
Delaware Uniform Electronic Transactions Act, the Minnesota Uniform Electronic Transactions Act, or any other similar state laws based
on the Uniform Electronic Transactions Act. This Agreement and any signed agreement or instrument entered into in connection with this
Agreement, and any amendments hereto or thereto, to the extent delivered by means of a facsimile machine or electronic mail (any such
delivery, an <B><I>&ldquo;Electronic Delivery&rdquo;</I></B>), will be treated in all manner and respects as an original agreement or
instrument and will be considered to have the same binding legal effect as if it were the original signed version thereof delivered in
person. At the request of any party hereto or to any such agreement or instrument, each other party hereto or thereto will re-execute
original forms thereof and deliver them to all other parties. No party hereto or to any such agreement or instrument will raise the use
of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated
through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense,
except to the extent such defense related to lack of authenticity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><FONT STYLE="font-variant: small-caps">Severability.</FONT></B> If any term, provision, covenant or restriction of this Agreement
is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants
and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and
the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially
the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><FONT STYLE="font-variant: small-caps">Remedies.</FONT></B> In addition to being entitled to exercise all rights provided herein
or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under
the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of
any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific
performance of any such obligation the defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><FONT STYLE="font-variant: small-caps">Independent Nature of Purchasers&rsquo; Obligations and Rights. </FONT></B> The obligations
of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser
shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction
Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereof or thereto,
shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create
a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions
contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including,
without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary
for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by
its own separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so
by any of the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><FONT STYLE="font-variant: small-caps">Adjustments in Share Numbers and Prices.</FONT></B> In the event of any stock split, subdivision,
dividend or distribution payable in shares of the Common Stock (or other securities or rights convertible into, or entitling the holder
thereof to receive directly or indirectly shares of the Common Stock), combination or other similar recapitalization or event occurring
after the date hereof, each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended
to appropriately account for such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signatures
on the Following Page</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT><B>,</B> the Company and each Purchaser have caused this Securities Purchase Agreement to be duly executed by
their respective authorized signatories as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; font-variant: small-caps">NeuroOne Medical Technologies Corporation</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page to Securities Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT><B>,</B> the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">NAME OF PURCHASER:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 14%">Subscription&nbsp;Amount:&nbsp;$</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 26%"></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">Number of shares of the Common Stock to<BR>
    be Acquired: <B><U>____________________________</U></B></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">Warrant Shares:<B><U>______________</U></B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 15%">SSN / Tax ID No.:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Address&nbsp;for&nbsp;Notice:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Telephone No.:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Facsimile No.:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>E-mail Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Attention:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">Delivery Instructions:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">(if different than above)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 6%">c/o</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 34%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Street:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%">City/State/Zip:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Attention:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Telephone&nbsp;No.:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-variant: small-caps">Signature
Page to Securities Purchase Agreement</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>ea021074001ex10-2_neuro.htm
<DESCRIPTION>LOAN AND SECURITY AGREEMENT WITH GROWTH OPPORTUNITIES FUNDING LLC, DATED AUGUST 2, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>LOAN AND SECURITY AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>THIS LOAN AND SECURITY AGREEMENT</B>
(this &ldquo;<U>Agreement</U>&rdquo;), dated August 2, 2024, is made by and between <FONT STYLE="font-variant: small-caps">Growth Opportunity
Funding, LLC</FONT>, a Delaware limited liability company (the &ldquo;<U>Lender</U>&rdquo;), and <FONT STYLE="font-variant: small-caps">NeuroOne
Medical Technologies Corporation</FONT>, a Delaware corporation (the &ldquo;<U>Borrower</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In consideration of the mutual
covenants and promises contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1. <U>Defined
Terms</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Defined
Terms</U>. As used in this Agreement, (a) the terms Account, Certificated Security, Chattel Paper, Commercial Tort Claim, Commodity Account,
Commodity Contract, Deposit Account, Document, Electronic Chattel Paper, Equipment, Financial Asset, Fixtures, General Intangibles, Goods,
Health-Care-Insurance Receivables, Instrument, Inventory, Investment Property, Letter-of-Credit Right, Money, Proceeds, Securities, Security
Entitlement, Securities Account, Software, Supporting Obligations and Uncertificated Security have the respective meanings assigned thereto
(or, if not so assigned, as used) in Article 8 or 9 of the UCC (as defined below) and (b) the following terms have the meanings specified
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<U>Business Day</U>&rdquo; means any day that is not a Saturday, Sunday or day on which banking
institutions in New York, New York are authorized or required by Law to close.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Change of Control</U>&rdquo; means an event or series of events by which any &ldquo;person&rdquo;
or &ldquo;group&rdquo; (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange
Act</U>&rdquo;)) becomes the &ldquo;beneficial owner&rdquo; (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or
indirectly, of equity interests in the Borrower representing more than 30% of the combined voting power of all equity interests in the
Borrower entitled to vote for members of the board of directors or equivalent governing body of the Borrower.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Debtor Relief Laws</U>&rdquo; means the Bankruptcy Code of the United States and all other liquidation,
conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization
and similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">&ldquo;<U>Default</U>&rdquo; means any event that, with the giving of any notice or passage of time, or
both, would be an Event of Default.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<U>FCPA</U>&rdquo; means the Foreign Corrupt Practices Act of&nbsp;1977.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">&ldquo;<U>GAAP</U>&rdquo; means generally accepted accounting principles in the United States set forth
from time to time in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public
Accountants and statements and pronouncements of the Financial Accounting Standards Board (or agencies with similar functions of comparable
stature and authority within the accounting profession) including, without limitation, the FASB Accounting Standards Codification, that
are applicable to the circumstances as of the date of determination, consistently applied.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Governmental Authority</U>&rdquo; means the government of the United States of America, or any
other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory
body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or
functions of or pertaining to government.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Intellectual Property</U>&rdquo; means, trade secrets and other proprietary information; customer
lists; trademarks, service marks, business names, trade names, Internet domain names, designs, logos, indicia and other source and business
identifiers and the goodwill of the business relating thereto and all registrations or applications for registrations that have heretofore
been or may hereafter be issued thereon; copyrights (including copyrights for computer programs) and copyright registrations or applications
for registrations that have heretofore been or may hereafter be issued and all tangible property embodying copyrights; unpatented inventions
(whether or not patentable); patent applications and patents; industrial designs, industrial design applications and registered industrial
designs; license agreements related to any of the foregoing and income therefrom; mask works, books, records, writings, information contained
on computer tapes or disks or other electronic media, flow diagrams, specification sheets, source codes, object codes and other physical
manifestations, embodiments or incorporations of any of the foregoing; the right to sue for all past, present and future infringements
of any of the foregoing; and all common law and other rights in and to all of the foregoing; in each of the foregoing cases whether now
existing or hereafter created or acquired and wherever located throughout the world.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ix)</TD><TD STYLE="text-align: justify">&ldquo;<U>Indebtedness</U>&rdquo; as to any Person means (a) all obligations of such Person for borrowed
money, (b) all obligations of such Person evidenced by bonds, debentures, notes, or other similar instruments and all reimbursement or
other obligations in respect of letters of credit, bankers acceptances, or other financial products, (c) with respect to any lease that
has been or is required to be, in accordance with GAAP, recorded as a capital or financing lease (excluding, for the avoidance of doubt,
an operating lease), the capitalized amount thereof that would appear on a balance sheet of such Person in accordance with GAAP, (d) all
obligations or liabilities of Indebtedness of others secured by a Lien on any asset of such Person, irrespective of whether such obligation
or liability is assumed, (e) all obligations of such Person to pay the deferred purchase price of assets (other than trade payables incurred
in the ordinary course of business and repayable in accordance with customary trade practices and not more than sixty (60) days past due),
(f) all monetary obligations of such Person owing under hedge agreements or similar instruments, (g) equity interests issued by such Person
that, by their terms (or by the terms of any security into which they are convertible or for which they are exchangeable), or upon the
happening of any event or condition (i) mature or are mandatorily redeemable, (ii) are redeemable at the option of the holder thereof
or (iii) provide for scheduled payments of dividends in cash, and (h) any obligation of such Person guaranteeing (whether directly or
indirectly guaranteed, endorsed, co-made, discounted, or sold with recourse) any obligation of any other Person that constitutes Indebtedness
under any of clauses (a) through (g) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">&ldquo;<U>Interest Payment Date</U>&rdquo; means each of the last Business Day of each month and the Maturity
Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xi)</TD><TD STYLE="text-align: justify">&ldquo;<U>Laws</U>&rdquo; means, collectively, all international, foreign, federal, state and local statutes,
treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation
or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all
applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental
Authority, in each case whether or not having the force of law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Lien</U>&rdquo; means any mortgage, pledge, hypothecation, collateral assignment, encumbrance,
lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement of any kind or nature
whatsoever (including any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title
to real property, and any deposit arrangement or financing lease having substantially the same economic effect as any of the foregoing).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xiii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Loan Documents</U>&rdquo; means, collectively, this Agreement, the Notes issued pursuant to
Section 2, that certain Fee Letter, dated as of the date hereof, by and between the Borrower and the Lender (the &ldquo;<U>Fee Letter</U>&rdquo;),
and all other certificates, agreements, documents and instruments executed and delivered, in each case, by or on behalf of the Borrower
pursuant to or in connection with the foregoing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xiv)</TD><TD STYLE="text-align: justify">&ldquo;<U>Material Adverse Effect</U>&rdquo; means (a) a material adverse change in, or a material adverse
effect on, the operations, business, properties, performance, credit standing, assets, liabilities (actual or contingent) or condition
(financial or otherwise) of the Borrower or any of its Subsidiaries; or (b) a material adverse effect on (i) the ability of the Borrower
to perform the Obligations, (ii) the legality, validity, binding effect or enforceability against the Borrower of any Obligation or (iii)
the rights, remedies and benefits available to, or conferred upon, the Lender under any Loan Document.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xv)</TD><TD STYLE="text-align: justify">&ldquo;<U>Monetization Event</U>&rdquo; means (a) one or more transactions (including, without limitation,
any capital raise, sale of securities), other financing, or the receipt of payments from Zimmer, Inc. or any of its affiliates under the
RF Agreement), with respect to which the Borrower receives or is entitled to receive cumulative cash proceeds in excess of $5,000,000
in the aggregate (excluding, for all purposes under this clause (a), the Private Placement described in Section 3(a)) or (b) a transaction in which the Borrower is sold to, merged with, consolidated or reorganized into or with, or all of
substantially all of its assets are transferred or sold to, another party. &ldquo;<U>RF Agreement</U>&rdquo; means that certain Exclusive
Development and Distribution Agreement executed by the Borrower and Zimmer, Inc. on or about July 20, 2020, as may be amended, modified,
supplemented or restated from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xvi)</TD><TD STYLE="text-align: justify">&ldquo;<U>Obligations</U>&rdquo; means all advances to, and debts, liabilities, obligations, covenants
and duties of, the Borrower arising under any Loan Document or otherwise with respect to any Loan, whether direct or indirect (including
those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest
and fees that accrue after the commencement of any proceeding under any Debtor Relief Laws, regardless of whether such interest and fees
are allowed or allowable claims in such proceeding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xvii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Permitted Liens</U>&rdquo; means (a) rights of setoff or bankers&rsquo; liens upon deposits of funds
in favor of banks or other depository institutions, solely to the extent incurred in connection with the maintenance of deposit accounts
in the ordinary course of business; (b) liens for unpaid taxes, assessments, or other governmental charges or levies that are not yet
delinquent or that are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect
thereto are maintained on the books of the Borrower in accordance with GAAP; (c) any interest or title of a lessor, sublessor, licensor
or sublicensor under leases or licenses permitted by this Agreement that are entered into in the ordinary course of business; (d) leases,
licenses, subleases or sublicenses granted to third Persons in the ordinary course of business that do not (i) interfere in any material
respect with the ordinary conduct of the business of the Borrower or (ii) secure any Indebtedness; and (e) Liens securing judgments for
the payment of money not constituting an Event of Default.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xviii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Person</U>&rdquo; means any natural person, corporation, limited liability company, trust, joint
venture, association, company, partnership, Governmental Authority or other entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xix)</TD><TD STYLE="text-align: justify">&ldquo;<U>OFAC</U>&rdquo; means the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets Control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xx)</TD><TD STYLE="text-align: justify">&ldquo;<U>Sanctions</U>&rdquo; means any economic or trade sanctions administered or enforced by OFAC,
the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury, or other relevant
sanctions authority.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xxi)</TD><TD STYLE="text-align: justify">&ldquo;<U>Subsidiary</U>&rdquo; of a Person means a corporation, partnership, limited liability company,
association, joint venture or other business entity of which a majority of the equity interests having ordinary voting power for the election
of directors or similar governing body (other than securities or interests having such power only by reason of the happening of a contingency)
are at the time owned or the management of which is controlled, directly, or indirectly through one or more intermediaries, by such Person.
Unless otherwise specified, all references herein to a &ldquo;Subsidiary&rdquo; or to &ldquo;Subsidiaries&rdquo; shall refer to a Subsidiary
or Subsidiaries of the Borrower.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xxii)</TD><TD STYLE="text-align: justify">&ldquo;<U>UCC</U>&rdquo; means the Uniform Commercial Code as in effect from time to time in the State
of New York; provided if perfection or the effect of perfection or non-perfection or the priority of the security interest in any Collateral
is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, &ldquo;<U>UCC</U>&rdquo; means
the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating to
such perfection, effect of perfection or non-perfection or priority.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Terms
Generally</U>. The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the
context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words &ldquo;include,&rdquo;
&ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation.&rdquo; The
word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word &ldquo;shall.&rdquo; The word &ldquo;or&rdquo;
is not exclusive. Unless the context requires otherwise (i) any definition of or reference to any agreement, instrument or other document
herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise
modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (ii) any reference herein to
any Person shall be construed to include such Person&rsquo;s successors and assigns (subject to any restrictions on assignment set forth
herein), (iii) the words &ldquo;herein,&rdquo; &ldquo;hereof&rdquo; and &ldquo;hereunder,&rdquo; and words of similar import, shall be
construed to refer to this Agreement in its entirety and not to any particular provision hereof, (iv) all references herein to Sections,
Exhibits and Schedules shall be construed to refer to Sections of, and Exhibits and Schedules to, this Agreement, (v) any reference to
any law or regulation herein shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from
time to time and (v) the words &ldquo;asset&rdquo; and &ldquo;property&rdquo; shall be construed to have the same meaning and effect and
to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2. <U>Loans</U>.</B>
Subject to the terms and conditions of this Agreement, and provided that no Event of Default (as defined below) has occurred, Lender agrees
to make during the period commencing on the date hereof and ending on the earlier of (x) the consummation of a Monetization Event or a
Change of Control, (y) the termination of such period pursuant to Section 9 and (z) November 30, 2024 (such period, the &ldquo;<U>Standby
Term</U>&rdquo;) one or more loans (the &ldquo;<U>Loans</U>&rdquo; and each a &ldquo;<U>Loan</U>&rdquo;) to the Borrower in an aggregate
amount of up to $3,000,000 (the &ldquo;<U>Term Loan Commitment</U>&rdquo;). Each Loan shall be in a minimum amount of $500,000 and increments
of $500,000 in excess thereof and shall be evidenced by a promissory note in substantially the form of <U>Exhibit A</U> hereto (each,
a &ldquo;<U>Note</U>&rdquo;). Lender will disburse the amount of each Loan made by it hereunder to the account of the Borrower specified
on <U>Exhibit B</U> no later than five (5) Business Days following the Borrower&rsquo;s delivery to the Lender of a written request for
such Loan in the form of <U>Exhibit C</U> (a &ldquo;<U>Draw Request</U>&rdquo;). This is not a revolving commitment and the Borrower shall
have no right to re-borrow any amounts repaid hereunder. For the avoidance of doubt, the Lender&rsquo;s obligation to make Loans shall
terminate at the end of the Standby Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3. <U>Conditions
Precedent</U>.</B> The obligation of the Lender to make any Loan is subject to the accuracy in all material respects on the date such
Loan is funded (each, a &ldquo;<U>Funding Date</U>&rdquo;) of all of the representations and warranties made by the Borrower herein or
in any other Loan Document, and to the satisfaction of the following additional conditions precedent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) In
the case of the initial Loan, (i) substantially concurrently with the execution of this Agreement, the Borrower has issued and sold to
one or more third parties common stock of the Borrower in a private placement for aggregate cash proceeds of at least $2,500,000 (such
issuance and sale, the &ldquo;<U>Private Placement</U>&rdquo;) and has received such proceeds; (ii) the Lender has &ldquo;control&rdquo;
(as defined in the UCC) over each Deposit Account, Securities Account, Security Entitlement, Commodity Account and Commodity Contract
included in the Collateral; and (iii) the Borrower shall have delivered to the Lender (A) copies or evidence of all insurance policies
of the Borrower, with appropriate loss payable endorsements in form and substance satisfactory to the Lender, naming the Lender as an
additional insured and mortgagee and/or lender loss payee (as applicable) as its interests may appear with respect to all insurance coverage
of the Borrower, and providing that (I) all proceeds thereunder shall, after the occurrence and during the continuance of an Event of
Default, be payable to the Lender, (II) no such insurance shall be affected by any act or neglect of the insured or owner of the property
described in such policy, and (III) that such policy and loss payable clauses may not be cancelled, amended or terminated unless at least
thirty (30) days prior written notice is given to the Lender (or in the case of nonpayment, at least ten (10) days prior written notice).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) No
Default or Event of Default has occurred and is continuing either before or immediately after giving effect to such Loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) The
Borrower has delivered to the Lender a duly executed Note in the amount of such Loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) The
Borrower has paid to the Lender all fees and expenses required to be paid by the Borrower hereunder or under the Fee Letter;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) The
Borrower has delivered to the Lender at least five (5) Business Days prior to the Funding Date a duly executed Draw Request for such Loan;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) The
principal amount of such Loan, together with the principal amount of all Loans previously made, will not exceed the amount of the Term
Loan Commitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4. <U>Loan
Payments and Interest</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Interest</U>.
Subject to clause (c) below, the outstanding principal amount of the Loans will bear interest at a rate of 10% per annum. Interest shall
be calculated on the basis of a 365-day year for the actual number of days elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Interest
Payment Dates</U>. Interest on each Loan shall be payable in arrears on each Interest Payment Date and at such other times as specified
herein; provided that (i) interest described in clause (c) of this Section shall be payable on demand and (ii) in the event of any repayment
or prepayment of any Loan, accrued interest on the principal amount of the Loans shall be payable on the date of such repayment or prepayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Default
Interest</U>. If all or any portion of the principal of any Loan is not paid when due, whether at stated maturity, by acceleration or
otherwise, such amount shall thereafter bear interest at a rate per annum equal to 15%. Upon the written request of the Lender, if an
Event of Default has occurred and is continuing, the outstanding principal amount of each Loan will bear interest at a rate per annum
equal to 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Fees</U>.
The Borrower shall pay to the Lender, as and when due and payable under the terms of the Fee Letter, the fees set forth in the Fee Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Prepayments</U>.
The Borrower may at any time and from time to time prepay the outstanding principal amount of the Loans, without premium or penalty, upon
not less than five (5) Business Days&rsquo; prior written notice to Lender. Upon the consummation of any Monetization Event or any Change
of Control, the Borrower shall prepay the outstanding principal amount of the Loans, together with accrued and unpaid interest thereon
and all other Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Maturity</U>.
On February 2, 2026 (the &ldquo;<U>Maturity Date</U>&rdquo;), the Loans shall mature, and all outstanding principal thereof and accrued
and unpaid interest thereon, and all other Obligations, shall become due and payable in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Payment
Requirements</U>. All payments made in respect of the Loans or otherwise hereunder and all cash fees payable pursuant to the Fee Letter
shall be made in immediately available funds in U.S. dollars no later than 1:00 pm (Eastern time) on the date such payments are to be
made (or, if such date is not a Business Day, on the next Business Day), to such account as may be specified by the Lender from time to
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5. <U>Security.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Grant
of Security Interest</U>. As security for the full, prompt and complete payment when due and performance by the Borrower of the Loans
and all other Obligations, the Borrower hereby pledges and grants to the Lender a continuing, first priority security interest (the &ldquo;<U>Security
Interest</U>&rdquo;) in and to all right, title and interest of the Borrower in and to the following, in each case whether now owned or
existing or hereafter acquired or arising, and wherever located (the &ldquo;<U>Collateral</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Accounts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Chattel Paper, including Electronic Chattel Paper;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Commercial Tort Claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">Deposit Accounts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">Documents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">Financial Assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">General Intangibles (including Software);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">Goods (including all its Equipment, Fixtures and Inventory), together with all embedded software, accessions,
additions, attachments, improvements, substitutions and replacements thereto and therefor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ix)</TD><TD STYLE="text-align: justify">Health-Care-Insurance Receivables;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">Instruments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xi)</TD><TD STYLE="text-align: justify">Intellectual Property;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xii)</TD><TD STYLE="text-align: justify">Investment Property (including Commodity Accounts, Commodity Contracts, Securities (whether Certificated
Securities or Uncertificated Securities), Security Entitlements and Securities Accounts);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xiii)</TD><TD STYLE="text-align: justify">Letter-of-Credit Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xiv)</TD><TD STYLE="text-align: justify">Money (of every jurisdiction whatsoever);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xv)</TD><TD STYLE="text-align: justify">Supporting Obligations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(xvi)</TD><TD STYLE="text-align: justify">to the extent not included in the foregoing, all other personal property of any kind or description;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">together with all books, records, writings,
data bases, information and other property relating to, used or useful in connection with, or evidencing, embodying, incorporating or
referring to any of the foregoing, all claims and insurance proceeds arising out of the loss, nonconformity or any interference with the
use of, or any defect or infringement of rights in, or damage to, any of the foregoing, and all Proceeds, products, offspring, rents,
issues, profits and returns of and from, and all distributions on and rights arising out of, any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notwithstanding anything contained herein
or in any other Loan Document to the contrary, the term &ldquo;Collateral&rdquo; shall not include, and the Borrower is not pledging or
granting any security interests hereunder in any of the following (collectively, &ldquo;<U>Excluded Assets</U>&rdquo;): (a) any of Borrower&rsquo;s
right, title or interest under any lease, license, contract or agreement and any property or assets subject to such lease, license, contract
or agreement, solely to the extent that such a grant would (1) under the express terms of such lease, license, contract or agreement,
result in a breach thereof or constitute a default thereunder or (2) violate any Law applicable thereto (including, in each case, any
requirement thereunder to obtain the consent or approval of any governmental or regulatory authority or any other Person (other than the
Borrower)), except to the extent that any such term or violation (x) has been waived (or such consent or approval has been obtained) or
(y) would be rendered ineffective pursuant to applicable anti-assignment provisions of the UCC or other applicable Law or principles of
equity; (b) any &ldquo;intent-to-use&rdquo; trademark for which a &ldquo;statement of use&rdquo; or an &ldquo;amendment to allege use&rdquo;
has not been filed with the U.S. Patent and Trademark Office, to the extent that, and solely during the period in which, the grant of
a security interest therein would impair the validity or enforceability of such intent-to-use trademark under applicable federal law or
(c) &ldquo;margin stock&rdquo; as defined under Regulation U of the Board of Governors of the U.S. Federal Reserve System; provided, that
&ldquo;Excluded Assets&rdquo; shall not include any Proceeds, products, substitutions or replacements of Excluded Assets unless such Proceeds,
products, substitutions or replacements would otherwise constitute Excluded Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Perfection;
Further Assurances</U>. The Borrower hereby:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">authorizes the Lender to file such financing statements and other documents (at the Borrower&rsquo;s sole
expense) and do such other acts and things, all as are necessary or as the Lender may from time to time reasonably request, to establish
and maintain a valid and perfected security interest in the Collateral (free of all other Liens, claims and rights of third parties whatsoever,
other than Permitted Liens) (and the Borrower further authorizes the Lender to file any financing statement that indicates the Collateral
as all assets of the Borrower or words of similar effect);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">authorizes the Lender to file any intellectual property security agreements and any other appropriate
instruments with appropriate Governmental Authorities, all as are necessary or as the Lender may from time to time reasonably deem desirable
to establish and maintain a valid and perfected security interest in the Collateral (free of all other Liens, claims and rights of third
parties, whatsoever, other than Permitted Liens); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">agrees to take all other action as the Lender may reasonably request, to perfect and maintain the first
priority of the Security Interest (subject to Permitted Liens).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6. <U>Representations
and Warranties</U>.</B> The Borrower hereby represents and warrants to the Lender as of the date hereof and of each Funding Date that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Existence;
Qualification; Power.</U> The Borrower (i)&nbsp;is duly organized, validly existing and in good standing under the Laws of the jurisdiction
of its incorporation, (ii)&nbsp;has all requisite power and authority and all requisite governmental licenses, authorizations, consents
and approvals to (A)&nbsp;own or lease its assets and carry on its business and (B)&nbsp;execute, deliver and perform its obligations
under the Loan Documents to which it is a party, and (iii)&nbsp;is duly qualified and is licensed and, as applicable, in good standing
under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such
qualification or license (except, with respect to clauses (ii)(A) and (iii), as could not reasonably be expected to result in a Material
Adverse Effect). The Borrower does not have any Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Authorization;
No Contravention</U>. The execution, issuance, delivery and performance of this Agreement, any Notes and each other Loan Document has
been duly authorized by all necessary corporate action, and do not and will not (i) contravene the terms of the certificate of incorporation
or the bylaws of the Borrower, (ii) conflict with or result in any breach or contravention of, or the creation of any Lien (other than
Liens created under the Loan Documents) under, or require any payment to be made under (A) any contractual obligation to which the Borrower
or any of its Subsidiaries is a party or by which the Borrower or any of its Subsidiaries is bound or (B) any order, injunction, writ
or decree of any Governmental Authority or any arbitral award to which the Borrower or any of its Subsidiaries or its property is subject
or (iii) violate any applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Governmental
Authorization; Other Consents</U>. No approval, permit, license, registration, consent, exemption, authorization, or other action by,
or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution,
delivery or performance by, or enforcement against, the Borrower of this Agreement or any other Loan Document, except for those that have
been duly obtained, taken or made and are in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Execution
and Delivery; Binding Effect</U>. This Agreement has been, and each other Loan Document, when delivered, will have been, duly executed
and delivered by the Borrower. This Agreement constitutes, and each other Loan Document when so delivered will constitute, a legal, valid
and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as such enforceability may
be limited by bankruptcy, insolvency, reorganization, receivership, moratorium or other Laws affecting creditors&rsquo; rights generally
and by general principles of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Compliance
with Laws</U>. Each of the Borrower and its Subsidiaries is in compliance in all material respects with the requirements of all Laws and
all orders, writs, injunctions and decrees applicable to it or to its business or properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Solvency</U>.
The present fair saleable value of the Borrower&rsquo;s assets exceed the amount of its current liabilities, and it has an actual operating
business with actual operating income. The Borrower is not engaged or about to engage in a business or transaction for which its remaining
assets are unreasonably small in relation to the business or transaction or for which the property remaining with the Borrower is an unreasonably
small capital. The Borrower has not incurred and does not intend to incur, or reasonably believe that it will incur, debts beyond its
ability to pay such debts as they become due (whether at maturity or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Financial
Statements.</U> Any financial statements delivered by or on behalf of the Borrower to the Lender or filed by the Borrower with the Securities
and Exchange Commission fairly present in all material respects the consolidated financial condition of the Borrower and its Subsidiaries
as at the respective dates thereof and the consolidated results of operations of the Borrower and its Subsidiaries for the fiscal periods
ended on such respective dates, all in accordance with GAAP, subject to, in the case of unaudited financial statements, the absence of
footnotes and normal year-end adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) <U>Disclosure.</U>
The Borrower has disclosed to the Lender all agreements, instruments and corporate or other restrictions to which it is subject, and all
other matters known to it, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.
None of the reports, financial statements, certificates or other information furnished in writing by or on behalf of the Borrower to the
Lender (other than forward-looking information and projections and information of a general economic nature and general information about
Borrower&rsquo;s industry) in connection with the negotiation of this Agreement or delivered hereunder (as modified or supplemented by
other information so furnished), when taken as a whole, contains any material misstatement of fact or omits to state any material fact
necessary to make the statements therein, when taken as a whole, and in the light of the circumstances under which it was made, not misleading.
The financial budget and projections in the Excel file titled &ldquo;NeuroOne Budget FY2024 updated as of 8-2-24&rdquo; delivered by the
Borrower to the Lender (the &ldquo;<U>Financial Model</U>&rdquo;) represents the Borrower&rsquo;s good faith estimate as of the date of
delivery thereof of the Borrower&rsquo;s future performance for the periods covered thereby based on assumptions believed by the Borrower
to be reasonable at such time of delivery (it being understood that such projections and budget are subject to uncertainty and that actual
results may differ materially from such projections and budget).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Intellectual
Property</U>. The Borrower owns, or is licensed to use, or otherwise has a right to use, all Intellectual Property necessary to conduct
its business as currently conducted. The conduct and operations of the businesses of the Borrower do not infringe, misappropriate, dilute,
violate or otherwise impair any Intellectual Property owned by any other Person and no other Person has contested any right, title or
interest of the Borrower in, or relating to, any Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Title
to Collateral</U>. The Borrower has and will have good record title, or valid leasehold or license interests in, the Collateral, and has
the power to transfer and pledge each item of Collateral, free and clear of all Liens and claims whatsoever, other than the Security Interest
created hereunder and Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k) <U>Perfected
Security Interest</U>. The Security Interest constitutes a valid and enforceable security interest in the Collateral in favor of the Lender
(except as may be limited by bankruptcy, insolvency, reorganization, receivership, moratorium or other Laws affecting creditors&rsquo;
rights generally and by general principles of equity). Such Security Interest constitutes a perfected first priority security interest
in the Collateral, subject to Permitted Liens, upon the filing of appropriate Uniform Commercial Code financing statements and the taking
of all other actions necessary to perfect such Security Interest, and all such filings and actions have been taken or made, or will be
taken or made, except to the extent not required hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Sanctions;
Anti-Corruption</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">None of the Borrower or any of its Subsidiaries or any director, officer, employee, agent, or affiliate
of any of the Borrower or any of its Subsidiaries is an individual or entity (&ldquo;person&rdquo;) that is, or is 50% or more owned or
controlled by persons that are: (i) the subject of any Sanctions, or (ii) located, organized or resident in a country or territory that
is the subject of Sanctions (including Crimea, the so-called Luhansk People&rsquo;s Republic, the so-called Donetsk People&rsquo;s Republic,
Cuba, Iran, North Korea and Syria).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Each of the Borrower and each of its Subsidiaries and their respective directors, officers, employees
and agents are in compliance with all applicable Sanctions and with the FCPA and any other applicable anti-corruption or similar laws.
The Borrower and its Subsidiaries have instituted and maintain policies and procedures designed to ensure continued compliance with applicable
Sanctions, the FCPA and any other applicable anti-corruption or similar laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m) <U>USA
Patriot Act</U>. The Neither the Borrower nor any of its Subsidiaries is in violation of any laws relating to terrorism or money laundering,
including Executive Order No. 13224 on Terrorist Financing, effective September 23, 2011 and the Uniting and Strengthening America by
Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (PATRIOT) Act of 2001, as amended, and the use of proceeds of
the Loans will not violate the Trading with the Enemy Act or any of the foreign asset control regulations of the United States Treasury
Department or any enabling legislation or executive order relating thereto or any similar Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7. <U>Affirmative
Covenants of the Borrower</U>.</B> The Borrower hereby covenants and agrees that, until the payment in full of the Obligations and the
termination of the Standby Term:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Financial
Statements</U>. As soon as available, and in any event within 21 days after the end of each fiscal month of the Borrower, the Borrower
will deliver to the Lender internally prepared consolidated and consolidating balance sheets, statements of operations and changes in
stockholders&rsquo; equity and statements of cash flows as at the end of such fiscal month, and for such fiscal month and for the period
commencing at the end of the immediately preceding fiscal year and ending with the end of such fiscal month, setting forth in each case
in comparative form (x) the figures for the corresponding date or period set forth in the financial statements of the Borrower for the
immediately preceding fiscal year and (y) the figures projected or budgeted for such periods (as set forth in the Financial Model), as
applicable, all in reasonable detail (including, in the event of a deviation from the Financial Model, a description of the reasons therefor)
and certified by the chief financial officer or the treasurer of the Borrower as fairly presenting, in all material respects, the financial
position of the Borrower and its Subsidiaries as at the end of such fiscal month and the results of operations, stockholders&rsquo; equity
and cash flows of the Borrower and its Subsidiaries for such fiscal month and for such year-to-date period, in accordance with GAAP applied
in a manner consistent with that of the most recent audited financial statements of the Borrower, subject to the absence of footnotes
and normal year-end adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Compliance
Certificate</U>. Within 21 days after the end of each month, the Borrower shall deliver to the Lender a compliance certificate, in form
and substance reasonably satisfactory to the Lender, in which the chief executive officer or chief financial officer of the Borrower shall
certify as of the date of each such certificate: (i) the currently estimated timing for the closing of any pending Monetization Event,
(ii) a calculation of the Borrower&rsquo;s monthly cash flows for the preceding month compared to the amount budgeted for such cash flows
as of the date hereof (as set forth in the Financial Model), (iii) the cash balance of the Borrower as of the end of the preceding month;
(iv) that since the date of this Agreement, no Material Adverse Effect has occurred; (v) that there have been no changes to the information
contained in the Perfection Certificate delivered by the Borrower on the date hereof or in the updated Perfection Certificate most recently
delivered pursuant to this clause (or such certificate shall be accompanied by an updated Perfection Certificate identifying any changes
to the information contained in the most recently delivered Perfection Certificate); and (vi) that such officer has reviewed the provisions
of this Agreement and the other Loan Documents and has made or caused to be made under their supervision a review of the condition and
operations of the Borrower its Subsidiaries during the preceding month, and that such review has not disclosed, and such officer has no
knowledge of, the occurrence and continuance during such period of an Event of Default or Default or, if an Event of Default or Default
had occurred and continued or is continuing, describing the nature and period of existence thereof and the action that the Borrower proposes
to take or has taken with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Notices</U>.
The Borrower shall notify the Lender promptly and in reasonable detail upon acquiring any knowledge of the occurrence of a Default or
Event of Default or of any event that could reasonably be expected to have or result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Preservation
of Existence, Etc</U>. The Borrower shall, and shall cause each of its Subsidiaries to, (i) preserve, renew and maintain in full force
and effect its legal existence and good standing under the Laws of the jurisdiction of its incorporation; (ii) take all reasonable action
to maintain all rights, licenses, permits, privileges and franchises necessary or desirable in the normal conduct of its business, except
to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect; and (iii) preserve or renew all
of its registered patents, trademarks, trade names and service marks, the non-preservation of which could reasonably be expected to have
a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Payment
of Obligations</U>. The Borrower shall, and shall cause each of its Subsidiaries to, pay, discharge or otherwise satisfy as the same shall
become due and payable, all of its obligations and liabilities, including tax liabilities, unless the same are being contested in good
faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Borrower
or such Subsidiary, in each case except to the extent that the failure to do so could not reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Compliance
with Laws</U>. The Borrower shall, and shall cause each of its Subsidiaries to, comply with the requirements of all Laws and all orders,
writs, injunctions and decrees applicable to it or to its business or property, except to the extent that the failure to do so could not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Use
of Proceeds</U>. The Borrower shall use the proceeds of each Loan solely for general corporate purposes of the Borrower. The Borrower
and its Subsidiaries shall not use the proceeds of any Loan in contravention of any Law or of any Loan Document or to purchase or carry
any margin stock or to extend credit to others for the purpose of purchasing or carrying any margin stock or for any purpose that violates,
or is inconsistent with, the provisions of Regulation T, U and X of the Board of Governors of the U.S. Federal Reserve System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) <U>Certain
Changes</U>. Without providing at least thirty (30) days&rsquo; prior written notice to the Lender, the Borrower shall not change its
name, jurisdiction of incorporation or organizational structure or its chief executive office. The Borrower will notify the Lender in
reasonable detail promptly following the acquisition or development by the Borrower of any Intellectual Property that is issued, registered,
renewed or the subject of a pending application and execute and deliver to the Lender such security agreements with respect thereto (or
supplements to security agreements) as the Lender may reasonably request. The Borrower will notify the Lender in reasonable detail promptly
following the acquisition of an interest in a Commercial Tort Claim and take such actions as reasonably requested by the Lender to create
or perfect a security interest therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Deposit
Accounts, Etc</U>. From and after the initial Funding Date, the Borrower shall cause each Deposit Account, Securities Account, Security
Entitlement, Commodity Account and Commodity Contract included in the Collateral to be subject to an agreement, in form and substance
reasonably satisfactory to the Lender, among the Lender, the financial institution or other Person at which such account is maintained
or with which such entitlement or contract is carried and the Borrower, effective to grant &ldquo;control&rdquo; (as defined under the
UCC) over such account to the Lender (each, a &ldquo;<U>Control Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Defense
of Security Interest</U>. The Borrower shall defend the Security Interest against the claims and demands of anyone other than the Lender
and other than with respect to Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8. <U>Negative
Covenants of the Borrower</U>.</B> The Borrower hereby covenants and agrees that, until the payment in full of the Obligations and the
termination of the Standby Term:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Disposal
of Assets</U>. The Borrower will not, and will not permit any of its Subsidiaries to, convey, sell, lease, license, assign, transfer,
or otherwise dispose of any of its or their assets or property (or enter into an agreement with respect to any such conveyance, sale,
lease, license, assignment, transfer or other disposition other than a Monetization Event that is consummated concurrently with, and the
proceeds of which are used for, the payment in full of the Obligations), except for (i) sales, abandonment, or other dispositions of equipment
that is substantially worn, obsolete or surplus, (ii) non-exclusive licenses of Intellectual Property rights in the ordinary course of
business, (iii) disposition of accounts receivable in connection with the collection or compromise thereof in the ordinary course of business,
(iv) sales and other dispositions of inventory in the ordinary course of business, (v) any involuntary loss, damage, destruction or condemnation
of property and (vi) to the extent deemed a conveyance, sale, lease, license, assignment, transfer or disposition for purposes of this
Section 8(a), and without duplication, the granting of any Permitted Lien.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Liens</U>.
The Borrower will not, and will not permit any of its Subsidiaries to, create, incur, or suffer to exist any Lien on any of its assets
or properties except the Security Interest and Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Indebtedness.</U>
The Borrower shall not, and shall not permit its Subsidiaries to, incur, assume, guarantee or otherwise become liable for any Indebtedness
other than the Obligations and Indebtedness (i)&nbsp;resulting from a bank or other financial institution honoring a check, draft or similar
instrument in the ordinary course of business or (ii)&nbsp;arising under cash management services in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Mergers,
Etc.</U> The Borrower will not, and will not permit any of its Subsidiaries to, (i) enter into any amalgamation, merger, consolidation,
reorganization or recapitalization, or reclassify its equity interests, (ii) liquidate, wind up, or dissolve itself (or suffer any liquidation
or dissolution), or (iii) suspend or cease operating a substantial portion of its or their business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Subsidiaries.</U>
The Borrower will not form or acquire any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Restricted
Payments.</U> The Borrower will not declare or pay any dividend or other distribution on account of any of its equity interests (or securities
convertible into, or exercisable for its equity interests) or repurchase, redeem or retire any of its equity interests (or securities
convertible into, or exercisable for its equity interests); provided that for the avoidance of doubt, the foregoing will not prohibit
or otherwise limit (i) payments by the Borrower pursuant to any warrants issued to the Lender, (ii) declarations or payment of dividends
solely in common stock of the Borrower or (iii) to the extent deemed a redemption or retirement of equity interests for purposes of this
Section 8(f), the withholding of equity interests that have otherwise vested in favor of employees solely for purposes of satisfying tax
obligations of such employees in connection therewith, in each case with respect to this clause (iii), in the ordinary course of business
or consistent with past practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9. <U>Events
of Default</U>. </B> It shall constitute an &ldquo;<U>Event of Default</U>&rdquo; if any one or more of the following shall occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) the
Borrower shall have failed to pay the principal amount of any Loan or any interest, fees or other Obligation when due, and, in the case
of Obligations other than the principal of any Loan, such failure continues for three Business Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) any
representation or warranty made or deemed made by or on behalf of the Borrower under or in connection with this Agreement or any other
Loan Document or any amendment or modification hereof or thereof, or any waiver hereunder or thereunder, or in any report, certificate,
financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment
or modification hereof or thereof, or any waiver hereunder or thereunder, shall prove to have been incorrect in any material respect (or,
in the case of any such representation or warranty under this Agreement or any other Loan Document qualified by materiality, such representation
or warranty shall prove to have been incorrect) when made or deemed made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) the
Borrower shall fail to observe or perform any covenant, condition or agreement (other than as described in clause (a) above) contained
in (i) Section 7 or 8 of this Agreement or (ii) any other provision of this Agreement or in any other Loan Document and, in the case of
this clause (ii), such failure continues for ten (10) Business Days after the earlier of (x) the date on which the Borrower obtains actual
knowledge of such failure and (y) the date on which the Borrower receives written notice of such failure form the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) the
Borrower or its independent registered public accounting firm shall have discovered a material misstatement in any of its publicly filed
financial statements or the Borrower shall have failed to timely file any document or report the Borrower is required to file with the
Securities and Exchange Commission pursuant to Section 13 or 15(d) of the Exchange Act, giving effect to any grace period provided by
Rule 12b-25 of the Exchange Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) an
involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i) liquidation, reorganization or other relief
in respect of the Borrower or any Subsidiary of the Borrower or the Borrower&rsquo;s or such Subsidiary&rsquo;s debts, or a substantial
part of the Borrower&rsquo;s or any Subsidiary&rsquo;s assets, under any Debtor Relief Law now or hereafter in effect or (ii) the appointment
of a receiver, trustee, custodian, sequestrator, conservator or similar official for the Borrower or any Subsidiary of the Borrower or
for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed or unstayed for a
period of 45 or more days or an order or decree approving or ordering any of the foregoing shall be entered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) the
Borrower or any Subsidiary of the Borrower shall (i) voluntarily commence any proceeding or file any petition seeking liquidation, reorganization
or other relief under any Debtor Relief Law now or hereafter in effect, (ii) consent to the institution of, or fail to contest in a timely
and appropriate manner, any proceeding or petition described in clause (e) of this Section, (iii) apply for or consent to the appointment
of a receiver, trustee, custodian, sequestrator, conservator or similar official for the Borrower or any Subsidiary of the Borrower or
for a substantial part of its assets, (iv) file an answer admitting the material allegations of a petition filed against it in any such
proceeding, (v) make a general assignment for the benefit of creditors or (vi) take any action for the purpose of effecting any of the
foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) the
Borrower or any Subsidiary of the Borrower shall become unable, admit in writing its inability, or fail generally, to pay its debts as
they become due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) there
is entered against the Borrower or any Subsidiary of the Borrower a judgment or order that, either individually or in the aggregate, has
or could reasonably be expected to have a Material Adverse Effect and the same shall not have been vacated, bonded, satisfied or stayed
pending appeal within thirty (30) days from the date of entry of such judgment or order (or within thirty (30) days after the termination
of any stay thereon obtained within such aforementioned thirty (30) day period); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) any
material provision of any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted
hereunder or thereunder ceases to be in full force and effect; or the Borrower or any other Person contests in writing the validity or
enforceability of any provision of any Loan Document; or the Borrower denies in writing that it has any or further liability or obligation
under any Loan Document, or purports in writing to revoke, terminate or rescind any Loan Document; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) any
Material Adverse Effect shall occur;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, and in every such event, and at any time
thereafter during the continuance of such event, the Lender may take any or all of the following actions, at the same or different times:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">by notice to the Borrower, terminate the Standby Term and/or declare all outstanding principal, all accrued
and unpaid interest in respect of the Loans and all fees and other Obligations (to the extent not already due and payable) to be immediately
due and payable in full, and upon such declaration the principal of the Loans so declared to be due and payable, together with accrued
interest thereon and all fees and other Obligations shall become due and payable immediately, without presentment, demand, protest or
other notice of any kind, all of which are hereby waived by the Borrower to the fullest extent permitted by applicable Law; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">exercise all rights and remedies available to it under the Loan Documents and applicable Law, including
rights as a secured party under the UCC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>provided</U> that, in case
of any event with respect to the Borrower described in clause (e), (f) or (g) of this Section, the Standby Term shall automatically terminate
and the principal of the Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, shall automatically
become due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower
to the fullest extent permitted by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These remedies are cumulative and are not exclusive
of any remedies provided by applicable Law. For the avoidance of doubt, if the proceeds of the Collateral are insufficient to pay or satisfy
all of the Obligations in full, the Borrower shall remain liable for any deficiency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10. <U>Application
of Loan Payments and Collateral</U>.</B> Any proceeds from the sale of Collateral (after the occurrence and during the continuance of
an Event of Default) received by the Lender shall be applied in the following order: (a) to the payment of the costs and expenses of enforcement
and collection incurred by the Lender, including, without limitation, attorneys&rsquo; fees; (b) to the payment of the unpaid Obligations
in such order as the Lender may determine in its sole discretion; and then (c) to the payment to the Borrower of any surplus then remaining
from such proceeds. The Borrower expressly acknowledges and agrees that all Loans are recourse obligations of the Borrower, and that the
Lender shall <U>not</U> be limited to seeking remedy against the Collateral in an Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11. <U>Obligations
Absolute</U>.</B> Notwithstanding any provision of this Agreement to the contrary, the obligations of the Borrower hereunder and the Security
Interest and the rights of the Lender hereunder shall be absolute, unconditional and, until the payment in full in cash of the Obligations
and the termination of this Agreement and the other Loan Documents, irrevocable, and all of the obligations of the Borrower hereunder
shall be performed strictly in accordance with the terms hereof, under all circumstances whatsoever. The Borrower hereby waives, to the
fullest extent permitted by applicable Law, notice (including notice of protest, notice of dishonor, notice of intent to accelerate and
notice of acceleration), demand, presentment for payment, protest, diligence in collection and bringing suit, and the filing of suit for
the purpose of fixing liability, in respect of the Loans and the other Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12. <U>Liability
for Contracts</U>. </B>The Borrower shall remain liable under all contracts included in the Collateral to the extent set forth therein
and shall perform all of its duties and obligations thereunder, in each case, to the same extent as if this Agreement had not been executed.
The Lender shall have no liability or obligation under any such contract by reason of this Agreement and shall not be obligated to perform
any of the Borrower&rsquo;s rights or obligations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13. <U>Power
of Attorney</U>. </B>The Borrower does hereby irrevocably constitute and appoint the Lender, with full power of substitution, the true
and lawful attorney-in-fact and agent of the Borrower, to execute, acknowledge, verify, swear to, deliver, record and file, in its or
its assignee&rsquo;s name, place and stead, all instruments, documents and certificates and to take all other actions, in each case, which
the Lender determines to be necessary or appropriate in its reasonable discretion to carry out the intent of this Agreement or to exercise
its remedies hereunder or otherwise with respect to the Collateral, in each case upon the occurrence and during the continuance of an
Event of Default. This power of attorney shall be deemed to be coupled with an interest, shall be irrevocable, shall survive and not be
affected by the dissolution, bankruptcy or legal disability of any party hereto and shall extend to such Lender&rsquo;s successors and
permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14. <U>Transaction
Expenses; Indemnification</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The
Borrower shall reimburse the Lender for all of its reasonable and documented out-of-pocket expenses incurred in connection with the execution
and delivery of this Agreement or transactions contemplated hereby or enforcement of the Obligations, including any reasonable and documented
out-of-pocket costs or expenses incurred by the Lender in connection with performing due diligence and preparing this Agreement and the
other Loan Documents, promptly upon the Lender&rsquo;s presentation of receipts or other reasonable documentation for such expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The
Borrower shall indemnify and hold harmless the Lender and its affiliates, and their respective directors, officers, employees, counsel
and agents (collectively the &ldquo;<U>Indemnitees</U>&rdquo;) from and against any and all liabilities, obligations, losses, damages
(including punitive and exemplary damages), penalties, claims, demands, actions, judgments, suits, costs, expenses and disbursements of
any kind or nature whatsoever which may at any time be imposed on, incurred by or asserted against any such Indemnitee in any way relating
to or arising out of or in connection with (i) the execution, delivery, enforcement, performance or administration of any Loan Document,
(ii) any Loan or the use or proposed use of the proceeds therefrom or (iii) any actual or prospective claim, litigation, investigation
or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory (including any investigation of, preparation
for, or defense of any pending or threatened claim, investigation, litigation or proceeding) and regardless of whether any Indemnitee
is a party thereto; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such liabilities, obligations,
losses, damages, penalties, claims, demands, actions, judgments, suits, costs, expenses or disbursements are determined by a court of
competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence, willful misconduct of such Indemnitee.
No Indemnitee have any liability for any indirect or consequential damages relating to this Agreement or any other Loan Document. All
amounts due under this clause (b) shall be payable within ten (10) Business Days after demand therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) The
agreements in this Section 14 shall survive the termination of the Standby Term and the repayment, satisfaction or discharge of the Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15. <U>Counterparts</U>.
</B>This Agreement may be executed by facsimile and in one or more counterparts, all of which shall constitute one and the same instrument.
Delivery of an executed counterpart of this Agreement by electronic mail shall be equally as effective as delivery of an original executed
counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by electronic mail also shall deliver an
original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity,
enforceability or binding effect of this Agreement. The foregoing shall apply to each other Loan Document mutatis mutandis. The words
&ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature,&rdquo; and words of like import in this Agreement and the other Loan
Documents shall be deemed to include electronic signatures or electronic records each of which shall be of the same legal effect, validity
or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent
and as provided for in any applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16. <U>Amendments</U>.
</B>All amendments to this Agreement require the prior written consent of the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17. <U>Governing
Law</U>. </B>This Agreement shall be construed, interpreted and governed by the laws of the State of New York, without regard to principles
of conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18. <U>Severability</U>.</B>
If any provision of this Agreement or the application thereof to any party or circumstance shall be determined by any court of competent
jurisdiction to be invalid or unenforceable to any extent, the remainder of this Agreement or the application of such provision to such
party or circumstance, other than those as to which it is so determined invalid or unenforceable, shall not be affected thereby, and each
provision hereof shall be valid and shall be enforced to the fullest extent permitted by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>19. <U>Waivers</U>.</B>
No waiver by the Lender of any Event of Default or any other default with respect to any provision, condition or requirement of this Agreement
or any other Loan Document shall be deemed to be a waiver of any other Event of Default or default of any provision, condition or requirement
hereof or thereof. No delay or omission of the Lender to exercise any right or power under this Agreement or any other Loan Document shall
in any manner exhaust or impair the exercise of any such right or power accruing to it thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20. <U>Notices</U>.</B>
Any communication required or permitted to be given hereunder shall be in writing and shall be deemed effectively given when (a) delivered
personally or by nationally recognized overnight courier or (b) sent by confirmed electronic mail, in each case to the applicable Person
and address set forth on <U>Exhibit B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21. <U>Successors
and Assigns</U>.</B> This Agreement shall inure to the benefit of, and shall be binding upon, the parties hereto and their respective
successors and permitted assigns; <I>provided</I> that the Borrower shall not be permitted to assign any of its rights or obligations
hereunder or under any other Loan Document without the prior written consent of the Lender. The Lender shall notify the Borrower promptly
following any assignment by it of any rights or obligations hereunder or any other Loan Document (but the failure to so notify the Borrower
shall not affect the validity of such assignment). The Indemnitees are express third party beneficiaries of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>22. <U>Entire
Agreement</U>.</B> This Agreement and any other Loan Documents constitute the entire agreement among the parties hereto with respect to
the subject matter hereof, and supersede any prior agreement or understanding among them with respect to such subject matter; <U>provided</U>
that, in the event of any conflict between the provisions of this Agreement and the provisions of any Note, the provisions of this Agreement
shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>23. <U>Further
Assurances</U>.</B> The Borrower shall execute and deliver such additional documents and instruments, and perform such additional acts,
in each case, as may be reasonably requested by the Lender to effectuate, carry out and perform the provisions and intent of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>24. <U>Waiver
of Jury Trial</U></B>. EACH OF THE BORROWER AND THE LENDER HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM
CONCERNING ANY RIGHTS UNDER THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS, OR UNDER ANY AMENDMENT, WAIVER, CONSENT, INSTRUMENT, DOCUMENT
OR OTHER AGREEMENT DELIVERED OR WHICH IN THE FUTURE MAY BE DELIVERED IN CONNECTION THEREWITH, OR ARISING FROM ANY FINANCING RELATIONSHIP
EXISTING IN CONNECTION WITH THIS AGREEMENT, AND AGREES THAT ANY SUCH ACTION, PROCEEDING OR COUNTERCLAIM SHALL BE TRIED BEFORE A COURT
AND NOT BEFORE A JURY. THE BORROWER CERTIFIES THAT NO OFFICER, REPRESENTATIVE, AGENT OR ATTORNEY OF THE LENDER HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT THE LENDER WOULD NOT, IN THE EVENT OF ANY ACTION, PROCEEDING OR COUNTERCLAIM, SEEK TO ENFORCE THE FOREGOING WAIVERS.
THE BORROWER HEREBY ACKNOWLEDGES THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE LENDER ENTERING INTO THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>25. <U>Consent
to Jurisdiction, Etc</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The
Borrower irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description,
whether in law or equity, whether in contract or in tort or otherwise, against the Lender or any Indemnitee in any way relating to this
Agreement or any other Loan Document or the transactions relating hereto or thereto, in any forum other than the courts of the State of
New York sitting in New York County, and of the United States District Court for the Southern District of New York sitting in New York
County, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction
of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such
New York State court or, to the fullest extent permitted by applicable Law, in such federal court. Each of the parties hereto agrees that
a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on
the judgment or in any other manner provided by law. Nothing in this Agreement or in any other Loan Document shall affect any right that
the Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Loan Document against the Borrower
or its properties in the courts of any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The
Borrower irrevocably and unconditionally waives, to the fullest extent permitted by applicable Law, any objection that it may now or hereafter
have to the laying of venue of any action or proceeding arising out of or relating to this Agreement or any other Loan Document in any
court referred to in paragraph (a) of this Section. The Borrower hereby irrevocably waives, to the fullest extent permitted by applicable
Law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) The
Borrower irrevocably consents to service of process in the manner provided for notices in Section 20. Nothing in this Agreement will affect
the right of any party hereto to serve process in any manner permitted by applicable Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>26. <U>Highest
Lawful Rate</U></B>. It is the intention of the parties hereto that the Lender shall conform strictly to usury laws applicable to it.
Accordingly, if the transactions contemplated hereby or by any other Loan Document would be usurious as to the Lender under laws applicable
to it, then, in that event, notwithstanding anything to the contrary in this Agreement or any other Loan Document, it is agreed as follows:
(i) the aggregate of all consideration that constitutes interest under law applicable to the Lender that is contracted for, taken, reserved,
charged or received by the Lender under this Agreement or any other Loan Document or otherwise in connection with the Obligations shall
under no circumstances exceed the maximum amount allowed by such applicable law, any excess shall be canceled automatically and if theretofore
paid shall be credited by the Lender on the principal amount of the Obligations (or, to the extent that the principal amount of the Obligations
shall have been or would thereby be paid in full, refunded by the Lender, as applicable, to the Borrower); and (ii) in the event that
the maturity of the Obligations is accelerated by reason of any Event of Default under this Agreement or otherwise, or in the event of
any required or permitted prepayment, then such consideration that constitutes interest under law applicable to the Lender may never include
more than the maximum amount allowed by such applicable law, and excess interest, if any, provided for in this Agreement or otherwise
shall be canceled automatically by the Lender, as applicable, as of the date of such acceleration or prepayment and, if theretofore paid,
shall be credited by the Lender, as applicable, on the principal amount of the Obligations (or, to the extent that the principal amount
of the Obligations shall have been or would thereby be paid in full, refunded by the Lender to the Borrower). All sums paid or agreed
to be paid to the Lender for the use, forbearance or detention of sums due hereunder shall, to the fullest extent permitted by law applicable
to the Lender, be amortized, prorated, allocated and spread throughout the full term of the Loans until payment in full so that the rate
or amount of interest on account of any Loans hereunder does not exceed the maximum amount allowed by such applicable law. If at any time
and from time to time (x) the amount of interest payable to the Lender on any date shall be computed at the Highest Lawful Rate applicable
to the Lender pursuant to this Section 26 and (y) in respect of any subsequent interest computation period the amount of interest otherwise
payable to the Lender would be less than the amount of interest payable to the Lender computed at the Highest Lawful Rate applicable to
the Lender, then the amount of interest payable to the Lender in respect of such subsequent interest computation period shall continue
to be computed at the Highest Lawful Rate applicable to the Lender until the total amount of interest payable to the Lender shall equal
the total amount of interest which would have been payable to the Lender if the total amount of interest had been computed without giving
effect to this Section 26. For purposes of this Section 26, the term &ldquo;applicable law&rdquo; shall mean that law in effect from time
to time and applicable to the loan transaction between the Borrower, on the one hand, and the Lender, on the other, that lawfully permits
the charging and collection of the highest permissible, lawful non-usurious rate of interest on such loan transaction and this Agreement,
including laws of the State of New York and, to the extent controlling, laws of the United States of America. &ldquo;<U>Highest Lawful
Rate</U>&rdquo; means the maximum non-usurious interest rate, if any, that at any time or from time to time may be contracted for, taken,
reserved, charged or received on the Obligations under laws applicable to the Lender which are currently in effect or, to the fullest
extent allowed by law, under such applicable laws which may hereafter be in effect and which allow a higher maximum non-usurious interest
rate than applicable laws now allow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature page follows]</I></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">In
witness whereof</FONT>, the parties hereto have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-variant: small-caps">BORROWER</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-variant: small-caps"><B>NeuroOne Medical Technologies Corporation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ David A. Rosa</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="width: 30%">David A. Rosa</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer and President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-variant: small-caps">LENDER</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-variant: small-caps"><B>Growth Opportunity Funding, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Robert Axenrod</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Robert Axenrod</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Authorized Signatory</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Promissory Note<BR>
<BR>
</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-variant: small-caps"><B>$_______________</B></FONT></P></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>New York, New York</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>[_____], 2024</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-variant: small-caps"><B>For
value received,</B></FONT> the undersigned, <FONT STYLE="font-variant: small-caps">NeuroOne Medical Technologies Corporation, </FONT>a
Delaware corporation (the &ldquo;<U>Borrower</U>&rdquo;), hereby unconditionally promises to pay to <FONT STYLE="font-variant: small-caps">Growth
Opportunity Funding, LLC</FONT>, a Delaware limited liability company (the &ldquo;<U>Lender</U>&rdquo;), the aggregate principal amount
of <FONT STYLE="font-variant: small-caps">$____________</FONT>, plus all fees and interest thereon as provided in that certain Loan and
Security Agreement, dated as of August 2, 2024 (as may be amended, modified, supplemented or restated from time to time, the &ldquo;<U>Loan
Agreement</U>&rdquo;), by and between the Borrower and the Lender, together with all other amounts due pursuant to the terms of the Loan
Agreement. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This promissory note (this &ldquo;<U>Note</U>&rdquo;)
is made pursuant to Section 2 of the Loan Agreement, evidences a Loan under the Loan Agreement, and it and the Loan evidenced hereby are
subject to the provisions of the Loan Agreement. Without limiting the foregoing: following the occurrence of an Event of Default and during
the continuance thereof, the outstanding principal of this Note shall (to the extent not already due and payable) immediately and automatically
become due and payable in full as provided by Section 9 of the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Note shall be governed
by, and construed and enforced in accordance with, the laws of the State of New York without regard to conflicts of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">To the extent not paid (or otherwise
due and payable) by the Maturity Date, all outstanding principal, all accrued and unpaid interest thereon and all other Obligations shall
become due and payable in full on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">In
witness whereof</FONT><FONT STYLE="font-variant: small-caps">,</FONT> the Borrower has caused this Note to be executed and delivered by
its duly authorized representative, as of the date and place first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD><B>&nbsp;</B></TD><TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>NeuroOne Medical Technologies Corporation</B></FONT></TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD></TD><TD>By:</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="width: 60%">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD><TD STYLE="text-align: justify; width: 6%">Name:</TD>
                              <TD STYLE="text-align: justify; width: 30%">&nbsp;</TD></TR>
                                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD>
                              <TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                        </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 240pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 240pt; text-align: justify; text-indent: 0pt"></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notice Addresses and Bank Account Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">[<FONT STYLE="font-variant: small-caps"><I>Omitted</I></FONT>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Draw Request<BR>
&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Date: [__________], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Reference is hereby made to
that certain Loan and Security Agreement, dated as of August 2, 2024 (as may be amended, modified, supplemented or restated from time
to time, the &ldquo;Loan Agreement&rdquo;), by and between GROWTH OPPORTUNITY FUNDING, LLC, a Delaware limited liability company (the
&ldquo;<U>Lender</U>&rdquo;), and NEUROONE MEDICAL TECHNOLOGIES CORPORATION, a Delaware corporation (the &ldquo;<U>Borrower</U>&rdquo;).
Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The undersigned hereby requests
a Loan as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Funding Date: __________, 2024
(a Business Day)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Amount: $________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In connection with the requested
Loan, the undersigned certifies that (i) the conditions precedent to the making of such Loan forth in the Loan Agreement have been and
will be satisfied; (ii) each of the representations and warranties made by the Borrower in the Loan Agreement and in any other Loan Document
are true and correct in all material respects as of the date hereof and will be true and correct in all material respects as of the Funding
Date (except to the extent such representation and warranty is made as of an earlier date, in which case, such representation and warranty
was true and correct in all material respects as of such earlier date); provided that any representation or warranty qualified by materiality,
&ldquo;Material Adverse Effect&rdquo; or similar phrases shall be true and correct in all respects; and (iii) immediately prior to and
immediately after giving effect to such Loan, no Default or Event of Default has occurred and is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD><B>&nbsp;</B></TD><TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>NeuroOne Medical Technologies Corporation</B></FONT></TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD></TD><TD>By:</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="width: 60%">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD><TD STYLE="text-align: justify; width: 6%">Name:</TD>
                              <TD STYLE="text-align: justify; width: 30%">&nbsp;</TD></TR>
                                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD>
                              <TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                        </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nmtc-20240801.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /Ksps7xRiXgOn8uFYHlMOa+M+aPtzJZzuekxt2p+HdkaPy4nbdFOPyaPFn4WYTUB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:NMTC="http://n1mtc.com/20240801" elementFormDefault="qualified" targetNamespace="http://n1mtc.com/20240801">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://n1mtc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20240801_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20240801_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>nmtc-20240801_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>nmtc-20240801_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://n1mtc.com/role/Cover" xlink:href="nmtc-20240801.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://n1mtc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140614266986656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  01,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NeuroOne Medical Technologies Corporation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001500198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0863354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7599 Anagram Dr.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Eden Prairie<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">426-1383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMTC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,2#!UD'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #$@P=9/:5$.^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>R$GV#Y/FLM+3!H,5-G8SMMJ:Q;&Q-9*^_1RO31G; ^QHZ>=/
MGT"M\D*Y@,_!>0QD,%Y-MA^B4'[%#D1> $1U0"MCF1)#:NY<L)+2,^S!2_4A
M]P@UY[=@D:26)&$&%GXALJ[52JB DEPXX;5:\/XS]!FF%6"/%@>*4)45L&Z>
MZ(]3W\(%,,,(@XW?!=0+,5?_Q.8.L%-RBF9)C>-8CDW.I1TJ>'MZ?,GK%F:(
M) >%Z5<T@HX>5^P\^;5Y6&\WK*MY?5WP^X+?;6LN&B[XS?OL^L/O(FR=-COS
MCXW/@ET+O^ZB^P)02P,$%     @ Q(,'69E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M ZHK_N!LIX^.B7V4C91?[. QGCB>)6(9BXR5H/#QPN8LRZP2</QS$'7J>]K
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MQ(,'63VE1#OO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ Q(,'69E<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #$@P=9VYDS
MJ54$  "3$   &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ Q(,'69^@&_"Q @  X@P   T
M ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #$@P=9EXJ[',     3
M @  "P              @ %U#P  7W)E;',O+G)E;'-02P$"% ,4    " #$
M@P=9JL0B%C,!   B @  #P              @ %>$   >&PO=V]R:V)O;VLN
M>&UL4$L! A0#%     @ Q(,'620>FZ*M    ^ $  !H              ( !
MOA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ Q(,'
M6660>9(9 0  SP,  !,              ( !HQ(  %M#;VYT96YT7U1Y<&5S
;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0210740-8k_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://n1mtc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0210740-8k_neuro.htm">ea0210740-8k_neuro.htm</File>
    <File>nmtc-20240801.xsd</File>
    <File>nmtc-20240801_lab.xml</File>
    <File>nmtc-20240801_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0210740-8k_neuro.htm": {
   "nsprefix": "NMTC",
   "nsuri": "http://n1mtc.com/20240801",
   "dts": {
    "inline": {
     "local": [
      "ea0210740-8k_neuro.htm"
     ]
    },
    "schema": {
     "local": [
      "nmtc-20240801.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nmtc-20240801_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nmtc-20240801_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://n1mtc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0210740-8k_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0210740-8k_neuro.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-24-066142-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-066142-xbrl.zip
M4$L#!!0    ( ,2#!UDM!5"HA2   !B?   6    96$P,C$P-S0P+3AK7VYE
M=7)O+FAT;>T]:5?;R++?]2OZ>>;>@7-MXQ4P$-]CC$D\ 4PP)"1?.&VI;2O(
MDJ(%X_SZ5]6+%ELV2UB2W)DS,X#42U5U575MW=K[[^W$(C?,\TW'?O-7N5CZ
MBS!;=PS3'KWYJ]5O=[M__;>I[8T#: 9-;?]-;AP$[L[&QG0Z+4ZK1<<;;90;
MC<;&+;;)B48[MYGM*J52>>/R^*BOC]F$%DS;#ZBMLZB39=K7R\?'MU'3@6>9
MJ:;X1$U2W5@8&MX:<8=DX\T-\3+5-,AL6A=- ]74])U:I;RU"@[1(NIPNZQM
M&6$&#-GE_ME1W#S(;A\WW0@\:OM#QYO0 )801ZH72I5"93,Q2,%G>FH@^+LX
M<F[N'&>[4"VK<186)XTIOAY0/Z*XP>;(K>:$%]"C4E,-/39<.NSF!KQ5#4._
M,*+4C1H/J3_@#>6+U*CPS',LYF>VYF]2S74GM -OE@VQ?)GJX'O!XM#P,-7H
MY/B\';6RRY- +^K.A#<I;9?*.10L1HVF1O"?O< ,+-;<VQ _M;T)"RC!W@7V
M+31OWN3:CATP.RB<SUR@LR[^>I,+V&VPP:5O WIMB"'W_J]0((<FLXP=TF?!
M+CFA$[9#;HW;7=(]X+]<E2H'5Q?]?U4.WK9:I_ # 2.%PCT[5\M7B.!5A-B5
M0NS^8]1J4:=']*XWKABP$T ._[8FS#;@O^#0HJ.K(;5\]H"1RHF1.C:LP*P-
M0WG4ZMH&NWW/9E<E4%YU^*^Q??]A-_>!O@=7Y2NI!\3X\.@!0U2N^F/J,?^J
M<L6UGAC#Y\\>, RN],&I'*JZ -"RL0>.,2-^,+/8F]P0&&Z'E$MN0,[-";0X
M85-RYDRHG1</\C"_9PZ1KPWS1G4S3-^UZ&R'V([-\)UYNX,\RCQ@?/Z':1C,
M1BG OZ#523B!<73!X;?!&6J(EM\;(H>@4@+1(:;Q)G=(]:"$_U1SQ :D82YF
M[J08(=?DG+"WD1KY1^:J)>?*9)5<,^:5K(DWDC@C&*#DF ?;+O/Y>U2E.S[?
M(P$<PC>^G3'7DS:(6D$)2O'6-W+R=0 JX4W.-R>NQ5 -R&E2(XNI?"?TY$S0
MB"_[CD2>(SJ'O%1.JB7C"*N'T6/3P!=#DWF$ \XRMYMV]WV:-O.=H\DVLF:3
M<[E 2,=8  $V?"\XH %KQM"K<>)W\[V 59;T46_F0$K.KIY)\J5(&MJFH"<(
MUSP1)XSZH<>:4@AWH(D:2KU*C8]C90\NY'G9^!)YWN:1$\1*8WX2D'!8N 6"
M8D_.[#1PO/CM@W&?!R]CS,2,!\QV)J9]QYQWTF-^THQAU>LD^O-DE*(72YH0
M>:GS]C:@;U/3M#WWH9IUER"?%:AECNP=HH-X,&^73*@W,NU"X+@[!(:('@R<
M(' F_%D.S H7YDSN%6>AQ0JG=,2WR:3"OL=XNV1J&L$882[]*Y?J/7 \0%/T
MWK>H?DTJ@);O6*:Q2^1+-9)X7X[?(R$*OOD=]J\R0OWO/\J;I5U!,?G_! 8;
M*11>F* *-/>E)]X;-"].NN>= ](_;YUW^GL;@^;CP1 S\*%)*0LJ/F&_T[XX
MZYYW.WW2.CD@G<OVN];)VPYI]XZ/N_U^MW?R$E!\:O7?=4_>GO=.\N2@V"Z2
M2JE>:[S$S&JQGW^FP][9,=GS76IS_8O&6Z-4Y]9IH7#@Z"%:-N@ 7.F1Y1S;
MT-]IX[Q>]NGWL67"<(\T<1I)$R<Y9ZZY77@_;]+L;2"TS6<GSH\*W/WH#WQ^
MUCDY)V>=T][9^6^"U&GH^2&U Q(XT%%'#Y^4J\3Q2+F^9JP39TB",<-7H6<&
M)O.USJT^IC8HUI8>X.MRHUK['8B!)AWB<\9<QPO(FOJ[0V$#9WY .C?04KYF
MQOH.N$#->7'<G!/'4VX3=H3!F"V7+DC=]XG;>#<V'B27(B+S)F?>!CL&C#Z!
MMF.#SF8,C!@[+;?E4I;<IH#+-5OA* 0TRWF"T_S>LCR_;BVY;L)K.V,CT\>P
M5X .<_:RA:/CSQ\_N9^/OP\>K4[+Y46/,3UWKGG"0L_IV8P<,\/4J47.F3ZV
M'<L9 5.2MN,!._+ W&LMV%KG%M#A>*"X>!'\A/K$=YF._IM!3"!WX!/0'2 ]
MWOK+\5! !Q:#5Y8%]- Q>IT#:<"_76H8ZN\'@Y&P<B/C57<LB[H^F*CJ-^X:
M[0721]@+C#E;6)EO V'N%NNQP7O#O  77"$'IE^V:2@AJ5;^E<G:U11K=VT]
M9IE^ (+?%C',MF,LXW16H9-ZMU;_/GJL@L(P,[K: 7,]YP9994%#519%826L
MH+"91:>@ZU8R?F LD#Z3L)*(2$/%/1E=[UZU1RQ0*;5 AZ;% ),!\[)7XUC?
MO@B_]F>CO[<?KW>JB\2.Y\5 3+E0*]6JC8>2]A6IF-;@Y_2V*V-'.F>?520M
MO_,J>O?;[$O]\13-B/TM@2'7K&S!$)O5:GWU)@N4@_]YRS3(/?4#*&@N.FC2
M.6#*>>0K6'(^["5\TQAX&TT-U+:9E+7U^\K-RF6^/X!M9S(Q?4PT$F1#(@B5
MAN)I9NJ>]4EGXEK.C'D"]_02D1.GN)XF_0;?0)J_A0LY+S2-E-"T#,-COB]_
M')DV*V<+3.W]R#L^<ZES:3U>8NJ+$I,!0*ZY56\T2,NF(X].R(%77"(S^077
M>#,+N3;\VO/.G:F=C=IH>[ ]TL/1R>77QZ.VN12U>/I<LP.<1TX]:GKFLCUL
M$:EV%E)<P'O>*>RM(,=+MO'^]9;3+=EOP7][/&9;2S&;@R'7/#Y9@M0"3EM9
M.)TZ8"]87TQWN6'BMMW/SO3K66-0?3Q&VTLQ2D&0:];KU=JK>45K$B:TL%T/
M"&RZX JP6W#+ _,&#6_08# 'M0WRW70U'4!^01O[Q1166;(*RE'+8W0Y<XR'
MS'A_>?G]\N9A;G6*.5+AKN2<N6:C7EG"#(5YH"L2Z",']JC3L6.O-/ N)B$[
M."NQ=NGQ!EXEY>_/SYMKUBJ;A7)UN_IJ[!Q[N?_^8[M2WMKUH9W%7 22V!Q*
M-$FL$!TT#8Q\2GX+EGZ!*;)HBZX84%3XZ)[ZDPJ=DM?,(1$Q/;"H4'D3B_H!
M>/(8Z?IE2?XU],&NF^6:[3$#_P*CF-0%]Q/4)YK# ^>6#)CE3(DI0IR'0!2R
M77BO#4T+F(Z8/G!@P&P#J!(X0)A): 749D[H6S/B@[GH#V>\I^S@#&!B847*
MJ&DB%A+".$!Q>Z;>#1T+)L=^Z!*;:/SZ.\]+B)\O+++2M5CB7):*E;H)YI/0
ML@D "T,Z,:W9SET@)C.)(FTVIZ^WI;[^Y)D!, !Z)Z$M'01_B5?^T?9;C4_G
M'QYF6R5CN /'L1BU>5'*G#9/A0DSH<+%;6S5:KM+-;K\D?2HGHZ"$B; -0D4
M<1/)!4S(DEJE+B4!1(##$2<6>#YAK;Q%VH=GI%(M%:'Q>A+NA#-\+[YY0OR4
MY#PK$1<G>46,EQE>?<<R=5@O>W0,6A14J94M$-_>MTWC^/#S>[_\'!*1BA8N
MPO3*XA #!'I90+0H"^4:+90K<^*02JY%PE K%47K?^3A9Y&'FI2'4X^A)L9"
M.IX*1WO!ZPV'RZS[;]>=#\P_G%W^_;#XPCWE(A7870[;*\L' %;0$Y#=N6^4
M:T:ALC98Y[!$$K-*6D3[?^3E9Y&74K:\='T_9-Z=4F-4;\[ZU>_C_O[#0O3W
ME)K:"JE9@/"7DYTJ*]36]/O+CFR?+3M/%@U_8M\/-MW8DA1^%_/ <W.SZEM0
M-2@_#-!_*K?K5_*P1/)MT<EZDMS<.1Y300(SJH^);E'?_QE2AN<>1;*3_FPR
M<*PU?_UG .I$UDUP4C$EE,"ET[$)3V)6SDH*KDR #0"<D>> R"-_.-X.^:/=
M[G0.#Q=7/3/ZNL0KEG(V*U<&?)V7Y%&,RP_N2/>^?'E\M6$EE2*:GS?71#4-
MA.H'CGZ=)R[UR VU0D;^+!5+I3)Q\<C!>%6!P#W3B_>A3D=21_*88+$E)F"E
MTA\=UX+PZP\$>%,IIM2DN2:>O7H.G,]!72[U"^7JJ&UE>>%48_.;_]DY/OWF
M/PS]^7(2E)6L2I+*5A;7).$""E'?H-^6Y:<X0Y%CZEVS@!P=M<F+)(2SPW3/
M-$?7QF(R#(/.B,[CH]#K&G0.XR4"Z>"E9F)BB8"Y@0./""B5:3!&P\/%@";U
MB<&&IBV*O$2<IU1?K!Q-%(Q6R1IBN;7+XSRJL<G+PUPL#\,HM;!>*H-"18ZE
M)<;*JD*-!D4K)NZ7&+;X@@'6IYW#8D,P_CIJ"=Z*)6C+)7BD>;FHQM+I936=
MF$U.EBW5'T^VZB6]%;PM/TN\)R-+FPG<O8WS7Y0-8@$>KA#)/ CBG'QK7+[-
MA;S$&*2766 8@_3:#C>30Y_Q5C"MS'[@ 7"3F\[BC!NN&I_+FN'D4Q.F1C:T
M 2-XX[$;TX=^H!.HK6/PB^K\I#3F\O#TO4$]PQ=Y#V.9C5Y=HY&-GA3VXN.9
M/6*-E^:!USA:E3@ZE7FT*G'TZN6/5MV'@L^[/HLK@QCMPA#?0G2M82:.'C>+
M%@D]=TPM:?,G%[)<R5C)31X?<=,+OW!T3)X%7)C?8_2Z,& @@0"CRV%.SKB9
M,2%"\< 9D^O]_$O]Q)$ \*JZ 9O LH 7T,&"8<SD.H02E1\@!VBPF+QTIC7R
M&(^D%)^M[.'9$#6;IYYY@WK^%!B18P$;WU,A\3([6<\FZ9,G>7+O,P]D#;<'
M+'.H )@#)(@T! 09L+82WI5WUS7NPW 3%3E!():P)T]##_88/\$.HLGB!(LM
MY^<2&Z(./CD%@QCV/IC7#/C<-\P/',_7E@_K^?/#Y5,;I @+8/=VO-D#:[N2
M$5S%"!FT6<(LB:DTBDCQ@@<3 Y^\H,QGEH76!AW!RY$\%K5FKI-*OE&KY6NU
M32(OAEB<LB^/5,]12&[L$H6H3D47'KW//7IMN4>?O>Y1,&"1@HC&F@D@3ZF'
M=H^/&+IJ)>=QJ^0KI>U\%=P4@1<62"?'SR)M][1#/LG!%]"E :Z0F@Z62N?S
M %J-$L<*SX?GT5#VP3#CQ21#@J50G'P<>DIP"DU.D0*_5-RJJQ68@S0/QI@?
M6GQ(8)/ "4":P%CTN?FEPU+S+KPPYM;$9*4U(W]6BIMU B:5A2(F]AIP\8Q0
MY^, "_.6AL9N76;[S"\2# TL<!?1+0?M0">2\(J0\%_7#7LAZZ2+I12V+6UA
MKDZ"+ KGDU)$8MD=FA;3:&3G\U'X\1N^+-%X%\5^,>F@(Y]%MG:B*#]#K#OM
M!2;7G1O $!A$N!@^Y3%@C0<!!'/B^/AG-J]RC<-CYJ$+S]@M\W3P(Y2N2$E8
M!DC1JVR54]3.$Z1"MR=-+N*'4;@UDV(@/M42,>C,5Q A>TM9S5R=WX#-SQ<(
MC_I(+@U?JP%0S+8Y&6R^UH94HGPUP9+. [%ON(Z-5C16@.5BN1&K]3PLPN K
M<#TN"C40"L'ER#A3T$<PA&MZ/#R.4\&B>* 987J\IXYZJKA.FX>AB(L#GBD,
MRT?@ZYN:C0_'O(E@4A ^PQ3Y-)\%Z.Z"Q)CV(A\* 1P[%C@%G"\X%Z6:@.<]
MBU%?Y&3TI956EW("3KMPCI&LX)4CM22,D:P#E"Z=*7&;(VV\4>+HF%K0Q)^^
M$S4UB@1-K,CNB/!;4..B$!=$Y92&%MD/]6O.3908L!9Z@ >+[,SM?-\!1Q^I
M<B ;^K^)2*A5$ 6B?C)J8@._1%OKT',FV435<&&&H<V7V'&98$F 9.IXU_A,
MIZZ)FS4N](C9T, BZH@6P[W?A;W5S\=5TI*Y!?M.)KC( /KW5$$J+/C9(0&Y
M%4\M<X)VJ6;1T-;'>1'28:H#8(%;/NS\-\QR7,D*,B:$X%,>\(E&DS$G_%4"
MD1B,:P832(G.M2 0V" B<D1<!Z^K W U 2#7P*!7=$SJ!("[,#"2RGN$\L+$
M=A*;S@@#F]CQ<2[/'(T#.0](EBNE'4\B>\R%)S!O1'DAA'C' 3>XE'GO)[+F
MB\:_  U-I)&#J^"'DPEJ(H/YNF>Z2?SG%"G,L3@<,1P>A^,+[ 4: #M@BI;"
M$C1]\BV$I4T>JT;R>2R8H>J(;O92.@-CK%PYW0> O/0PN-T9!* Z@$$H!MS'
MY@"GJA7+O&NY!+^,8:; R2O:@AZV9D)=QP<* 4IL!I F@?M--,$*+I)2<,-L
M3FZ,@E.5)4GRDA8OOC*0T@LU!8H!0 :J;PL-=!0^;#8 O3 T \5?*"PXKUSV
M#.;*'A^?PB:E#5AR1^3*01:52%.)VV4#4?2.Z'A4> 1RXB)IZ;#HJ(R0"U;
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M I&6#/-GVX[S\?XL_OK!>+_VB'@_>?)XO_:#\7[R2O'^URRODB6\E6*I2MI
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M64^,,S 0]\.V4ZA0*68*0LKY!&O<:!( M7B:+%$S[X/$$(((!=N$[AM,A*M
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M8J@1&]95O#:17OJ4+GV"7Z9Q13T:UR9N[Z7=7;.9'HA./A$[4O=KP:YQ3,)
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MQ/K!68.1UM#)16%5A2S(P-@$<=%4.F?E7L-?VD3B2"4H<RY90:2+N]4&#:6
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M65L%217[VI_!7D!A5F=1S=BSG6/@N\5]B7H$%\_.\[SB477O;-P"]KC/HZ1
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MMI:WF"*"-'29,T/B:$Q94VXQ* PEW;JMR$>3^GO.!5M[=B5=H%+HE\;Q^.G
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M]%M7N QG7?ZP@4@BS^ZU;YW+BO(+3 ]SDUQ!QC5>I+#I3%M9)F'[$'?627!
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MS4QIY1A'910ZD"[1E(K/?$8TFG&H9FU>M$DYL'=:QW/6(F(D<P947RPP+YM
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M2>V6HO:$.O0^W=TF5#3"O>.2W1DE_^U'UZ7-6=:_PVY+G'XKQ0G559Q>QH^
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MMHDH>C]X^L;WP98S^P'THFP,FY%V5,^M;E4A%(E7%=PJU>R!?%*ZM-ZY0@9
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M0!VJG/ FDKU1<1UR6*];#_<1ZN3>*52!JXC4X:TX(:(7Q/GTVI02:<AM+"9
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M9E%O*6:/N!'E&U)&IDE4)/%*[28I.?AN&A$B)?B:C(O%F[9A5J-1/NB;E)N
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MWZH,R7:[#PS,%DR,4RW:&E:[KJ.#9.6I%[2BN#-7H,6M8(V3!A4WW%9)=);
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M<-/_1PO#>_2 :+<>4-XZH@XQW8_3US&7-:6\B1@G9;ED#A.=27*LIOVDTJU
MO5N!>FO[Q;OB!YQN.6D1G/S!.SREE.10RXG](#*>.R'<8F.!'<3D\ VW9\60
M^C57<Z *#2(R\'&7%L .:;8$Y-].V*,Z42*Z=.K(0P@30/%8Y'&;P"EN.:_
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M,H:,!,?SM$LA'^J;!K+1/RD$H;WTFV!2,.&G2N9F8%*<O<+=AYV^<\3.!'L
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M]P"[?YA46%F+2TLP'*MA6U%>*58W1!]+9X0.&^>/[!.C3;><&#<5=-^,$$.
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M9RM*Q9&69(I=B;XN#<9@Y<X5$>;7KB[D4%P3) P2]A*]1KYR[A N1(,^9ZM
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M3,A*48[;%S0!\"6<U^ *EZ:A'QN-&7EI_9X)'(+=%(R%,-XR*% $$4R]_G7
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MIBYONY-)BS#I5E)0C*9WV]VP67@:\?RKM,B(18%E"2?2!CO!7C]N2X@0N4:
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M A 7JP*$NCE<O0C)'?( .*N;$@'&STR$S>XK?V;6DI!Z@2H^TF*6UZK7X&_
M7()F8R\-LRD^<1"#6E*D6>Z)S;)!X&1T;*3@P!2@!OQ[-;T@H0S6H+=6O83M
M8 1?E^?Z0Y8C^8+CD?=9K-$P'0--Q-.@S>%W=*1PT\-QCC-/(Y C<[@Z"(HH
MRU( 75?)Z,Z8N1DT7(*H#'@&IP>'8H3J-$/9'#9,8NDT1FDZ06V(/N?+>5RH
M#Q.XWVJQ@'@I;#K3=X!DUY %\"D '''^DJ:=@YI*.J'@+3X!]"U.I[76Q/]E
M!N=,_/^VMH+#.)I/7P1G0#1>PNC_60'MB.#Y8&M+_&>O#OKO7$\56X)V'U>8
M@G[#[\9I!E=&?[<'JL3'8'?[&2PV3^?Q%%92]GTM"]L&\NI7F+5B >,L"C]N
MC2,D)"\ -7'5]J)^JU@3+O2N4UJ@^15AP^"X7[C2&J,P9$0AYD1XFYH-(Z!6
MBD.*[B'=6$01L1DD!9H-*&DS XP#RH0T+7\!BFR;?B?]E-@I:81QSM334[(T
M!VLV[&'(3BO*^.X3I!7ZT[/6M*W68(G8/=&!@RX,#C_O/G_RE"2,<$&B3Z5"
M:%XI:8-(TZ9ZU1-2Z N4!X@)QW.2.68$$%GX5#;#@A73MC@!)%\PQ5J10<!;
M-JY6<2E[/2\!C@S(9F,"T@H/F@,VL'*@S$":B&HF.W.A#QK5=;J:H_["!K0K
M%DN$)<*&0*=-!+C7R)_P]4-8+ *N8!E3T>5F ^TI2B$C>U8[N(8#5L/!J6H;
MC6/W8(*O)4.<8R(B@X\A)%M.\7$6T%@H8:Y!\@!L([U(4&]L-BP<-5:0&&6T
MK6D$L@@/(NSQ!AC6@F!6+<]U",@ >("\I6M9:U4B00U\ &LL<8/A+C(7G%8!
M8I$V0RU78V!KM)NM/)K/O=O%YR=\/E?'#<O[U3]R94DM'[.6ELQ9KUL\'Z3U
MO'V8,"O@"?H!W'.%,6<K7';]^:8S.*9U0,.3BY::))"R4H@Q(+GA-2OPD<WY
M]S:(<C&JR<"*4!CAJV5)"A9LYN$UT-%L-8]RDJQ!>!49(I?SOFD;-8@U)8#B
M38KW+?X]:/W6#D!:*BYS8ZW=$!V^K73R ]F('F^S!KZ9E4CATD L\=N!92MR
MQAB#$'(!.E0RA9L[3[,7:/@OHD>O44S6IA(@461U(F*AS*2NXD"&^W0V0[,_
M4U9T?BY!-UZ)E;;&7F0L.'J5HY+0KUP*07J=1%E^&2^5/4=[:3LLFR,IRZ:D
ML</%781 N4*FK:Z>PXHI7 @Q$%5P,Q^*%;X*5G02P%2X"3/E4X$%:",6^U%X
M%VQ]98H@\%3/H3$BS/DJ(% 6X0VLOT/7E7TH$:E8/)Q+,'+U!%OTZ.JVFXV2
M@9EU'P4 G&$*@&=F"0)D(<M7SAN]-,_@+LL$Q2>=KU"7Q2-19FJE[RNH(JG"
MV339D^?$+#2-D0B-5T2%!$=X6J8DI$PC,23ZK&QY':5U 5% +P60&52/%96$
M:Y&%V<V]I15/[F!/9MS.E)EDQL06;K%C7@Z&1L8$C1.80@CZ$ LW>#SK^(0<
MB1CYE<V9/8[$AL(\90N"+:ZBY]"YKXBN\D"G;!4@T]9U3#9P92!0.P$"P[:!
MCB$CY$S4GAT6.@4E27I&YNO1%W79?:K0N<5!Q8B\#&_(0J$0VH*87D<1_@Y0
M:\5D'FUO!^=+,1,AH%":-T<5I)E^#YV'":#1M7&(+:O]6Z0KY 4\Q)1<;$^+
MTA5O:2G!&KCDI 3<U= I>9XB,EI,E+CG057/E*=Z'TARM&F$F8SV^\HC4<30
M#.G>J#',5"PL @H!R2<;7LVL*)>X,Y,IF-C8+4L@*XHRCB$]#2<H:M%]$ Y@
MPT6Q';,#+9WKB9 *1ZRP6(.-Y02L-Q6B"J/!  Y1C4#RO1#K4IPH#PX17UF0
M<9=>"J$7ZGX9>J\XD')9QEVNVA)4-_)L$QA9]YM&<Y"BLT!6H.,:1"0'1@)\
M8ADE>41H;R];J7JP-*6W ID[!TR>!U/TS<,&8&I]Q]S+,C.7A2%B4Y5UO$^.
M2F@1<SK<R27_K&ZSQ9A$\W3%%]%80A"/)FS$9JY8P[@"2_C*]9"N0Y],K_@3
M;@'?C)-5)%*/91& )\-Y9 O[N=Z 6/QRT<PMI&C1)4-OM4:^-FR%U"$,(UG-
M"SKW>70![#><7L5YFI70"!8"@M'W8<,;!^_8W/IK!LU]H>56+72-P?+QR^!T
MR=YU7+5<G9?!.[2%P\_?RIZY.0C+L8\;1=K!9!88% !>!J.;)<:P9>$XGKP,
M3@ ?&4@G*6[]L6/15&_A+_?>VOJ_?I&>HI!L0H^0X!VL#+]0U!=UTN^SHQ_%
MW$V^?YR^.Y^S(Q6%Y# KR0I&H!%ECZ1;D7_*K#5FV1;6BDQUB0ZRHE!ZNJUN
M5L1-L;N[+G JJ(B,^JQ(*#8E.[%.]])-)JX/F'Z$5G0Y2!1 JDW4XQLE\HF[
MW?4DF[=8#M+V%-))PJ(()Y=H3 *1#_]8 3;MDD0&(U7Y'M1=/J'1RM8:TERC
M0NQ3,!Z(9V0VV0[>@R8+DZ=)%+1VVSKJX2"\\<S6[+V?J7UI[X":/3B1K106
MA/AB+,*/D=8#_=?.G&B)1(?6^T)?7F\$&D>X2 73J3(]P?' =<&Y;74O5'EB
MDS"_G$=YKE\4N%%H3!J@VWM"<0UQ4K51Q\*G/4H[XLE@259%/-!ZQ'+M#Q/G
M"J1&Y5*8PAX2%;% A&."-C9C@R"8R7HP^#37IH9TUB8#65*'+!6!BR]U!&N'
MU:6X\K!B%>:CELUDB.6"3T E;4&LPB7SY8$3ZZ%T1Y+[-Y]3:X'E/>G] -8X
MY[ -ZP'@?]Q*%7F5LX/Q]#!Z8<J%UP$@J1M ]#Z:PI^()1>K$%$7]-J6]L 4
M(*[A>.8WC(4 , ,7YUB>M@H?JYC<FI8QS[E_VFTDOD4*%F&%E)0[M2O+WD,2
M+GEM2'-S(Z:UK74;5S!A&Z:EYM;1!C_($)4DF0#O]P31>CXWFFO%VI0K%6\>
MPZ#.(F(L!8Y=R#63U)$;911Q@*E40V65[I GP+>"./8ODSG ;U^P&20L*!24
M+8!JJ];]50.!L &OA,O+CH?->CL(@&;#L?:4]&5]7)U;2.Q5&,])=)EQ^"A/
MH5]7 LD%G''"\@<;ZP,BH["MA&T,X0)=H4%>A.)RY8"DB;*!/RC&7W*YSU">
M/[!)J7NNCB!/EE7CB:V*#'8-.("5BV4! D,+8ZB!,B1 $ZZ0D6/0'WF2X'RO
M02YY[)!?M&-KL=0AX>V."91#DA3E6BA0#I )4*FX8"M@> &7Y@*IMT'<ZL05
M6T PCFI8B,JJ<5@V#:XA 1L;I^E'3,#);EA6T/S5M]9ILS4&5A;WUMGRVQV<
M+?MP8!<1VMM&9.I'8MAC@Z?K;NDKRNZS$TGU0HDLYY#G:AQ8K4-PS:2;C04&
M'>,1IX#6$UJ>ZX;3 =QDQK7=#NBNZ'A8$,R(8^M0G0FR(73AP[/XO;+NMJ+?
MK=0<N".6_Z@(%TL0SM&#U*XP*=I,CY#7!DE'V<?E F@HR\16[.4RC'V?\$N*
M<%>R'TJ#'8SSNDROX:IG_%D+3I4&7ENV $F?%5?8.KTE7 *^IXVZ6[.-K9B!
M=)7.KXS0[5NS\>D2*GA\3%0);4:..>8'U646M8ADX<(<LL-NL* [PX@L&)MX
M&;&KLD3%03A+S"M4_-(X:W'?,,(8AD%=6D& PDPHB@S?14,R3(_6:(K^R%P_
MBXVU$FJ"@3CXD[=;%^&_)X/] 6C2IN&L3QX,P6((?O)@"/X)\/J/=PILT+F:
MMC3HLEF/+\:4(A%3'D<GF*<YA]G/(U+LI^A#2V_8*N S ,T>V2G*^KAXD*U\
M4E;<R L?%ZPQ,H.=,@5SE#^58LJNM7D<K9CV5PS@*5RV,MBAM+\TP: ^"9#"
MG&\"BNB)D8G"@/W Y#FH*44*(H=GB5$\%T##D1VS0D-F):&$*B82PY@H 97,
M>I3PC%_AZB9PSH :&:638&"##@'!,U\DE"=&V\PB^'.<)NR?%SFY%,RU'719
M@$ ^Q_DW9=\Q+RK.)JM%3HJJ$@;">2Y1+2")D+A+CS(7<\)3=)@CAW1DZ22:
MKB2*E/A]]8MP.-ET"TWFZ*G-BSRHB&U!!S;E6&+*#::KVSN(<VOO'N\,%<Y6
M!#I8268.XU9V#UJO1GD[I=I:'H7BA":&!Y<*&X]*#QI'O@Y'H!PKNAI>',*]
MY<U_NA,-RZ/LRL1F>1JM3<KL,(U)"IHII[J3];*@<(T.&2[@\ O:&TC(\ZA$
M_D -P,N!PAA&2^'TK(1\C**E,8W :E9:;C2J*8:<(W:O0)_(* L92<\J$3JH
M@_BO449;)3+^U*N[(!'(Y4A"4$MA<A3^XD(CEHFTJ90$*X(7)0+-MO&N,0?I
M#&HW )8NMJ6=,52T1E^:'Y7OS(JHG:$)C,/6,?IU2>G6$M$C&A?3$0[M(.5*
MVZ+4<S-TF^5D*K-%>N-X:!7A1X)7@MEY$XK-YS/3Q7B8>#GQ(5:FR//V]CK4
M0G3RX)6G&CY.T \K=QQ 1&"*;1V7#MIUC5@ZH6^DKG8 < :W8IIH&T</#W&8
M*[B<4_R@,;,36$B)\?8WK!'BQR1-ML(<M$7R8+H H, G\J;H"AP2ZX_YE:SA
M6<PT 4H)PQ GI6(HJXPMGW;QCI+V+N.H%5H5-01WE<9^%:=S1RFT@#8/KP,G
M.)\$"16/ZZ<&63G:=N8'X>(*F37RAU+B!QVD,395;8(3BUT@SE89XFNS44VI
M4)ONZ#VR41BS(*XS]!!3>DUN(8HRE_&I(! $CY%$)!,\C4@0+#-YJ&:]S08O
MV'8TWTH=OP__DCGO(]]\?A<[6Y1AT'^ST35DKL0M/:)"%[^."6B*?PMSR9S8
M.T-D*X+Q\5J;0D9DY[%B&Y_?S_@"BC6AV]AL'$C:,S.H(28]XR$JM<U*/+G3
MQ>U0.B7P&I1IW01K]-&@_&*3,;(Z&:$%??CXHI.W(%':G%2(1EHNPR*CV\*/
M68;R!]6%JI1Y'#N5F,GI/'J:8<U03%9SV^A85^Z*LB,!>QD:.4'"7K!^K]GP
MHLH1U8'=9!=P=V[S3G0D&9#SUM=-X\>NTRQTR_4T)!37O #'UHJOV@S^G/V,
M=$)L,Q6>:5YV#XW8R)3U'?RR9@X7$>F$$JWM:BVXRM&N#:@+4.-B0&Y6:D.0
M"54.GXBE6'6$&'=@IQ))F8=Z<"NN9L,V7BRBJ50;D# %]O^0)TO)87 54BI6
M\ FS!J5)FPU[5G:&F4E!<T]N+$(9D$/"=E#!F:%!!2]MR1^L5P78I%SH*$>7
M9R2A6#*S* 9":1=NN0?<$6Z P[M-(3J.I*8<4*GHH$E&YM""CJ56B-_ Q)!(
MO@LN0LJ 6)$ 8ZR$-(M_5]ESSBP2:F+)J7+G>2_T%IGI9VG668MN./UBN2([
M M$7.*(YJ_B"S9B)2:QMO,KQAN:ZRH@-/T$6$*[*[DUO2EW7PDT&= Y23R^1
M?2B1<FZ7I14X,,E+J%.)-8@VF="<3\$?VW]K'E!A-$R$F6;FDI9C5>2XETQ\
M4^?#TP?G@S@?GCXX'WYPG.; UZXESU,$2=_R1=O\#]=)E9.02EZ#3(!\H!2E
M;%5W=#T*(K*@=S^:SW/E "C;/#"JPQ38I-@]%0U(/$5$3QP(&!HG$]>5R'1]
MZ_ &I@V5^/IUPN-=1G.25]),<5(@E&)?<J6BMK<*]A<XRR36YS[5%C.^4[/6
M+\!JTA#-2=BUZ-K-A@[)JN)0)*U)X%W+C4JU'HCU,V2%ET1%E$;9B"^KZ!K+
MB[,&6BJ5Y)427SKR]B">KXB;J,6;'@T\<;7<5'JMDN%[2S<1'[#XU<3$V):!
M]]*R-K$$([:^Q&:VU?'+)0ZOL1-OD!TJ@0OA-#(JI^>-PS(GO'\97]B&S=)\
MJCH&&^+T\K:#0R\SKUQJS>!^A]T^:&R:QXNX$&N9$@UUV2PEQU18#JI!69&U
MR(0,P='V*U 2>)J-L6WZ_'+E)OE?-*?<P>[RA:MO?](:4/('-G3^6L&6M#[)
M:GOUZ_GK4HTZ-[/D@L)?.CY5I:!CXNRY*)<H3:I2%(A3%VRIUYY=?*U-C\GD
M)FT23A#C]_P:RDC#&)4Q,IN_*RFVN6._<"U-OBM!IV7S"G!5^!P:4K&23"ZU
M7TR%&6/'G0GUIXHS%*YCU>*HMV]5S&BL(5YU#Y#=I>BL+C_DTE^?1@JA,Z;P
M$G1JXMPMG9:.H,Q(Q-&>SDN%/R1^2ZD9^#>=--F&2ARP)7JB>CS2D=Y*_+\5
M9SKL0-5[;^M7!::Z=*F'/TS%2@5L2Y0$;DC'9D7UV B$[BNB8Z[P,;@-'>D*
M?W5\#!QT5'DM)DL-*YQ3D@/F3*AK3&8-K(=$H?FKA<(1 2H'=;/%R)%-5-D&
M4Q),AZO9>7#&CU1<ZO@_\@VAQZ_V6#3X;T%5'P*W(V?@XB:;U R .^4CL,%O
M E<^G0#=U!RWOY0[G+6N0F6=G%?IWK&]^[?1NR6T$O^:Z$4CW-G9168$XQV&
M/Q:J"!E<80Z2E&*DIB)*>^.[)?[E[T[K;4NT CAL=)53]+MU;RBZ1BX,6ZTR
M;8F68[O4-8;LF5N."_R,G-SMBDO0;-02[#MC?O#9B-]L?"',]R>[ ^(OYZN<
MST=[.IU8 HMBU1*J#J>Q)=$L)D05E4?9I.]P9-O-1H\KT6%B$PB-T6+)H4;2
MN2-)E3/X=N7"F,S11JR10>R$I;CP6H.X67K-#:F\CSZ?N^U TIGFAA6K-+1M
M70#_)C=]S4:^G/GQIU4>-C%$/GLP1(HA\MG]-$3^M-A-[HVR;EQ-#390E>^L
M(E?HQM;D=CWDX%NHRC7T$OFR$$S%)N_ 4;^@%HO5Y>^FQ@9WT&(WUUT-]ZD_
MS5KQJ(9IKE=BK4#.6D4V;",^2X&N6U79KX8MEI)Z=VRI5C*#+Z-C-AN?IV1N
MHE]NHE6"LGHGM.$E54B_=](>ZY#OQ@O1N;-B:":O50TK5_^=%,5;825;O1-8
MOI#Z5GT\MVASFZEPGTR<;D@G8KS]5CI1Y3(<,#0;2D4*OK.&5,;9+Z%[W(%F
M<M'$6 *3:<PJ1^2ZR3!Q2V_9-VDHI<W<5Q^05K#@99BC"X8SOF)31MJ+2I)Z
MQ.5:%27CK*[%_@GGB]KSF@-V:F=4PNU! WS-H3\D).\+6P>J+D8+::N4!0,)
MZ-G76.^(RZ;02%;JF*F<I;-4US03C.N(VU"'$;H=6&$A4G)6$56')$:=S[3T
M=50*.+4MPW8&C/RU+\ %S)18Q+^1U&_V3(NTYM=54FJ#-CGZ/F>GO_I@BV4M
M*W,%FR%Q"1>TR_,4N?334!RZ= "YQPLZ50TXL&P/Q3C:_GNK.^EC$#[;57YT
M;@8JM7E<D9LOG,HOL#98$?DF9*_2R\U-)BS!WYZ0*P#'6%[^,IR6C% UY-#!
M26>=4WNA4X/7TI*N#E<Y D7>(L'"C&$=3D;=X"K+V%NP,XE49):U<G%4B,CF
MCJ^X3;?(,;N9&U@#HAO;]Q]4N?XW&((;A(2Y&^MJPBB'JS'F<RYUQ<"V9)%5
M'H34>1 ]?!JI=IORO1T*PMF7%#" NGGB*J"\:CJB6I&;1+SJ&ROZ:;59NE.Z
MB)Y67?;6(MKZ&JT&D1-%6763J.)8381G77B)8HXJWM9.PN"KY@2>F&DK):K"
M":-Y8*<;&51_>S"HBD'UMP>#ZD^%W90QPK*B:8RH;*H6.QR(FJB%1(MA2$>I
M.NJ+OYE TF! I?G$2L $OZI[F.4W4AI1YA!K3UDR^JV5U.D&9OIE-9W.5DX\
MR:N]UT -J5Z#V@E&N(JMJZ-J6CC.T;N"P)\0GD^3J34E6;#UI"BLI1>1:/ +
M$%]RXK]HB<%>91<9Z5A6 \P.5YE,"$P+3'VQ?LPUNU# S!4T\PI(VS_.RA"F
M!"D"<133"EO=-@MX(#+,(VR4R^N\BG)*LC%E!J5]'')D6/ >RPQ4<7^Q4%58
MK<H2(.C]CF(+%>J@I",^= 9RL]':+X]@FN91X4G01DE_G,5)2!4CVV)[44G]
M=2&XONC@&QM57V7$&^T)N*F)Z-)F4I(+8FHC):8*92?]#%,PBFDJ+ RQX#K,
MW>GE\E75LI4 *SPD)7(&X3B]BDHV*&4LK,8_5=; !A,%']EPTM>DHRQR-^UJ
MP%;=CXYMO&OU&6S,-H>3RQ31U25C[\0<UFR8A#45_:!TTU9?!BIW\UU'0! :
MID-O6ZFBMZ[&#Y;K: &Q3#'4$LFFV_^T=:XW'5HZNE?#QADQI1[/&B6Y%WA-
MQ+Z'6%=MS3_J$B9UM&F]PD>:Q2>$V=/MP0K0NDU3E2VTD,RRH$4AA)8O!Q?K
MATE[] +MQEH-K=I8G8;%=8LH[2TM50(A*FLW+Q;>=BM^M;G"@$]_\-TD4JZ7
M<G2?W>?3YJ$*--O-QF:GN$9KKSC$JB0(RV!B3DZO6\IK;[;Z5@5DO_!Q&LI_
MVWD&GW><^NJ[G<9]DYL88Z_QW"J>X$^Y%%=1#46E?VIN4=I8U;W0";YW1!U*
M"7&ZH2,.V+L)X;O+153$DR#$ BH7&E+OWG?/K"1PVR'%0H#D.F"62.N96Y"V
MVI; MUHIY%(B;%/*M!E."W/G!HYJB5AJ)5]E5US3D=)M;\CF5K;@8>EP2C&/
MO9(CDC,ES,\=J[/V:!S"MN8B,'2^%6&KO0APESZ)L%5<"Z]4-I&^/(^D&I#)
M_%UW2B1489L&2GY67L$U06V;($RK;#V4$D3N+K@8D>,<]P@CB]5U-]B"EF;C
M_TY!=,/4>"_4PNF-19>"81AF&L=74NDMI6IV3F#%-;>6P,(UK=V=-EPR+#VA
MLP#3"7?"EC+NQE"-]7D0W+AE"3%W5:1W^H<>ON)H1XRQM]'#*B#(<JMIAUDV
M-A2^Q V]&IZ?O2XN7_V*_Z7=V2E-U+C06RC5.4BHU-\R(OT;2XTM!85 ],O"
M&#4A=1QY-%==T]:>"R)).9V?;(!J3.".2OV84:D,PO:80W#(UDDN>'6PW&1T
M$2;QC"+(LRS-]+2SR*\M7)K.*#OC-$O\\(P':^)&UL0_/E@3Q9KXQP=KXD^%
MW2UE3!Q(S0]T U6&81925D@J; C;555(TMHZ*Y4U$K%DB4CO"S0],2A,!1,L
M+FK7+V&^Z50TVJ!<D,7*X:GZ()#6GEE SCZQL>2B67:O3Y<8;.>77:"D5AHR
M+7 JS:JS#=QCZS1J[<.?8KFAS&5$-MC9W_?1;GHOD4%N<:FLM&J5_J+?X_XN
M],ER.MK@K12K'OA/ZTK%AHR,V$#V?JMR'-_8D[1 T<@*V+U!04FW-5/-6W4I
M-QC4-O7@*!U/-.)3-2T%YBE:L8-A.-?A!_7V5ICB CO7*IGW_QYO[^Q@'8.*
M^G.E8G/.XD):')=<R./?T3_^&PBJA4A^*+!V)!C62#1):D<+V/5$2U[:"DC<
MR\HXK0DBVUD&2L(@+,+@P+KG7Z:TG:8<$46N47$IPT1\UH&-M4I9K+IS-Y._
MF#I'3*,Q"."H$DJ=.*M<Z(T3P^.7QO-FQ8*?F1'E+?N#+LK45B7B3#7<:]7#
MPN<A#HVSU]31]=^4*F@\8J3H4IURIRBYTQ_./II2(T%'U0S+=>7L)GT&\:=L
MU=8<JU0FKF.;STT N56"C!232;Q$JH'E+:4>B 5O(4;<4NSW(JIH^&W%&UGC
MB947%A4[W4 PZHB*O9 =X-9J<^$$U583.J):+M;7S&RI^!MT-V5<6 6.RD3C
M4/TQK[-'QVK?61&_P]HO6YHNXZ7UDTL%=;_"7:P\J=L%EJODV1Q8HNB4L(&&
M)Y#>K"Q^^T 05S+R5"2I(Z.HUSIF; Z,,:8M>;+N B-/8*G&TMZU0*A/%O=7
MC2NMJE)UC#_5J*/KNYM^<@Y"F@1B9QX[ZH9L>Q9ZH3DVTO6'/NW$ZHK<2T^>
MF@M$*ZF\0-(2BR#08O$6Q^;@[TD,W,ZL4P=@V@?CUN>_;8ZV*2-B6>7*;VF*
M0-<1H3V.;LBWI Y=A:>GS@U>P?[G?*IA!O2'DT^HUJ?$%A)^TOF348^%5^DY
MI=;ZU@UP5ROELT5(FZBJSS_>9L,^7_;OQ?:*58RA)E*F?>G4(2_W4L[8M +?
MGQXL*V)9^=/]M*S\1#C=FJ+L?+A*IN&"6LHU&R,K?H>[._9GGU0,VI&XIS'P
M730[$^57G\CA9P</9='<C_# %HL4)IK;WJJ44XSP(C@>'2='C^8BR<?.D1)9
M>Z/E63,#KP\Q< (CC? _H$<F'+. #5L79&]77=8DI/=&Q8]I6] 25%&U7.KI
MEG'3(;0\4.RV--HC]QI[CKR-H= A$ N!RF<2'U4%."7Q6SNT]]>Q&[W2HHLH
M86XT8PA;"1'X3>OZDD/#6,TP\5BD![AI:'%N]06W55<6Q-9)7Z9G/7))2DM3
M"W.#H^-,YUK--)!M;[+V5V4I#"IAVLC5R,+$O76-UF2MR;$ /-OY11V"G5KL
ME\66=U!(=E^Z2LFJM%09JFS6H)?1&U7<>$?<80WKZUP?7ZM"'U&:782)](&6
M##VNVJV_L_LZF!VSLW"Q7,US;&K%]A1]0*5#9_7!-[;HZK_S&Y4C0_%X*D.&
M1V,1_/839@5U0^B1K'H;^*P@/U/:7N7F6%JR=DSJ=6IWKU6ZN"I%HMEP<B2\
M ^F4CJ,3Y$M@?7 G.Q8US">7D51X1I)\08MI*R^_?3D96=,5B=EGTNF&(C?&
M-Z+05#_.6FB4;W0]ZNO'U[UMWQ/=M'W]1>&P$S>*3,GAQ24L^N(2L:%C>I>0
M3BDQ@S7Q$!AHF*'US3V(9J/%+FC+5_RJ_]KBG8'%.I59PRT^*M6/6*$;YR00
M%;5*?(7E NT+?(^TLBCNAXZ)4W&Z;+"V6<J&<C)1O&[%3B2+5 (M^]39"5VS
M?9V:E"YM"J+Z)]UFG"CKI&E- RC9JW+-WUY"7QP1JPEV$&)3%^,UXMXDS4 %
MTX301[<8#7?EF!CK+8G:]OH<>,9 -]X <*@[)XPK(C<"Q<<A.W6Z2ANN$^.X
M X+)I=X(4"8 V!?T[*S%2EQ9OYBO</CEQ#9M,C%)5B2QE (9<-S:"OM+9"N9
MJA5L91VBR=$H\37'AP&KID.]"9;2CZ, 93^O+Z7;PWA-+8ZD!&OO$HH%1 EJ
MTIEQJ>P,]NZ;#:F["^.S8:%N7S&;9W6XO*379=$,(TJ468*8*8:[.,%%*@B]
M(,D!MI88$;<.,.3772<Q7L TTBSF,J4]Y-IDNTX<9#N?CB2D?=7A;9TY;*RF
MUP;BTAIJX5BHN7/#%^J0'&5<Q\E5<^B;N]0ZRJK$H5%X0/689&$1>75QJ4--
M1'L4NR81X3,.!\<\_+9J35=M\$PE*-ZF*+:B"2MECE-(A#^)=Q)*]60'NWVH
MZ"D3:4VRFG6[:[:$-DBBZ"CR99:].%6YZ1CC!FM)X-Y.HIH6>G78TK:4*X=^
M<L,J@T1C;#QR8YV.?(\N$!->B8CKY'*X$;SOK'A\@C[66B#PRXJS:!%R[/$J
M,18])UK16J/RM%O0\ &[#@--I7/@ADZWEH[R@M2=B31D4;%]!N<TRA#RIG/;
M4X%O$*DN1P/KU_;2D - #DCX3S-QO;IWF;KY>K9MU9]&'YRC]%9< DT'BILE
MJ1; 21?E(-F6M*,BML0I0SI/OZTO3-4YRY%L<)*J1PXJO!S8,",W(??5C77P
ML-#6<LF2DNVA,HNNEF@H>P&MPMW^.%+41X.'HNYSW1U,M$NM.156WV8S<+0!
M8R $9J+L'R@SNU (-'V=2KZ[%P9[M[U;=T#5(3$-B^I6[$$;-X"XK4X-.1<<
M&M=SF?@<>;T@0+_6S5N.Z2%%0?-%T<%R>Y$:[9L-1?S%,^O?!VE8:>]L,T[6
MOFU;VZX4[05STV7Q1&C0E\.$Q7>K8Z5%^AR1C0;<4N-9M4UPY<?I- **,<:.
MB&B>4.3!6=+I.V\!P,6!F_!=36""-$4Q_,+V-=J)_#<*$7VF5LV"'%HZ(TF'
M%ZM%8VY*J^0T4&F[;93EXOSC%K7.)=T7@W(SSE',4 Y-68X08G&^/=R&B4#\
M6V4W_!SGTX!,%:=3ET\1&Q]'Q744E9E*!8O5>K^U0:>\3]UNE:3;^WT9RZ4X
MH+(9E.V94#0Q13M?46O7.6*FL]+=G1T"N/D=UE(ZW;?O1D'U";:L(\3.W_%_
MN2O)D]^>T;BPRY6QJ'$C^+9UV%9 N*-5Z;NB,L0V$4LV 1F 9K\MG 3(PIR$
M$#\-="55-"2:PDK>=CK76<7V_!%<SA.K["I=HT>*B+E: F9&D-#CYAGIMYQ!
MC<NY?J<'A.9:"A*K!&'G9^%K&?;4-.*3\96=LCU<[7^C+*6^]CC'&&YB>LW!
M^%Y#YRH1 2DZM3Q1!:VN8Y69/6.MW^F"H_J/(VI/N3ZI909TSJ!M"V<D.BM[
M&Z4V["F;)^4UI))1Z(G]E'B@@*!],0K2=Y#AW?;'C)$3ZE G^K]P(BL!JE;%
MJ<U_0A9L[#UH7BZ1>9_GE0PWU-8(=L7Q1=AP6=4E5)93P*P+%9?CB@%6LQO=
M$%>0A\_'WL1!.EEQN&!--V]36TU(K94Z^P2]@8[97CI#:^,V#4L"&]<F(,_5
MQ&G-G<,N<B9O-R6=9EH2U/DG8$3**H3]Z[5E 5AL>-.NMRR5KI2K;E89'SLJ
M",-;')J0=852#OVP(6["\GP!2,DY*KY/&HXJV,5)7F1T)IZG+X\7<.NR&HA*
MD&>SH5:@>S?9RK)*9+79=)5ES^W"JO2WLOZ._A&J2DD6&KXV;3*^ WDF]JS,
M*M5&0RM.C24-;:]<W^%YLV@UVP9HL%<9 3?#$K:)Z>IE;M$YB4'C>$+7Y,@/
MH HB]S$5 W@=D%N8C5AP(#H[H:6/6[5M; U0[1NY;FLFX,G-3:M9H2@%MZ.+
M+D/B 8.9<#E7HMF *UY8ED"LJ9 N@'-6R]RU_H:[&!W:<K#JEAB*A-JU19+6
M7#>3\W:NL@W\-,*;6Y"KDC)8'<BF4Y.RB^*BXB/:7L%J2@7-;^4I*Y"LMR(I
MK4QVS&X%FV?69*<6)MQ19)IF$*5SVH3K<"% 2UNHWI] A)XF"AF%4U-KQ5.#
M9=H26.$O[SNR\JK\1CI@W!-2VW:G=APR-FP\D.&DVBN$"JZ^&@Q$=LZ1F<7V
M^JLM"98C-2%*-V4Q:;,=*B,^RQ.;R1#NA+=)%*Z_QARNWCK'04LUQ5P9]>P#
MJ^8O=P%T!V.DI69L$BY8,;:GX;CJATC$-9&(SQ\B$242\?E#).(/CM.M"",1
M3T@:(>'.B6*0/)YAO%C-@6-'Z2I7M#ATVY57UX2M+$%E]^FM'*54*+HREH()
M(<K]*U-[@O/@52E1G;UF>J2#KB6E<8T$YFZ99P/N0J*#<B=-;Q&EM5VFKC:M
MJ0:,$A=(@2)76+UP;4!<6D7+2O!0":U&+E;[KYF]=J^N.2DTL>BF8EI]">'Z
M* 2[=ZWO%Q7G _>M)6=HDHHO%%EZ!1;9M8?)P<9( H?J"O*.^%Y\I5JG/]/=
MGN'=MFH_\G5N-KIDL#%?5W3VA6OJ5J"5"YY$(1FJTR3:XJH9$BHQD2 \^R%2
M;;S*<O?S)"Z(RJ9%+$V-K(1<#O:NTWU83=BD:+#;=1U=7D6NJGF095+;9\1&
M@HH ,.2\\"TU0*L6RV(N4:9%Y-_ICEL.KU-G]-(UK$LR[S*+T-B!1A3,@:>H
M6/3'1D4ARFUQ636K9AN@(\,;CBEX33]K_9NB@YEXB4OT4$61XEHVZ#'IJHIN
M!<6.*GRMB)X3WGK!,6P9#E2FFKE8U<0# ?"=1D4HB4^H4DOD"NO=/O- QS.2
M?5&HE4E,3MO%$W)"Z@-7-CHT;BUO-/ZQ&\(^J;*%4;[Q(P"T\1ODJWN:P-2Z
M]"[_O@0N1EQ!2"=+=S9)\; /#^W_7)B!@J3M>@PF0=C/8"9'D(/?.G1:1VBY
MD7!(2-PZ%AL4G+?+.MR2^RQY!%[R<\EX6A$%@D/$(()D-RJ3>P6KR>+_\J[$
MZ@UG&-7V?3-N(RZY2X4OX@GNF6:6^$T>"I8SDZGKS.&4J>TMA8R#Z7P%#V<8
MBP>*^)P3:@%L_UGI7!H,LI+2^QPF3H1MAH6O?-N""FR6"H"JX&]"6*;M"K0Y
M G=M37NR6Q5Q@70>H^TS3 E%1R"[W9#XH.$N+,6CR5C59OU0K409PNS:L;IN
ML%M%S#%"6E[53.K-H$=)92V(VRK1^<L2-"\9G)'$4V )$S]TD[3JBG1?&/XJ
M+:+J K76\E^2H;64:JR2B^&PYBM.9E:@L4]&L&<:D01=2):Z2?$-9^H'E&T!
MMXWK8Z+)AC(\<UDU70_&:;1@3;H=]!,=%TW>W#O2F?6W"E%D_;4*/OM6N;V&
M;JQ"!!-@M,*RI8)!W1@LY *U1$\EWU& K#M2H8)-/PG):X.O-\%XPNBUGK;8
MSHH![JZ6@4 GBHI^=@R=D'P*?6^I",]DGN9>4IA7P?>B+:%F,W:I2;*UE('6
MH^$Z="E"[<3N&$<@IZ I.X&YR//PNMGPKY>JRU(3>&BQ*1.^)!4]C6/ 6MV]
M%#$VM4SN[CR8)L4TN;OS8)O\P;&Z1>6LWBG!J=FPBJ;OW5B%)]%$:0I%D:=W
M-==A=Q?:S.'%?!U36767U:$)RHZ%GZXRK;]%%#&+?,;BF\!^5]Q:AYF'1,Z7
M6N\(@^3@<ER88GD2OX=KHPE9,+.28%3,QE@%4T]5,+4.V_OB-3CO4O7RN^&)
M6<#NSC9>FL/3DY$][]95"!#$1_,%\*4M4"GR1Z_/.)"+@.>>$IIB< RBI\&H
MTKYKHK]5.XRXK0O/B_3?MJ4$P"BRD)#LDV)T#?#B+)( 8?*18XP4ZD?:D\CB
M::4Q5.57ZGQ(G)=:.JN5J4XF)K2*K:MEL8:[D#I"C9_/Y]E'N,V4TS73,&AM
MD:\R^S_!CLC/=6J$55:QBSGQ;@N",%=Y-_F++UM3;_<'J.MWUS7\/?AS\"'X
M1ZN[M=?^M?O/!X!0UO0#8JCR;G_74>X45)O?XMZR>\0X=_][[^;'@>B'*H@6
M*2IDM7#U%9OJ+%Z2$3B$2W.2[[WG'P?NW2JXEPN)KNG;='MDO^DXZ7!7"@./
MW<SD9H.MMGAP8@(@5ZYH[:JG^9P"\)+R>"]1T'LX7#G<O:K#]3W;<+!^'06G
MBVP5F+^RV/O%@5@SBY],/P =)MA]^I3<,ZOYA=OO3+>BT2(4UTC 5**$;)/T
M:%Z@GXZ<8)./27H]CZ875%5.S)6^?*?[]MTJ7]HV42LOI:JHM%0P*77E4V9J
MM 92&@RK0BJ8H2Y6P9L"\^0H AS+4UKI(P[II=ZV67R!\2%8@X3WJ8M&&H @
M-8%?E=$Q3E;,,[&$"4?<JEI2](I8AZ-0N][8B=)L5#585B!L;P,&JS[JU24A
MG\#B3,8)*1?P\SR.5OAYEC'@T3]"T&F[D13DUB,LJ757CC%+OZ!\6TD/^C[J
MXV9*FZ=EBI;V(R^W:J'K3'.[#Z8Y99K;?3#-W==;L[N+EIPCDX%"-%VQ>XZ5
M^1X;^5%,HB%5^(?IO; Z2D^O+N&/?W ^+7L;J[RXZ'I4D>5KJJ$8EKVN-C&%
MA^@AW#H<E#FUSKR$#FW5JPM8:+VZA>J5%/:28!HE(F:VO(_>6CLTT50F8E_Q
M1-R!?J/86RLUF0K*6.'NNJ+I,-KTNK-9/,>5Y*9$E5WF#3>"ZD-=/6:W8@"M
M>&PM<VJBK;QLSYDG31K!HC5M:\-Q3UGRNJRT<HGCX!]/MY\__^<_GN._OW#F
MI5-0_CC\/5ZL%K@'Y 9 !/VR\DH+\Y5F$;P0%):[V<[G6E>;P:M@8,[2MKMR
M]0K*.2]7@*QO(&V?)\"G?*"T:/=,@V]YI!PF4WNFP5V.5(<4U(#*RF]9TQ":
M=#.[^F#-^90+A;E$A>/;G$:=!F/653>40OU.Q3[TX&2HZ(LNL-E(QGP@=1I8
M+%;MFGVW] (3Q-&0  0)]K9H-G9WMOZ&:(B?@ =L_;43E+O4= + '/N$+6VC
M' R@*J]@V^10E<J<<!1H.26^HCILZ[]M"SLE6,'K.R>YIVZ<7N!&8KI@K+NJ
M!KH<>,BN!"_ZT(\U+;,BG>B.A3%:3[R>?12= !"..:Y1@DM@3Y3=GJ4)@&5!
MD9+KO!HU6_#QF0-G*!9--;2X$S99&JMR;0 7H(!_EV49EGT%=$)BP6PF7$NV
M[*A8]U*YM"N/DXG5^2%DWZ$5/WJGC5W3/<&$!HQ#V;O1IRPXY@:#EJXGU_5
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M!_KO@ ""6\63T'/Q4\T&7-83.'L  ;R+EPB. .C.71!&D 270Y,1D+IP<_J
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MN8?P\>SPKQU8PW@ 2QV-A]WVN#OHP\M]-1ZV^J/CSK!UV.WA'EO](WRFU>O
M,N#ODQ;": S[A!T<XQ8!$8,>_'O:ZQR]Q8_O/IX.8-(VK.P(UX,?AA^ZHXX9
M' '3^:7=.1WC[D\[PY/N>+P-6#ASZ_2TUVTCI.NU&[<-RSD;CLY:?=DDXF/8
MPEWBHW\_:_6ZQS"8_@+0>')*'W"MG>/AX&1/=?OO 3B#(6#\W>"L=X1[;GU
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M9+TV!1&/!X4++V++NK:QFZO#2"9S'_I!KJZ2]0(-1.RBN.3+7"Y@V!"<R%B
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MSCATE$P/)EF)="JI)FHP)XA^(_VX'F#[@(XE8R;,/#.3?!JG&,[]O,(G#:"
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M%!-GFSC8G&#/9BI16A4\P58-8CIQJSDY=8^TU0"4C8OMF<<*U1/>OA3S7W#
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MJ6VIY&3T6T-[Q;RW+Q@09%X$,>73>)5L"Q+&/0T+/'QS\&3OSW]Z\>I.W<]
MH7*"I^HU&N"^PN_IK8/1^J!('EM?3D7'.."UCK.G%'0@^?+&;0<4'@M-FPH#
MFY0$LA.(1XG+=97<2LJI&F E,4? OZD,@!MM8FO2)^B;G(&T?&6*.X-DGJ/0
M@UV=9+ABY1II[AUX(I7XKN@KS)'17GE.:M^9<!Y_O"&4H&'BB8F_E/9_?WG
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MH#3SZ3K7AJ;,-HS#[DOS:,K>7;F**/^20QO14#SEB@SD4_W,R39/-^>]?(:
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M]4W7\I/<K#?)OU8X)7++?P%02P,$%     @ Q(,'63;6,%%2!P  SU<  !4
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MY=Z^:H_\#U!+ 0(4 Q0    ( ,2#!UDM!5"HA2   !B?   6
M  "  0    !E83 R,3 W-# M.&M?;F5U<F\N:'1M4$L! A0#%     @ Q(,'
M6=]^4UW!<P  !)\" !L              ( !N2   &5A,#(Q,#<T,# Q97@Q
M,"TQ7VYE=7)O+FAT;5!+ 0(4 Q0    ( ,2#!UF:6\>PZ6@  #Q- @ ;
M          "  ;.4  !E83 R,3 W-# P,65X,3 M,E]N975R;RYH=&U02P$"
M% ,4    " #$@P=9_TV\6(A+   /B $ &@              @ '5_0  96$P
M,C$P-S0P,#%E>#0M,5]N975R;RYH=&U02P$"% ,4    " #$@P=9AXU"ZP@\
M  #T+P$ &@              @ &520$ 96$P,C$P-S0P,#%E>#0M,E]N975R
M;RYH=&U02P$"% ,4    " #$@P=9"(*/Z2@#  #:"P  $0
M@ '5A0$ ;FUT8RTR,#(T,#@P,2YX<V102P$"% ,4    " #$@P=95"H?XOX*
M  " A@  %0              @ $LB0$ ;FUT8RTR,#(T,#@P,5]L86(N>&UL
M4$L! A0#%     @ Q(,'63;6,%%2!P  SU<  !4              ( !790!
L &YM=&,M,C R-# X,#%?<')E+GAM;%!+!08     "  ( "L"  #BFP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea0210740-8k_neuro_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nmtc-20240801.xsd" xlink:type="simple"/>
    <context id="AsOf2024-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-08-01" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-08-01" id="Fact000004">0001500198</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-08-01" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-08-01" id="Fact000010">2024-08-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-08-01" id="Fact000011">NeuroOne Medical Technologies Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-08-01" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-08-01" id="Fact000013">001-40439</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-08-01" id="Fact000014">27-0863354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-08-01" id="Fact000015">7599 Anagram Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-08-01" id="Fact000016">Eden Prairie</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-08-01" id="Fact000017">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-08-01" id="Fact000018">55344</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-08-01" id="Fact000019">952</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-08-01" id="Fact000020">426-1383</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-08-01" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-08-01" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-08-01" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-08-01" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-08-01" id="Fact000025">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-08-01" id="Fact000026">NMTC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-08-01" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-08-01" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
